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Abstract
Cerium Dioxide Nanoparticle Exposure and Microvascular Dysfunction:
Potential Mechanistic Links
Valerie C. Minarchick
Cerium dioxide nanoparticles (CeO2 NP), an engineered nanomaterial, have great
potential from a consumer and therapeutic perspective. Currently, CeO2 NP are added to
diesel fuel to decrease the soot emissions commonly associated with diesel engines.
CeO2 NP also have therapeutic applications (e.g. improve outcomes following stroke and
radiation treatments) due to their anti-oxidant capabilities. These applications increase
CeO2 NP exposure risk not only for manufacturers, but also for the general community;
however, there are currently limited studies that investigated the effects of CeO2 NP
exposure via multiple exposure routes. Furthermore, there are no studies that investigate
the microvascular consequences of CeO2 NP exposure despite its importance in blood
pressure and flow regulation.
Therefore, the aim of the first study was to determine the microvascular impacts of
pulmonary CeO2 NP exposure. Based on previous studies with other nanoparticles, we
predicted that CeO2 NP exposure would cause microvascular dysfunction that was dose
and microvascular bed dependent. Microvascular function was assessed in mesenteric
and coronary arterioles via isolated microvessels. Following exposure, endotheliumdependent and -independent arteriolar dilation was significantly impaired. CeO2 NP
exposure also resulted in pulmonary inflammation (assessed via bronchoalveolar
lavage). Finally, these impairments and inflammatory changes were dose dependent and
microvascular bed dependent.
The aims of the second study were 1) determine the microvascular impacts of
CeO2 NP exposure via non-pulmonary exposure routes (e.g. injection and ingestion) and
2) investigate the underlying mechanisms of microvascular dysfunction. Isolated
mesenteric arterioles were analyzed 24 h post-exposure. Endothelium-dependent and –
independent dilation was significantly impaired following the injection and ingestion of
CeO2 NP and the severity of dysfunction was dose and exposure route dependent.
Finally, this study determined that these impairments might be mechanistically linked to
decreased soluble guanylyl cyclase activation, cyclic guanosine monophosphate
responsiveness, and nitric oxide (NO) bioavailability. Finally, this study, along with the
first study, established the dose, which caused a 50% impairment in arteriolar reactivity
(EC50) for each exposure route.
The final study in this dissertation aimed to determine the in vivo anti-oxidant
activity of CeO2 NP in the presence of a pre-existing pathology. Based on CeO2 NP
catalytic activity, we predicted that exposure would decrease the microvascular
dysfunction and oxidative stress associated with hypertension. Endothelium-dependent
dilation was assessed via intravital microscopy and was significantly improved in
spontaneously hypertensive (SH) rats following CeO2 NP exposure. Vascular oxidative
stress was also significant reduced in the SH rats post-CeO2 NP exposure. Finally, CeO2
NP altered the expression of pro-inflammatory cytokines in the Wistar-Kyoto and SH
groups.

In conclusion, these studies indicated that CeO2 NP exposure results in
microvascular alterations, which are microvascular bed, exposure route, dose, and
pathology dependent. Furthermore, these alterations may be due to changes in
inflammation, oxidative stress, NO bioavailability, and/or intracellular signaling. These
studies improve our understanding of the microvascular effects of CeO2 NP, which is
essential for the development of these nanoparticles in commercial and therapeutic
applications.
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I. Literature Review
Introduction
Exposure to foreign materials has been associated with increased morbidity and
mortality due to cardiovascular events since the 1930s (Helfand et al. 2001; Nemery et
al. 2001). Historically, ambient particulate matter (PM) or air pollution contributed the
majority

of

these

inhaled

xenobiotic

particles.

Recently,

the

emergence

of

nanotechnology has led to the development of new foreign materials that may also be
associated with adverse cardiovascular effects. Engineered nanomaterials (ENM) are
compounds manufactured from various elements (e.g. carbon, cerium, titanium, and iron)
with specific size dimensions (<100 nm) that take advantage of unique characteristics
(e.g. surface area, and charge) (Borm and Muller-Schulte 2006).
The emergence of these novel xenobiotic materials is evident in the tremendous
surge of consumer products that contain ENM. In 2005, 212 products contained ENM
compared to the 1,868 products currently commercially available worldwide (Consumer
Products Inventory 2014). ENM are being utilized as anti-bacterial agents (e.g. silver, and
zinc), to create stronger and lighter equipment (e.g. carbon), to increase computer
memory storage while decreasing mass and size (e.g. carbon, silica), and to filter the air
or water (e.g. titanium and cerium). However, despite these many commercial
applications, perhaps the greatest potential of ENM is their ability to enhance medical
diagnostics and therapeutics (Hartmann et al. 2013; Janz et al. 2010). For example,
Celegene Abraxane is an ENM based cancer treatment approved by the Federal Drug
Administration (FDA). Celegene Abraxane directs chemotherapeutic drugs to breast
cancer cells. This drug targeting helps protect healthy cells from exposure to the toxic
drugs (Roco et al. 2010). This ability for ENM to have both therapeutic and diagnostic
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properties is termed theranostics (Kelkar and Reineke 2011). Other potential theranostic
applications for ENM include improving magnetic resonance imaging, stroke outcomes,
and decreasing the side effects associated with radiation treatment (Celardo et al. 2011;
Degnan et al. 2012; Kaittanis et al. 2012; Richards et al. 2011). The multitude of
applications and uses has expanded ENM exposure risk from (the traditional) inhalation
exposures to include other non-pulmonary exposure routes (e.g. intravenous and oral)
Furthermore, many of these products and ENM have not been extensively examined to
determine the health effects associated with their use, specifically the cardiovascular
effects (Roco et al. 2010).
The need for investigations into the unintentional effects of ENM is evident by the
formation of the National Nanotechnology Initiative (NNI) in the United States. This
committee is dedicated to supporting and funding nanotechnology research and
development (Subcommittee on Nanoscale Science et al. 2014). Currently, the NNI
intends to dedicate approximately 7% of their 2015 budget to evaluate the toxicological
outcomes of ENM, which is only fraction of the $4.2 billion that will be invested in the
development of new ENM (Subcommittee on Nanoscale Science et al. 2014).
The cardiovascular consequences of ENM exposure is an area in need of
additional research because disruptions in cardiovascular function can have significant
impacts on overall health (e.g. nutrient exchange, fluid balance, cardiac output, blood flow
regulation, and blood pressure). Optimal cardiovascular function is essential for whole
body homeostasis. Homeostasis is the ongoing maintenance of an internal physiological
environment for a given tissue or organ despite various external physiochemical changes
(e.g. metabolic demand, osmolality, temperature) (Woods and Ramsay 2007).
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Functionally, the cardiovascular system is responsible for providing nutrients (e.g.
oxygen) and removing wastes (e.g. carbon dioxide) from the body’s organs and is
involved in temperature regulation, fluid balance, and immune responses (Renkin 1984).
Many of these functions are finely controlled by the microcirculation (see Cardiovascular
Function). Microvascular responses (e.g. dilation and constriction) ensure an organ
receives the appropriate blood flow despite minute-to-minute changes in blood pressure
and/or metabolic demand (Zweifach 1984). Microvascular dysfunction may result in
homeostatic disruptions that, if unresolved, may contribute to the development of
systemic adaptations and/or pathological conditions (e.g. hypertension, cardiomyopathy,
and obesity) (Prewitt et al. 2002; Schwartzkopff et al. 1998). Therefore, it is pivotal to
understand if and how ENM affect microvascular function, especially if the full range of
ENM applications are to be realized.
This literature review will highlight the current outcomes that are associated with
different ENM exposures and draw attention to areas of ENM research that are presently
lacking. These aims will be achieved via three avenues. First, potential mechanisms and
current hypotheses for ENM will be presented. Due to the complexity and wide range of
effects, the proposed mechanisms will primarily focus on proposed sources of
microvascular dysfunction. Second, the major effects currently associated with ENM
exposure routes will be discussed. Finally, this review will highlight the areas within the
literature that are currently lacking for ENM evaluations.
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Engineered Nanomaterials
ENM possess physical and chemical characteristics that are distinctly different from
their larger counterparts. These properties allow them to be developed for a myriad of
applications ranging from medical theranostics to consumer electronics. The following
section will explain some of the physical and chemical properties associated with ENM
and the key applications that utilize these properties. Additionally, these ENM features
may also influence the observed effects that follow exposure, and will be discussed in
detail later (see sections Potential Mechanisms of Dysfunction and ENM Exposure
Routes and Specific Outcomes).
Shape
ENM can be created with many different shapes depending on the targeted
outcome and these shapes can influence their activity in vivo (Albanese et al. 2012). In
addition, many ENM have the capacity to exist in two or more shapes (e.g. carbon, cerium
and titanium) (Baker et al. 2008; Ji et al. 2012; Stapleton et al. 2012). The multitude of
shapes that ENM can exist in makes it near impossible to discuss them individually;
therefore, one potential characterization method that can be used is the aspect ratio of
the ENM. ENM that have a high aspect ratio are <100 nm in one dimension but are
typically several microns in another dimension. One general group of ENM with a high
aspect ratio are fibrous ENM. These ENM have a spear-like or rod-shaped appearance
(e.g. nanorods, nanotubes, nanowires) and commonly have a high tensile strength
(Demczyk et al. 2002). These factors make carbon nanotubes (CNT), an example of a
fibrous ENM, an ideal material for developing more durable fitness equipment while still
maintaining a light weight (Demczyk et al. 2002). Despite this commercial application, the
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high aspect ratio of some ENM has been associated with in vivo cellular damage. These
ENM are able to penetrate and damage cells indicating these ENM are less than ideal for
therapeutic applications (Mercer et al. 2010). Furthermore, these ENM have also been
compared to asbestos, due to their similar shape and inability to be cleared from the
lungs; therefore, it is reasonable to speculate that fibrous ENM may also be associated
with an increased risk of developing cancer (Pacurari et al. 2010).
ENM sheets also have high aspect ratios but may have different toxicities
compared to the fibrous ENM due to their difference in shape and surface area
(Stankovich et al. 2006). These ENM have high thermal conductivity and tensile strength
which makes them ideal to be used for the improvement of electronic devices (Stankovich
et al. 2006). Unfortunately, studies investigating the toxicity, both in vitro and in vivo, of
ENM sheets are extremely limited. Although there does appear to be some cellular toxicity
associated with these ENM, the extent and long-term damage is currently unclear (Mao
et al. 2013).
ENM that have low aspect ratios are similar in size in all dimensions and include a
variety of different shapes (e.g. spherical, triangular, and cuboidal). Research indicates
that low aspect ratio ENM may be easier for immune and non-immune cells to engulf
compared to fibrous ENM and therefore may result in less damage and cell death
(Johnston et al. 2012a; Limbach et al. 2005; Niu et al. 2011; Singh et al. 2010). This
potential for decreased cellular toxicity makes low aspect ratio ENM ideal candidates for
theranostic applications. The spherical shape of iron oxide nanomaterials allows them to
be encapsulated by red blood cells with limited toxicity to the red blood cells (Jung et al.
2012; Rahmer et al. 2013). This encapsulation, along with the improved imaging
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resolution and magnetic properties of these ENM, presents the potential of directing them
to particular locations and tracing blood flow distribution, which could help detect areas
of ischemia and tumors earlier (Jung et al. 2012; Rahmer et al. 2013). It appears that the
shape of ENM helps dictate their potential applications and toxicity; however, other factors
(e.g. size and valence state) are also vital for ENM development.
Size
The primary size of an ENM may also greatly influence its effects within the body.
The primary size is the average size of single ENM with at least one dimension being
<100 nm and changes in the primary size can greatly impact the toxicity of an ENM (Borm
et al. 2006; Suttiponparnit et al. 2011; Zhang et al. 2011). For example, silver
nanomaterials with a primary diameter less than 40 nm increased cellular permeability to
a greater extent than the particles over 40 nm (Sheikpranbabu et al. 2010; Trickler et al.
2010). The primary size of the ENM also affects the surface area. The immense increase
in surface area compared to larger particles is particularly important for the development
of ENM as an antibiotic. Silver and zinc nanomaterials are used in food packaging,
adhesive bandages, and medical devices because their high surface area creates a
barrier that decreases bacterial growth (de Mel et al. 2012; Ragaseema et al. 2012).
The ENM size can also affect interactions with itself and local environment. ENM
are typically suspended in solution preceding in vitro and in vivo exposures. Once in
solution, the ENM interacts with other nanomaterials to form larger masses. These
agglomerations form based on several parameters (e.g. primary ENM size, surface
charge, Van der Waals interactions, and hydrophobicity) and can be up to several microns
in diameter. Therefore, considerations for agglomerate size should be accounted for
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when assessing ENM effects, since large agglomerates may not be able to penetrate
deep into tissue or be remove by filtration and/or phagocytosis (Banerjee 2013; Gobre
and Tkatchenko 2013; Mercer et al. 2010).
Functional Groups
ENM are modified or functionalized by adding reactive chemical groups (e.g. lipids,
methyl groups, citrate, and drugs) during the engineering process. These compounds are
intentionally bound to the ENM to alter its purpose and/or function; thus adding another
complication to determining the effects of ENM. The addition these functional groups has
many purposes. First, coating the ENM with a biological compatible coating (e.g.
aluminum oxide and citrate) has been shown to decrease the toxicity associated with
some ENM (Shannahan et al. 2015; Taylor et al. 2014). The ability to control and alter the
toxicity of ENM is especially important as these nanomaterials are developed for
theranostic applications; because ultimately researchers want to eliminate the
unintentional effects associated with the pharmaceutical agents and the ENM.
Furthermore, if an ENM can be coated with another compound while still maintaining its
original function (e.g. electrochemical properties), then the hazard risks associated with
unintentional exposures would be greatly reduced.
From a therapeutic perspective, the addition of functional groups along with the
increased surface area could decrease the amount of a pharmaceutical agent needed to
treat a certain condition. Decreasing the dosage may also decrease the side effects
associated with the drug. In addition to the FDA approved ENM based drug Celegene
Abraxane, other ENM (e.g. gold, silver, and iron oxide) are being investigated for their
drug delivery potential due to the ability to add a variety of functional groups (Bae et al.
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2012; Johnston et al. 2012b; Prades et al. 2012; Roco et al. 2010; Zhang et al. 2013).
Iron oxide ENM can be functionalized with drugs, and a temperature specific coating (Yu
et al. 2010). Once injected, these ENM can be directed to a specific location (e.g. heart)
and then triggered to release pharmaceutical agents by increasing the local temperature
(e.g. heart) (Yu et al. 2010). It should be noted that although many of these ENM have
great therapeutic promise and may reduce side effects associated with known
pharmaceuticals, it is also important to analyze the potential off target effects that may be
associated with the ENM.
The addition of functional groups can also alter the charge associated with a
particular ENM, and can impact the in vivo effects due to alterations in the development
of a protein corona (Lundqvist et al. 2008). The protein corona is a “shell” that develops
on the ENM after it is exposed to serum or cell culture media. This ability to develop a
protein corona may be limited based on the charge of the ENM. Many circulating proteins
have a negative charge and therefore, would be attracted and potentially bind ENM with
the same charge. The formation of a protein corona may have divergent effects on ENM
toxicity and biological compatibility (Mao et al. 2013; Shannahan et al. 2015). On one
hand, the protein corona may increase the ENM toxicity thus hindering its use as a
therapeutic or antibacterial agent. On the other hand, the protein corona may hide or
mask an ENM from the body thus increasing its ability to interact with target organs and
its therapeutic potential. The unknown influences of the protein corona and functional
groups on ENM toxicity highlight need for additional research. Furthermore, it is
imperative that the in vivo interactions associated with the addition of functional groups
be understood to realize fully the potential of ENM.
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Valence State
The valance states of an ENM impact its use in various applications. The valance
state of an ENM helps determine its influence in oxidation-reduction (redox) chemistry.
Redox chemistry is the transfer of electrons from one chemical to another; therefore, ENM
that can undergo redox chemistry have an increased propensity to scavenge reactive
oxygen species (ROS) due to the unpaired electrons in these compounds. This potential
redox chemistry makes ENM with multiple valence states prime candidates for the
development of catalysts and anti-oxidants. Regardless of these promising applications,
ENM with multiple valence states also have the potential to generate ROS particuarlly if
the ENM cannot adiquitely quench ROS or transfer the elelctrons to other compounds.
Further research is needed to determine when and how these ENM either scavenge or
produce ROS in various environments (i.e. mechanical and biological).
When activated by ultraviolet radiation, titanium dioxide nanoparticles (TiO2 NP) act
as a catalyst and are thus being added to paints and building materials in an attempt to
decrease air pollution by reacting with ambient free radicals (Lv and Zhu 2013).
Additionally, cerium dioxide nanoparticles (CeO2 NP) are added to diesel fuel where it
acts as a catalyst to increase the combustion efficiency, thus, decreasing the large soot
emissions associated with diesel engines and ultimately contributing to decreased air
pollution (Cassee et al. 2011). Finally, from a therapeutic standpoint, CeO2 NP have antioxidant capabilities and may protect patients from some of the deleterious effects of
strokes and radiation treatments (Celardo et al. 2011; Kaittanis et al. 2012). Despite these
promising uses that are possible due to ENM redox chemistry, it is still largely unknown
how the valence state of an ENM affects its toxicity, especially in an in vivo model. Overall,
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a full understanding of the physical and chemical characteristics and their potential
alterations is essential as ENM continue to be developed and modified.
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Cardiovascular Function
The cardiovascular system significantly contributes to homeostasis and
disruptions in this system can have major implications in function and overall health
(Prewitt et al. 2002; Schwartzkopff et al. 1998; Woods and Ramsay 2007). Historically,
studies with PM have shown cardiovascular effects, which include cardiac and vascular
dysfunction (Brook 2008; Brook et al. 2010). The cardiovascular influences of ENM are
an area of active investigation, and due to their similar size, it is reasonable to speculate
the ENM may affect cardiovascular function in a matter similar to PM. The following
section will highlight basic cardiovascular physiology and some potential ENM effects.
Cardiac and Macrovascular Function
The cardiac cycle is a complex process that can be disrupted in a myriad of ways.
The known effects of ENM exposure on the cardiac cycle are extremely limited but some
studies have investigated the influences on stroke volume, electrical signaling, and heat
rate. In the simplest terms, the heart functions as a pump that forces blood out of the
ventricles and into the circulation (pulmonary and systemic) and the amount a blood that
is ejected from the heart during one cardiac cycle is the stroke volume. Silver
nanomaterial exposure has resulted in decreased stroke volume, which if unresolved
could have significant impacts on heart rate (HR), and cardiac output (Raieszadeh et al.
2013). Alterations in either of these parameters can lead to decrease organ perfusion,
structural remodeling in the heart and heart failure (Raieszadeh et al. 2013). Stroke
volume (and cardiac output) may also be altered due an increased afterload, which makes
it harder for the heart to ejection blood. One source of altered afterload is from decreased
compliance in the aorta and conduit arteries. This decreased compliance can be the result
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of arterial stiffening due to macrovascular dysfunction. Although ENM have not been
directly linked to arterial stiffening, ENM have been show to impair macrovascular
function, which if unresolved over time may contribute to decreased compliance in the
aorta and conduit arteries (Akbar et al. 2011; Wingard et al. 2011).
In addition to stroke volume, cardiac output can also be affected by changes in
HR. ENM exposure has resulted in decreases and increases in HR depending on the
ENM utilized in the study (Asharani et al. 2011; Park et al. 2013; Stampfl et al. 2011).
These alterations can be attributed to a variety of mechanisms and the exact mechanism
is currently unknown. One proposed mechanism for altered HR following ENM exposure
is changes in neural signaling (e.g. sympathetic and parasympathetic).

Sympathetic

stimulation results in the secretion of norepinephrine which binds to adrenergic receptors
(α and β) within the heart (Gordan et al. 2015). This results in an increase in HR,
contractility, and electrical conduction velocity, all of which lead to an increased cardiac
output. Parasympathetic stimulation results in the secretion of acetylcholine which binds
to muscarinic receptors in the heart (Gordan et al. 2015). In the heart, acetylcholine slows
the depolarization rate of cells within the sinoatrial node and decreases contractility in
cardiomyocytes, which results in a decreased HR. Given the small size and various
charges of ENM, it is reasonable to speculate that they may bind to various receptors.
Furthermore, ENM are capable of depositing in the heart (Stapleton et al. 2012; Yokel et
al. 2012). Based on this observation, these ENM may interact with neurotransmitter
receptors within the heart that could impair autonomic signaling and alter HR and cardiac
output.
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The influence of sympathetic and parasympathetic control within the heart is
partially regulated through baroreceptor and chemoreceptor activation. Baroreceptors are
located in the aortic arch, carotid arteries, atria and venae cavae (Gordan et al. 2015).
These mechanoreceptors respond to changes in pressure within these structures and
trigger autonomic signaling within the heart that results in increases or decrease in HR
and cardiac output. For example, if venous return was increased the mechanoreceptors
in the atria would be activated due to the increased blood volume. This would cause an
increase in HR due to increased sympathetic stimulation and sinoatrial node firing rate. It
has been speculated that ENM may altered blood pressure and venous return due to
alterations in cellular permeability and/or microvascular function (Nurkiewicz et al. 2009;
Trickler et al. 2010). These changes could affect baroreceptor activation and thus lead to
changes in autonomic control, HR and cardiac output.
The activation of peripheral chemoreceptors can also have a significant impact of
autonomic signaling. These receptors respond to changes in the level of oxygen, carbon
dioxide, and pH of the blood (Gordan et al. 2015). These factors can be influenced by
changes in respiration rate. ENM have been linked to the development of fibrosis and
may interfere with the signaling of C-fibers in the lung, which over time can lead to
changes in respiration rate (Hubbs et al. 2011; Lee 2009). Increases and decreases in
respiration rate can alter the oxygen and carbon dioxide levels of the blood, which would
lead to the activation of chemoreceptors in the aorta, carotid arteries, and brain and would
result in altered HR and cardiac output.
Disruptions in electrical signaling and autonomic regulation within the heart have
been speculated following ENM exposure, due to their similarity in size to PM. Heart rate
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variability (HRV) is the change in time between cardiac cycles and is typically used to
predict the risk of developing and/or detecting alterations in cardiac electrical signaling
(Shaffer et al. 2014). Both increases and decreases in HRV can indicate physiological
alterations in cardiac electrical signaling. Increases in HRV by indicate impaired cardiac
function (e.g. decreased cardiac out, and/or stroke volume); whereas decreases in HRV
are associated with the development of pathologies (e.g. cardiovascular disease) (Shaffer
et al. 2014). Changes in this parameter are largely unknown following ENM exposure;
despite this lack of research, there is evidence that xenobiotic particles can alter electrical
signaling both positively and negatively. Therapeutically, ENM have been used to treat
atrial fibrillation (Pok et al. 2014; Yu et al. 2010). Whereas PM has been linked to an
increase incidence of arrhythmic events and therefore it is reasonable to speculate the
ENM may also induce cardiac arrhythmias (Carll et al. 2015; Yu et al. 2010). Furthermore,
ENM have been shown to translocate from the lungs to the heart and brain (Mercer et al.
2011; Oberdorster et al. 2004; Stapleton et al. 2012). Due to this translocation and the
electrical conductance properties of some ENM, it is reasonable to speculate that ENM
could alter autonomic signaling within the heart through any one of the described
mechanisms. Despite these basic observations, the full extent of ENM exposure on
cardiac function is largely unknown, even though this understanding is essential for the
therapeutic development of ENM.
Microvascular Function
The microcirculation has important roles in contributing to blood pressure and flow
regulation within an organ (Renkin 1984; Zweifach 1984). This control helps to ensure
ample nutrient exchange and maintains proper waste removal, which contributes to
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overall homeostasis within an organ (Woods and Ramsay 2007). Briefly, the
microcirculation can be defined as the arterioles, capillaries and venules that are
contained within a specific tissue and each of these vessels have unique properties that
contribute to overall microvascular function. Due to the small size and homeostatic
importance of these vessels, and the even smaller size of ENM, there is a clear potential
for the microcirculation to be impacted by ENM exposure.
Resistance Arteries and Arterioles
The resistance vasculature significantly contributes to autoregulation within the
microcirculation by responding to various factors (e.g. chemical, neural, and physical).
Chemical mediators [e.g. carbon dioxide, nitric oxide (NO), and adenosine] interact with
both endothelial and vascular smooth muscle cells by binding to receptors and/or by
diffusing directly into the cell and initiating various signaling processes. In addition to
chemical stimuli, arterioles respond to autonomic signaling, both parasympathetic and
sympathetic (Khaisman 1975). Overall, sympathetic influences are greater that
parasympathetic innervations and therefore have a greater impact on microvascular
function by promoting vascular smooth muscle signaling cascades via norepinephrine
(Ohyanagi et al. 1991). Finally, physical forces (e.g. shear stress and pressure changes)
also contribute to maintaining microvascular function (Henrion 2005). These physical
forces can activate receptors on the endothelial cells that trigger signaling cascades
within the endothelial and vascular smooth muscle cells (Bevan and Laher 1991).
Regardless of the initial stimuli, the end physiological response is either
vasodilation or vasoconstriction of the arteriole that influences the overall homeostasis of
an organ. Furthermore, these factors do not work independently of one another but in
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concert to help regulate pressure, flow, and microvascular tone (Henrion 2005). ENM
have the propensity to alter any of the factors that contribute to proper arteriolar function.
Research has repeatedly shown the ENM exposure alters NO signaling; however, their
influences on other chemical mediators, sympathetic stimulation, physical forces, and
vascular tone are largely unknown (Du et al. 2013; LeBlanc et al. 2010; Nurkiewicz et al.
2009).
Capillaries
Capillaries are a single endothelial cell layer and are the primary sites of nutrient
exchange and waste removal. This function is primarily completed by filtration and
reabsorption, and can be summarized by Starling’s Law:
Jv= Kf [(Pc – Pi) – δ(πc – πi)].
This equation summarizes the net movement (Jv) of fluid out of the capillaries, and
establishes that this movement is dependent on hydrostatic [Kf (Pc – Pi)] and oncotic [δ(πc
– πi)] pressures within and outside of the capillaries. It is important to note that this net
movement of fluid varies based on vascular bed and cellular permeability within the
vascular ben (e.g. brain, kidneys, and skeletal muscle) (CRONE 1963). Due to their size,
ENM are capable of interacting with capillaries (Longmire et al. 2008). This interaction
could potentially disrupt permeability within the capillaries, and depending on the vascular
bed could have serious consequences on organ function (e.g. increased fluid in the brain,
or decrease filtration in the kidney).
Furthermore, filtration and reabsorption rates in the capillaries are influenced by
changes in hydrostatic and oncotic pressures, respectively (Spitzer and Windhager
1970). The net result of these pressure changes is the movement of fluid into and out of
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the extracellular space. Hypothetically, if circulating ENM form large agglomerates or
development an extensive protein corona it could alter the oncotic pressure within a
capillary, which would lead to changes in reabsorption. This altered reabsorption,
particularly in the kidney, may lead to alterations in fluid and solute balance (Imai and
Kokko 1972; Spitzer and Windhager 1970).
Venules
Venules are the primary site of inflammation in the microcirculation (Ley et al.
2007). This is the primary sight of inflammation due to the low endothelial to smooth
muscle ratio and the low flow environment. As leukocyte extravasation increases there
are changes in cellular permeability within the venules (Ley et al. 2007). This change in
permeability can lead to edema and may result in tissue damage if unresolved.
Additionally, this increased permeability may allow ENM to enter the interstitial space.
Here the ENM have the possibility of being trapped in the tissue or entering the lymphatic
system. Furthermore, due the low flow in the venules there is the potential that ENM may
agglomerate, and depending on the size of the agglomeration may impair blood flow and
increase tissue damage. The effects of ENM exposure on the lymphatic system and
venules are unknown and require additional investigation.
To date, very few studies examine disruptions in microvascular function despite its
central role in blood pressure and flow regulation. Additionally, disruptions in
microvascular function can lead to the development of long-term pathologies (e.g.
hypertension, diabetes, and cardiovascular disease) further emphasizing the need for
more ENM studies that have a primary emphasis on microvascular consequences.
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Potential Mechanisms of Dysfunction
There are three prominent hypotheses that attempt to explain the mechanism(s)
of action for ENM. These hypotheses were initially developed following PM exposure but
the basic mechanistic principles of these hypotheses are easily applicable to ENM.
Additionally, it should be noted that, due to the complexity of ENM and the physiological
outcomes and potential exposure routes, a single hypothesis would likely not adequately
explain the complex effects for a specific ENM. Therefore, it is reasonable to speculate
that a combination of these or other mechanism(s) are responsible for the microvascular
effects that follow ENM exposure.
Inflammation
This hypothesis states the ENM exposure triggers an innate immune response that
can have effects on multiple systems, including the microcirculation. This increase in
inflammation has been well documented for several ENM (e.g. TiO2 NP, CeO2 NP, and
CNT) and exposure routes (Nurkiewicz et al. 2008; Porter et al. 2010; Wingard et al.
2011). Specifically, CeO2 NP have been associated with increased mast cell activation,
and increased circulating leukocytes and neutrophils (Cho et al. 2010; Hirst et al. 2013;
Wingard et al. 2011). This change in inflammatory status is also associated with an
increase in circulating pro-inflammatory markers [e.g. vascular cell adhesion molecule-1,
intracellular adhesion molecule-1, interleukin-6 (IL-6), and tumor necrosis factor-α (TNFα)] (Duan et al. 2013; Kasper et al. 2011; Liu and Sun 2010; Napierska et al. 2013;
Srinivas et al. 2011). These cytokines and adhesion proteins initiate the translocation of
leukocytes into the interstitial space, which can disrupt endothelial and arteriolar function.
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Increased inflammation is also associated with an increase in ROS generation. In
addition to inflammation, ROS generation can by increased in a variety of ways including
the ENM themselves, mitochondrial dysfunction, increased nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase activity, increased myeloperoxidase (MPO)
and NOS uncoupling (Celardo et al. 2011; Ide et al. 2000; Nurkiewicz et al. 2009;
Nurkiewicz et al. 2011). ROS is capable of reacting directly with NO, which impairs its
ability to diffuse the smooth muscle. This reaction also results in the production of
nitrosative reactive species (e.g. peroxynitrate) that are associated with cellular damage
(Corbalan et al. 2012; Du et al. 2013). Regardless of the source of ROS, the outcome is
the same; the free radicals react with chemical messengers such as NO, resulting in
decreased NO bioavailability (LeBlanc et al. 2009; LeBlanc et al. 2010; Nurkiewicz et al.
2008; Nurkiewicz et al. 2009; Stampfl et al. 2011).
NO bioavailability can be altered by other mechanisms (i.e. increased MPO and
NOS uncoupling) in addition to changes in ROS. The level of available NO can be
decreased due to NO production via NOS uncoupling. It has been documented that
exposure to nano-sized particles can cause NO synthase (NOS) uncoupling, which leads
to an increase in superoxide and a decrease in NO production (Campen et al. 2003).
Secondly, increases in MPO can also result decreases NO bioavailability, by reacting with
NO (Nurkiewicz et al. 2009; Nurkiewicz et al. 2011). The decrease in the NO that is able
to react the VSM results in impaired arteriolar dilation. Furthermore, microvascular
dysfunction may also results due to changes in VSM intracellular signaling cascade
(Courtois et al. 2008). Under normal conditions, NO diffuses to the VSM where it activates
soluble guanylyl cyclase (sGC). The activation of sGC increases cyclic guanosine
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monophosphate (cGMP) and cGMP-protein kinase (PKG), which results in a decrease in
intracellular calcium and VSM relaxation. Disruptions anywhere within this signaling
cascade could result in an impaired VSM response to NO, which would contribute to
impaired vasodilation and microvascular dysfunction.
Microvascular reactivity can also be altered by the vascular influences of
arachidonic acid (AA) signaling mediated by cyclooxygenase (COX). This pathway can
result in the stimulation of several vasoactive agonists, including thromboxane and
prostacyclin. AA is unsaturated fatty acid that is stored within the cell membrane and is
release is regulated by phospholipase A2, which is influence by several factors including
inflammation, hormones, and chemical irritants [e.g. ENM (speculation)] (Miller 2006).
COX then mediates the metabolism of AA into endoperoxide (PGH2), which can be further
biotransformed into thromboxane A2 (via thromboxane synthase) and prostacyclin (via
prostacyclin synthase) (Wong and Vanhoutte 2010). It should be noted that PGH2 may
also increase vasoconstriction through the activation of thromboxane-prostanoid
receptors (Wong and Vanhoutte 2010). Thromboxane A2 (TXA2) also causes
vasoconstriction through these same receptors. The observed vasoconstriction is the
result of Rho kinase signaling within the VSM (Wong and Vanhoutte 2010). Prostacyclin
normally has the opposite effects of TXA2 and initiates VSM signaling via prostacyclin
receptors (Miller 2006). The binding of prostacyclin results in the activation of a G-protein
signaling cascade that increases cyclic adenosine monophosphate (cAMP) (Miller 2006).
This activation causes VSM dilation, through a NO-independent mechanism. The
production of TXA2 and prostacyclin can be modulated by changes in inflammation,
pathology and potentially ENM (Knuckles et al. 2011; Miller 2006; Zareba et al. 2009).
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Overall, the inflammation hypothesis is the most researched to date and many factors
associated with inflammation may contribute to observed microvascular alterations.
Direct Interaction/ Translocation
It has been well documented that ENM are capable of translocating from a target
organ (e.g. lungs) to other organs (e.g. spleen, liver, kidneys, brain, and blood) (Geraets
et al. 2012; Oberdorster et al. 2004; Reddy et al. 2010). It has been suggested that this
direct contact may cause alterations in cellular signaling and impact microvascular
function. In vitro studies have shown that ENM are capable of being internalized by
endothelial cells, cardiomyocytes, and epithelial cells (Shannahan et al. 2015; Singh et
al. 2010). This internalization can alter the function of the cell and could result in the
release of cytokines, increase ROS generation, and/or trigger apoptosis (Bauer et al.
2011; Hussain et al. 2012; Pacurari et al. 2012; Shannahan et al. 2015; Singh et al. 2010).
However, other studies have shown the direct particle contact does not alter vascular
inflammation or ROS generation (Colon et al. 2010; Gojova et al. 2009; Hussain et al.
2012). Furthermore, some studies have shown the certain ENM (e.g. CeO2 NP) are
actually capable of mimicking biological enzymes, specifically superoxide dismutase
(Heckert et al. 2008; Pagliari et al. 2012). These conflicting studies, sometimes utilizing
the same ENM, highlight the challenges in determining ENM toxicity and their
mechanism(s) of action. It also emphasizes the sensitivity and complexity of the ENM,
implying that a small change in the particle (e.g. size, charge, and/or valence state) may
have a significant impact on its toxicity.
Neural Alterations
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The third hypothesis suggested that microvascular dysfunction is a consequence
of altered autonomic regulation (Brook et al. 2011). Of the three hypotheses, neural
alterations are the least researched, potentially due to the complexity of assessing these
changes. Studies with PM, both human and animal, have documented reduced HRV and
increased HR after exposure (Magari et al. 2001; Rhoden et al. 2005; Tankersley et al.
2007). It reasonable to speculate that ENM may have similar responses and a few studies
have documented changes in HR following ENM exposure (Asharani et al. 2011;
Legramante et al. 2009). These overt cardiovascular changes may due to disruptions in
sympathetic and parasympathetic signaling; however, limited ENM studies have
documented changes in sympathetic alterations after exposure (Asharani et al. 2011; Kan
et al. 2013; Knuckles et al. 2011; Legramante et al. 2009). Autonomic alterations could
not only affect microvascular reactivity but also baroreflex function and HR. Furthermore,
ENM have been shown to deposit in the brain following exposure where they may
interfere with neuron signaling indicating that they make affect autonomic regulation
independent of specific cardiovascular effects, (Boyes et al. 2012; Chorley et al. 2014;
Kan et al. 2013; Oberdorster et al. 2004; Yokel et al. 2012). Additional studies are needed
to fully examine the neural influences of ENM.
Exposure Route Influences
The previous sections provided a general description of the three prominent
hypotheses for the effects of ENM; however, it is important to note that ENM exposure
route may have a significant impact on the prevalence of these mechanisms. Inhalation,
injection, and ingestion may result in differential exposure to specific cell types, which
could impact the dominance of various mechanisms (Figures 1A-C). Inhalation of ENM
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results in primary exposure to pulmonary cells (e.g. macrophages, epithelial cells, and cfibers), which trigger responses that are specific to the exposure route (see ENM
Exposure Routes and Specific Outcomes). Briefly, xenobiotic nanoparticle inhalation
is typically associated with pulmonary inflammation; however, not all ENM exposure
results in this type of inflammatory response (Nurkiewicz et al. 2004; Nurkiewicz et al.
2009; Toya et al. 2010). Pulmonary inflammation is driven by innate inflammatory
responses in the lungs (e.g. macrophage activation), which help to ensure foreign
substances are removed from the lungs. In theory, this inflammatory response results in
systemic inflammation due to cytokine signaling and/or spillover. Therefore, it is
reasonable to speculate that systemic inflammation may be a more prominent driving
force behind the toxicities associated with inhalation versus the other hypotheses,
particularly if initial pulmonary inflammation is present.
Ingestion exposure may result in the ENM passing through several organs (e.g.
stomach, intestine, and liver) prior to translocation to other distal organs (e.g. heart,
kidney, and brain). This multiple organ exposure may greatly influence the ENM physical
and chemical properties and may also significantly affect the exposure dose for specific
organs (Stapleton and Nurkiewicz 2014). Furthermore, this multiple organ exposure may
alter the influences of neural alterations (specifically within the enteric nervous system),
direct organ interaction, and systemic inflammation on the observed physiological effects.
Finally, intravenous injection exposures result in the ENM being directly exposed
to the vasculature. In theory, this would result in the highest level of direct endothelium
exposure especially since inhalation and ingestion require translocation for the
vasculature to be exposed to ENM (Stapleton and Nurkiewicz 2014). Furthermore, this
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presumably high level of direct ENM exposure may significantly impact the resulting
toxicities, specifically the cardiovascular effects. Overall, the exact influence on specific
exposure routes and the roles of the previously described mechanisms are unknown, but
this understanding is essential as these ENM are developed for various applications.
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ENM Exposure Routes and Specific Outcomes
Due to their diverse applications and fates, ENM have several potential exposure
routes. These exposures can be unintentional due to environmental bioaccumulation and
manufacturing or intentional due to specific uses. Once an exposure occurs, there is the
possibility for both positive and negative outcomes that may be local and/or widespread.
The following section will describe the most likely exposure routes and provide an
overview of the significant cardiovascular effects associated with each route.
Inhalation
The high occupational exposure risk and well document pulmonary effects of PM
have resulted in ENM (initially as a PM surrogate) being extensively studied in the
literature. ENM have an increased propensity to become airborne during manufacturing,
processing, disposal, destruction and/or recycling (Maynard and Kuempel 2005; Yu et al.
2013). There is also a growing potential for undesired community exposures as some
ENM have commercial uses such as fuel additives. The addition of CeO2 NP to diesel
fuel has been shown to significantly decrease the PM, carbon monoxide, and nitrogen
oxide emissions of diesel engine exhaust (Erdakos et al. 2014). These compounds have
been historically associated with the development of cardiovascular disease and their
decline may result in lower mortality and morbidity due to air pollution. This application
also results in a 25-fold increase in inhalable CeO2 NP but the biopersistence and health
effects of inhaled CeO2 NP are relatively unknown (Erdakos et al. 2014). Despite the
limited research on pulmonary CeO2 NP exposure it is reasonable to speculate, based
on the results from other ENM, that once inhaled CeO2 will remain in the lungs inducing

25

an inflammatory response and will likely be linked to systemic cardiovascular dysfunction
(LeBlanc et al. 2010; Ma et al. 2011; Pairon et al. 1995).
The airway distribution that results following ENM inhalation is size dependent.
The airway distribution for PM has been well established and can be applied to ENM
distribution as well (Driscoll et al. 2000; Stapleton et al. 2011). Course PM (>10 µm)
deposit in the tracheobronchial region of the lung and have a higher chance of being
cleared from the lungs. Fine PM (<2.5 µm) is capable to reaching the alveolar space and
deposits in both this region and the tracheobronchial region. Finally, ultrafine PM (<0.1
µm) and ENM, although capable to interacting with the entire airway, tend to be largely
distributed in the alveolar spaces of the lungs. This deposition has been associated with
not only increased inflammation but also the development of granulomatous lesions and
ultimately fibrosis (Ma et al. 2011; Mercer et al. 2011). However, the unwanted effects of
pulmonary ENM exposure are not limited to the lungs. In fact, current research reflects
that almost every physiological system may be affected by pulmonary exposure
(depending on the specific ENM being analyzed). CeO2 NP have been associated with
liver toxicity, whereas CNT are linked to an increased incidence of kidney disease
(Nalabotu et al. 2011; Reddy et al. 2010).
Experimentally, the effects associated with pulmonary ENM exposures can be
examined using two common methods: inhalation and instillation. Inhalation requires the
generation of an artificial environment, which aims to emulate an occupational setting. A
benefit of this technique is the animals are able to breathe normally while inhaling the
ENM, but the equipment and time needed for this technique can make it cost prohibitive
(Wong 2007). On the other hand, intratracheal instillation requires exposing the lungs of
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an anesthetized animal with ENM suspended in a solution (e.g. saline) via a ball tipped
needle (Wong 2007). This technique is also cost effective and is often referred to as the
“poor man’s inhalation” (Driscoll et al. 2000). Regardless, both these techniques result in
similar ENM distribution in the lung when equivalent concentrations are used (Henderson
et al. 1995).
In regards to the cardiovascular system, coronary damage from ischemia and
reperfusion injury can be aggravated in animals previously exposed to carbon nanotubes
(Katwa et al. 2012; Urankar et al. 2012). Pulmonary exposure also resulted in cardiac
inflammation and fibrosis that ultimately lead to the development of impaired myocardial
cells at 30 days post-exposure (Baky et al. 2013; Chuang et al. 2013). This exposure
route is also associated with extra-pulmonary arteriolar and aortic endotheliumdependent dysfunction (LeBlanc et al. 2009; LeBlanc et al. 2010; Nurkiewicz et al. 2008;
Nurkiewicz et al. 2009; Reddy et al. 2010; Stampfl et al. 2011; Stapleton et al. 2012;
Wingard et al. 2011). Finally, pulmonary exposure also resulted in impaired microvascular
function in pregnant and fetal rats (Stapleton et al. 2013). Overall, these effects highlight
the widespread influences of pulmonary ENM exposure. Furthermore, the majority of
pulmonary studies have indicated this exposure route is likely associated with enhanced
ENM toxicity, as few studies have indicated any positive benefits for this type of exposure.
Injection
Injection exposures are a growing concern particularly as ENM are being
developed for theranostic purposes. These applications would likely result in direct
administration of the ENM by various injection methods (e.g. intraperitoneal,
intramuscular, intravenous and subcutaneous), and each method may influence the ENM
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responses in unique ways. For example, intravenous injections result in the ENM being
directly exposed to the blood stream and vascular endothelial cells; whereas,
intramuscular injection would result in the muscle receiving the bulk of the ENM
concentration.
From a therapeutic perspective, injected ENM are associated with many positive
effects such as a treatment for cancer, stroke, and arrhythmias (Kim et al. 2012; Roco et
al. 2010; Yu et al. 2010). The injection of functionalized iron oxide nanomaterials have
had positive results when targeting them to a specific location in the heart to treat atrial
fibrillation (Yu et al. 2010). CeO2 NP have also displayed beneficial results when injected
into animals that have had a stroke or received radiation treatments (Kim et al. 2012;
Madero-Visbal et al. 2012).
Despite these positive results, there are still studies that highlight the negative
effects associated with injection exposures. ENM injection has resulted in decreased
mean arterial pressure, HR changes, and decreased tension in mesenteric arteries, which
may indicate potential microvascular dysfunction and sympathetic alterations (Akbar et
al. 2011; Asharani et al. 2011; Borak et al. 2007; Chen et al. 2013; Iversen et al. 2013;
Stampfl et al. 2011). Systemically, injection exposures have resulted in granuloma
development in the spleen and liver (Yokel et al. 2012). These organ effects indicate that
there may be complications when filtering and removing these ENM from the circulation.
Finally, ENM injection has produced alterations in vascular growth, which may or
may not contribute to potential microvascular disruptions. ENM that have vascular
endothelial growth factor (VEGF), a critical molecule needed for new vessel growth,
attached to them can be directed to the specific organs (e.g. heart) with the intention of
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promoting new vessel growth or angiogenesis (Zhang et al. 2012). Silver and gold ENM
have also been to shown to promote angiogenesis, both in vivo and in vitro, despite the
lack of VEGF attachment to the ENM (Kang et al. 2011). During periods of growth or after
severe organ damage (e.g. myocardial infarction), angiogenesis is a restorative process
that helps ensure the survival of a tissue; however, uncontrolled angiogenesis has been
associated with tumor growth. Therefore, the ability of injected ENM to modify
angiogenesis needs to be monitored and assessed to prevent any unwanted vascular
damage. Furthermore, the implications of ENM affecting angiogenesis during growth and
development are also unexplored.
Overall, the effects associated with injection exposures appear more promising
than pulmonary exposures. There are numerous studies that highlight the short-term
beneficial effects; however, the long-term consequences of injected ENM are largely
unknown (e.g. cancer development, cardiac failure, hypertension). Additionally, many of
the positive studies focus on one specific system or organ so the injected ENM influence
on other organs (outside the target organ) is also largely unknown. Finally, these results
add to the complexity of determining ENM toxicity and highlight the need to examine ENM
using multiple exposure routes.
Ingestion
A common route of drug administration is by oral exposure thus ENM used for
theranostics applications could be ingested. Intentional ingestion is not the singular way
that ENM can access the gastrointestinal tract. Unintentional or accidental exposure risks
are more prevalent due to food and water contamination. One source of this
contamination is ENM transferring from food packaging to the food and then being
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consumed. Additionally, the environmental biopersistence of ENM may also increase the
prevalence of accidental gastric exposures (Utembe et al. 2015). ENM are manufactured
under extreme conditions (e.g. temperature, pressure, and pH) that are not common in
the environment; therefore, the ENM do not typically degrade naturally. They can enter
the water and food supplies and thus create the potential for orally consuming ENM (Yokel
et al. 2012). Finally, inhalation exposures present an unexpected risk for unintentional
gastric exposure because some inhaled ENM are removed from the lungs by the
mucociliary escalator and then swallowed thus entering the gastrointestinal tract (Kreyling
et al. 2002).
One of the major complications with gastric exposure is determining the influence
of the various pH environments within the digestive tract. As ENM pass through the
gastrointestinal tract, they encounter multiple pHs for variable amounts of time. Initially,
the ENM are exposed to a highly acidic environment in the stomach, followed by a basic
environment in the intestines. It has been established that different pHs are capable of
biotransforming an ENM (Tok AIY et al. 2013). These potential alterations may impact the
ENM size and/or charge, and may modify how it interacts with various tissues. Another
experimental consideration is determining if the ENM is absorbed by the intestines or
excreted in the feces because this will impact the actual exposure dose for the ENM.
Following oral exposure, if large amount of the ENM are excreted in the feces the
concentration that was absorbed would be significantly lower, thus the effective
concentration would also be lower than initially estimated.
The intestines are specially designed to absorb nutrients and given ENM small
size it is possible they can also be absorbed (Brun et al. 2014; Jani et al. 1990). The
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mechanisms of potential absorption are unknown. Hypothetically, ENM may be absorbed
directly through various channels and/or between intestinal cells similar to many nutrients
(Stevens et al. 1984). Theoretically, ENM may also be encapsulated in phospholipids to
form a micelle (Yao et al. 2014). This micelle can then easily cross cellular membranes
(Yao et al. 2014). If the ENM are absorbed by either of these methods, they will first
interact with the liver increasing the potential for liver toxicity Therefore, liver toxicity
should be monitored following ingestion exposures. Current literature indicates that liver
toxicity following oral exposures is ENM dependent. Oral administration of CeO2 NP and
zinc oxide nanoparticles (ZnO NP) both result in liver deposition; however, CeO2 NP had
no observable toxic effects whereas, ZnO NP had an increased toxicity (Hirst et al. 2013;
Pasupuleti et al. 2012).
Finally, the known cardiovascular effects following ENM ingestion are extremely
limited. One study has associated the development of microscopic lesions on the heart
with ZnO NP, but the results with other ENM are unknown and requires further
investigation (Pasupuleti et al. 2012). Despite the limited studies, it appears that gastric
exposure results in the lowest toxicity of the exposure routes discussed herein. These
differences may be due to an increased clearance rate and volume in the digestive system
compared to the lungs (Stapleton and Nurkiewicz 2014; Yokel et al. 2014). Furthermore,
ENM may also be excreted with the feces, trapped in the liver, or chemically altered to
make them more biocompatible, all of which could significantly influence toxicity. Finally,
the toxicity associated with oral exposure may be delayed or limited to specific organs
(e.g. intestine and liver). These changes in toxicity may also be due to ENM being trapped
or reacting with bile acid, thus permitting them to be recycled and pass through the
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intestines and liver several times (Zwicker and Agellon 2013). Future studies will need to
address these potential influences on ENM toxicity to determine why the overall effects
are less severe for orally consumed ENM.
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Future Directions
The previous sections have attempted to address what is currently known about
ENM toxicity and the potential mechanisms for the observed effects. Despite this
research, there are still extensive knowledge gaps in the field of nanotoxicology (aside
from fully understanding the mechanism(s) of action). Specifically, federal regulations and
toxicological assessments are currently lacking and need to be established to realize the
full potential of ENM. Finally, many of the previously mentioned outcomes were assessed
either in vitro or in vivo in young, healthy models and the effects of ENM in models with
secondary confounding factors (e.g. disease) are largely known. Currently, $291 million
dollars are invested in ENM research which is mere fraction of the $4.2 billion invested
into the development of novel ENM (Subcommittee on Nanoscale Science et al. 2014).
For these future directions to be realized there must be an increased financial investment
in exploring the health effects of ENM particularly as the number of unique ENM continue
to grow.
Federal Regulations
Currently, there are few federal regulations that restrict the manufacturing and use
of ENM in consumer products. The Occupational Safety and Health Administration
(OSHA) require all workers to wear proper respiratory protection when handling ENM.
Additionally, OSHA recommends manufacturers restrict employee exposure to ENM
concentrations to no greater than 5 mg/m3 within an 8-hour workday. This is the standard
permissible exposure limit (PEL) used for all ENM; however, depending on the ENM
toxicity this exposure limit may be too low or too high. Recently, results from pulmonary
exposures to CNT and TiO2 NP have led to revised recommendations from the National
Institute for Occupational Safety and Health (NIOSH), which suggest the recommended
33

exposure limit (REL) should be decreased to 1 – 300 µg/m3 (Centers for Disease Control
and Prevention 13 A.D.). To date, these are the only ENM with defined REL for
occupational workers and these limits have not been accepted as a federal regulation by
OSHA. Additional toxicity studies are needed to determine if more or stricter federal
regulations are needed. These assessments need to not only include toxicity evaluations
but also examine potential off-target effects, delayed on-set effects (e.g. cancer risk), and
utilize multiple exposure routes.
Toxicity Assessments
In order for the safety and toxicity of ENM to be determined, toxicological studies
need to be completed. This includes establishing proper dose metrics, a dose-response
curve, temporal assessments, and clearance rates for specific ENM. Prior to any
toxicological assessments, it is essential to characterize properly the ENM (e.g. size,
shape, charge, valance state). Not only is ENM characterization good science but it is
pivotal for experimental reproducibility.
Dose Metrics
Prior to toxicological assessments, it is important to establish a proper dose
metric. The doses used for ENM studies can be calculated based on a variety of
parameters including surface area, mass, and particle number. The proper dose metric
for a study should be determined based on the aims of the individual study. It has been
suggested that for pulmonary exposures determining the surface are of the ENM may be
the best dose metric when establishing a dose-response relationship for the observed
effects; however, it has also been presented that particle number may be the best dose
metric for this exposure route (Oberdorster et al. 2005; Wittmaack 2007). Furthermore,
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these dose metrics may not be the most relevant when investigating the effects of nonpulmonary exposure routes. In this case, ENM mass may the proper dose metric, since
it is likely the more therapeutically relevant metric. Overall, it is currently unclear which
dose metric is correct, especially since the proper dose metric may be influenced by a
variety of factors (e.g. exposure route, and ENM physiochemical properties). This
ambiguity in the establishment of the most relevant dose metric highlights the need to
understand the in vivo alterations of ENM via multiple exposure routes.
Dose-Response Curve
The establishment of a dose-response curve provides important information
about the overall toxicity or safety of an ENM. One of the main goals is to establish the
ENM concentration where negative or toxic health effects are first observed. Additionally,
this dose also implies that any amount below that concentration would be considered a
safe exposure level with no off-target effects. Another important dose to establish is the
amount that causes the greatest amount of toxicity or damage known as the maximal
effect level. From a therapeutic standpoint, this can be considered the highest dose
before negative effects or deaths from the drug are observed. These parameters also
help to determine realistic exposure doses for experimental evaluations.
To date, very few dose-response curves have been established for ENM. The
dose dependent studies that exist focus primarily on pulmonary exposure and the
outcomes in the lung (Porter et al. 2010). Additionally, dose-response curves following
the injection of ENM are also limited and primarily focus on the therapeutic window for
the ENM of interest (Kim et al. 2012; Madero-Visbal et al. 2012). Although a dose-
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response curve was established, these limited studies did not investigate the off-target
toxicity of the ENM, an angle that warrants consideration in the future.
Temporal Assessments
Time course studies evaluate the health effects over a given period of time and
can range from seconds to several months or even years after initial exposure (Dorato
and Engelhardt 2005). The ability to determine the short (acute) and long-term (chronic)
effects of ENM exposure is critical because initial negative effects may resolve over time
and other new effects may emerge.
Like the establishment of a dose-response curve, few temporal studies have been
completed with ENM. Typically, only one time point is used to assess ENM toxicity. There
have been a few time course studies, which have examined microvascular dysfunction,
but the majority has focused on pulmonary toxicity (Porter et al. 2010; Stapleton et al.
2012). CNT exposure resulted in not only long-term pulmonary damage but also resulted
in microvascular dysfunction that was not resolved one week post-exposure (Porter et al.
2010; Stapleton et al. 2012). A simple time course study has also been completed with
instilled CeO2 NP that resulted in liver and spleen damage 90 days after initial exposure
indicating long-term damage (Yokel et al. 2012). Together, these results indicate that
many ENM may have long-term, off-target effects that need to be considered when
developing ENM for various applications, and the mechanisms of these effects are
currently unknown. Additionally, these limited studies also highlight the need for more
temporal studies that not only focus on off-target damage but also focus on the
microvascular impact. Furthermore, these temporal studies are critical especially
because the development of some diseases (e.g. cancer, hypertension, and diabetes)

36

are significantly delayed from time of initial exposure. This risk for ENM is currently
unknown, but due to some ENM having similarities to asbestosis and silica, both known
to increase cancer risks, it is reasonable to speculate that ENM may have similar risks
(Pacurari et al. 2010). Furthermore, the influences of the proposed mechanisms (see
Potential Mechanisms of Dysfunction) may also change overtime. Acute exposure
may result in an initial increase in inflammation, which over time can decrease or increase;
however, chronic exposure may result in more pronounced effects from neural or direct
ENM interactions due to potentially increased translocation of the ENM. Similar to other
time course influences, the impact of these mechanisms and time are unknown and
warrant further investigation.
Clearance Rates
Finally, toxicity assessments need to take into account ENM clearance from the
body. ENM accumulation within a tissue may affect the organ’s function (e.g. lung, liver,
and kidney) and ENM clearance can usually be assessed by monitoring removal from the
body or translocation to specific organs (Geraets et al. 2012; Hirst et al. 2013; Zhu et al.
2009). Urine and fecal collections typically are used to evaluate ENM clearance from the
body (Hirst et al. 2013). If tissue accumulation is occurring, it is essential to identify the
organs where the ENM are located using various microscopy techniques and monitoring
differences in tissue weight (Stapleton et al. 2012; Yokel et al. 2012). ENM clearance also
varies based on exposure route and dose; ENM given by pulmonary instillation are not
cleared as rapidly as ENM given by oral or injection exposure routes (Hirst et al. 2013;
Mercer et al. 2010; Porter et al. 2010).
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Overall, monitoring ENM clearance is needed because if the ENM is trapped in an
organ for a long period of time, then the toxicity to that organ can change versus a more
transient exposure of the same organ (Yokel et al. 2012). Furthermore, the clearance of
an ENM can influence the effective dose. Regardless of the existence of several studies
that assessed the clearance of ENM, these assessments are largely absent in the
literature despite the importance of this toxicological evaluation (Mercer et al. 2010; Yokel
et al. 2012).
Confounding Influences
Another area where more ENM research is needed, is determining the outcomes
associated with exposure in the presence of various pathologies. There is the potential
for both positive and negative outcomes when exposure is combined with a pre-existing
condition. ENM exposure during stroke has been shown to be beneficial by decreasing
the ischemic area (Kim et al. 2012). CeO2 NP have also been shown to reverse some of
the negative effects (decreased oxidative stress) associated with cigarette smoke and
diesel exhaust exposure (Cassee et al. 2012; Niu et al. 2011). From the perspective of a
negative influence, TiO2 NP increased plaque progression in animals with atherosclerosis
indicating these ENM may enhance the progression of this disease (Mikkelsen et al.
2011). These conflicting results highlight the need to test various ENM in the presence of
various conditions, specifically diabetes, hypertension, and obesity. These conditions are
increasing in the general population but the influence they have on ENM toxicity is largely
unknown and warrants additional investigations.

38

Purpose of Dissertation
An ENM that holds great consumer and theranostic potential is CeO2 NP. These ENM
are currently being used in commercial applications as a glass polish and a fuel additive.
As a fuel additive, CeO2 NP increases the combustion efficiency of diesel fuel, which
decreasing the large soot emissions commonly associated with these engines. To date,
there are no federal regulations that limit the use of cerium and it has been predicted that
ambient CeO2 NP could increase by 25-fold in the next few years. This increase would
result in an increased inhalation risk, both occupationally and communally. Pulmonary
exposure to CeO2 NP has resulted in inflammation and granuloma formation. Other
studies have shown that pulmonary exposure to ENM may result in extra-pulmonary
microvascular dysfunction; however, the microvascular effects of this ENM are largely
unknown. Therefore, it is reasonable to speculate that pulmonary CeO2 NP exposure will
also result in microvascular alterations.
From a therapeutic perspective, CeO2 NP have the ability to act as an anti-oxidant
and may be able to decrease elevated levels of ROS that are associated with various
pathologies. Currently, the treatments for stroke are extremely limited and there is a
pressing need to develop additional therapeutics for this disease. In regards to radiation
treatment, there are also limited drugs available to combat the tissue damage associated
with this often live-saving treatment. Therefore, the development of ENM that improve the
outcomes of these two conditions is pivotal. CeO2 NP are being investigated to treat
stroke and protect against radiation damage by decreasing the level ROS and thus
decreasing the tissue damage associated with these conditions. In addition to stroke and
radiation, CeO2 NP have been shown to decrease the detrimental effects associated with
diesel exhaust and cigarette exposure; however, it is currently unclear if CeO2 NP can
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improve the outcomes of other pathologies (e.g. hypertension). These applications also
introduced the need to assess the health effects via alternate exposure routes.
Therefore, the present studies were designed to evaluate 1) the microvascular effects
of CeO2 NP given by different exposure routes, 2) establish a dose-response curve for
each exposure route, 3) begin to provide mechanistic explanations for the observed
microvascular effects and 4) examine CeO2 NP anti-oxidant potential in a hypertensive
model. The findings of these studies will help improve our understanding of the toxicity of
CeO2 NP and will provide valuable information that is needed for its continued theranostic
development.
The specific aims of the studies are listed below.
Study 1
Sprague-Dawley rats were intratracheally instilled with a range of CeO2 NP doses
(10 - 400 µg). 24 hours post-exposure mesenteric and coronary arterioles were assessed
using the isolated microvessel technique. This preparation provided an understanding of
the arteriolar alterations (e.g. endothelium-dependent and endothelium -independent)
that follow CeO2 NP exposure. Furthermore, this study established a dose-response
curve for pulmonary exposure. Finally, the potential functional differences between
vascular beds were analyzed.
Study 2
Sprague-Dawley rats were intratracheally instilled, intravenously injected, or
gastrically gavaged, with a range of CeO2 NP doses (50 - 900 µg). 24 hours postexposure mesenteric arterioles were assessed using the isolated microvessel technique.
This preparation provided an understanding of the arteriolar alterations (e.g. endotheliumdependent and endothelium-independent) that follow CeO2 NP via alternate exposure
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routes. Furthermore, this study established a dose-response curve for intravenous and
gastric exposures. Finally, potential mechanism(s) of action for all three exposure routes
were analyzed.
Study 3
Spontaneously hypertensive (SH) and Wistar-Kyoto rats were intravenously
injected with 100 µg CeO2 NP. 24 hours post-exposure mesenteric arteriolar reactivity
was assessed using intravital microscopy. This study examined the in vivo anti-oxidant
potential of this ENM by determining if microvascular function is improved in the SH rat
after exposure. Additionally, vascular levels of oxidative stress were analyzed in both
animal lines using isolated arterioles intraluminally infused with dihydroethidium. Overall,
this study provided information, which helped to determine CeO2 NP influences in the
presence of a previously existing pathology, and helped to further establish its potential
as a therapeutic.

41

Figure Legends:
Figure 1 Potential Cellular Interactions and Outcomes of ENM Exposure Routes: A:
Inhalation B: Injection C: Ingestion
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Abstract:
Cerium dioxide nanoparticles (CeO2 NPs) are an engineered nanomaterial that
possesses unique catalytic, oxidative, and reductive properties. Currently, CeO2 NPs are
being used as a fuel catalyst but these properties are also utilized in the development of
potential drug treatments for radiation and stroke protection. These uses of CeO2 NPs
present a risk for human exposure; however, to date no studies have investigated the
effects of CeO2 NPs on the microcirculation following pulmonary exposure. Previous
studies in our laboratory with other nanomaterials have shown impairments in normal
microvascular function after pulmonary exposures. Therefore, we predicted that CeO2 NP
exposure would cause microvascular dysfunction that is dependent on the tissue bed and
dose. Twenty-four hour post exposure to CeO2 NPs (0-400 µg), mesenteric and coronary
arterioles were isolated and microvascular function was assessed. Our results provided
evidence that pulmonary CeO2 NP exposure impairs endothelium-dependent and independent arteriolar dilation in a dose-dependent manner. The CeO2 NP exposure dose
that causes a 50% impairment in arteriolar function (EC50) was calculated and ranged from
15-100 µg depending on the chemical agonist and microvascular bed. Microvascular
assessments with acetylcholine revealed a 33-75% reduction in function following
exposure. Additionally, there was a greater sensitivity to CeO2 NP exposure in the
mesenteric microvasculature due to the 40% decrease in the calculated EC50 compared to
the coronary microvasculature EC50. CeO2 NP exposure increased mean arterial pressure
in some groups. Taken together these observed microvascular changes may likely have
detrimental effects on local blood flow regulation and contribute to cardiovascular
dysfunction associated with particle exposure.
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Introduction:
Engineered nanomaterials (ENM) have recently emerged both as integral
components in manufacturing, and as innovative materials to address challenges in
therapeutics and diagnostics, ranging from drug delivery to imaging. However, answers to
questions regarding ENM toxicity remain far behind production. ENM are defined as a
homogenous mixture of particles that are less than 100 nm in size in at least one direction,
and are engineered to take advantage of unique physical characteristics displayed at this
size (1). Additionally, the Environmental Protection Agency (EPA) recently recognized that
ENM have different inherent characteristics and should be considered distinctly different
from their larger counterparts of the same composition (2).
ENM are being developed specifically for use in food, drug delivery, and numerous
industrial and household products (3;4). Cerium dioxide nanoparticles (CeO2 NPs) have
been implemented for public use, in the United States and Europe, widely as a diesel fuel
additive (5). In this regard, CeO2 NPs act as a catalyst to increase combustion efficiency,
which decreases the large soot emissions commonly associated with diesel engines (5;6).
This use holds great promise in decreasing particulate matter (PM) air pollution emissions
that have been historically associated with increases in cardiovascular morbidity and
mortality; however, because CeO2 NPs is released in emissions, a widespread inhalation
hazard exists (1). Furthermore, aerosolized nano-CeO2 poses a serious environmental
hazard as well. Although the half-life of CeO2 NPs in water or soil is unknown, it is
reasonable to speculate that CeO2 NPs will remain in the environment for an indefinite
amount of time due to the extreme conditions needed for degradation (7). Additionally,
CeO2 NPs has been shown to be biopersistent in the body and can remain in the lungs for
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at least 15 years (8-10). This evidence supports the concept that CeO2 NPs may potentially
enter the water supply or food chain, ultimately posing an additional human exposure risk.
Aside from its catalytic properties, nano-CeO2 also possesses the ability to drive
reduction- oxidation (redox) chemistry (11). CeO2 NPs exists in two valence states (Ce3+
and Ce4+) and shifts between these states by reacting with free radicals such as superoxide
(11;12). Researchers are taking advantage of this shift between valence states and using
CeO2 nanoparticles to help reduce cellular damage from radiation therapy and strokes
(13;14).
Due to its unique properties, CeO2 NPs have the potential to enter the body by
multiple exposure routes (inhalation, injection, and ingestion), and may therefore pose a
threat to human health (15). CeO2 nanoparticle toxicity research has focused essentially
on pulmonary exposures. Pulmonary CeO2 nanoparticle exposure has been shown to
increase neutrophils and eosinophils and stimulate granuloma formation in the lungs, as
determined by the increase in cellular damage (16;17). Additionally, there has been
increased alveolar macrophage activation and death after pulmonary CeO2 NP exposure
(16).
The microcirculation needs to be thoroughly examined following ENM exposure
because normal function at this critical level of the vasculature contributes significantly to
total peripheral resistance and blood flow distribution. Furthermore, many pathological
conditions (e.g. hypertension and diabetes) initially manifest in the microcirculation (18;19).
The microcirculation is broadly defined as the arterioles, capillaries and venules contained
within an organ. The arterioles are primarily responsible for resistance, thereby distributing
blood flow and decreasing pressure to a level that does not cause damage to downstream
capillaries (20;21). The arterioles respond to a variety of chemical, mechanical, and
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metabolic stimuli; if these resistance vessels do not respond appropriately to these factors,
a change in total peripheral resistance may occur that could alter mean arterial pressure
(MAP), blood flow distribution and/or cause downstream over or under perfusion (19). The
impact of CeO2 NP exposure on cardiovascular function is poorly understood. This ENM
has shown signs of liver toxicity, as well as vascular impairment in the aorta; however, to
date, no studies have focused on identifying the impact of pulmonary CeO2 nanoparticle
exposure on systemic microvascular function (22;23).
Previous work in our laboratory has determined that pulmonary ultrafine titanium
dioxide (TiO2) exposure causes systemic microvascular dysfunction, despite relatively
minor lung inflammation; however, pulmonary inflammation following CeO2 NP exposure
is greater than that reported for ultrafine TiO2 at similar doses (16;24;25). Based on these
differences in inflammation, we hypothesize thatCeO2 NP exposure will impair
microvascular function to a greater degree than that of ultrafine TiO2. The goals of this
study were: (1) to examine the effects of pulmonary CeO2 NP exposure on mesenteric and
coronary arterioles and (2) to identify a dose response curve. These two microvascular
beds were selected to determine if there was a difference in microvascular function after
ENM exposure between microvascular beds with high (coronary) and low (mesentery)
metabolic demand. Because the metabolic state of a given tissue may influence the
ultimate impact of any toxicant associated mechanism, it is important to study divergent
microvascular beds.
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Methods and Materials:
Cerium Dioxide Nanoparticle (CeO2 NP) Production and Characterization:
CeO2 NP powders were synthesized by a hydrothermal process (26). Cerium (IV)
ammonium nitrate (99+% Alfa Aesar) was added to de-ionized water (H2O) and this
solution was added drop-wise into a basic solution of tetramethylammonium hydroxide
pentahydrate (TMAOH) and de-ionized H2O. The pH of the dispersion was altered to ~10.5
with ammonium hydroxide and was maintained throughout the reaction. The dispersion
was placed in a 300 ml Autoclave Engineers EZE-Seal autoclave at 240˚C for 1 h. Once
removed from the autoclave vessel, the dispersion was placed into a centrifuge and the
liquid was removed and replaced with ethanol. After the washing step, the dispersion was
dried at 60˚C overnight and sieved through a 200 mesh screen for characterization. The
synthesized CeO2 nanoparticles displayed an average surface area of 81.36 m2/g
measured by Micromeritics ASAP 2020. The average agglomerate size in Normosol
(isotonic saline) and 5% fetal bovine serum (FBS) was determined using dynamic light
scattering (DLS) technique using a Malvern Zetasizer version 7.01.
The chemical states on the surface of the nanomaterials from the Ce 3d orbital, C
and O 1s orbitals were characterized by x-ray photoelectron spectroscopy (XPS, PHI 5000
Versaprobe XPS). The x-ray source was operated at 15 kV and 25 watts using Al Kα
(1486.6 eV) radiation. A 0.05 eV step was used for the detailed scan. All coatings surfaces
were cleaned prior to spectral analysis to remove atmospheric and post-depositional
contamination with Argon ion sputter cleaning at 2 kV accelerating voltage for 30 sec. The
analysis chamber pressure was maintained at (~10-11 Torr) during the measurement. The
nanomaterial morphology and agglomerate size was imaged using a JEOL JEM-2100 High
Resolution Transmission Electron Microscope (TEM).
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Experimental Animals and Exposure: Male Sprague-Dawley rats (8-11 weeks
old) were purchased from Hilltop Laboratories (Scottdale, PA). The rats were housed at
the National Institute for Occupational Safety and Health (NIOSH) or West Virginia
University animal facilities. The rats were housed in ventilated cages, under controlled
humidity and temperature, with a 12 h light/dark cycle and food and water were provided
ad libitum. The animals were acclimated for at least 2 days prior to use. All procedures
were approved by the Animal Care and Use Committees at West Virginia University and
NIOSH.
CeO2 Nanoparticle Exposure: For the stock solutions, the dry powder was weighed
and added to 10 ml of saline (Normosol) with 5% (FBS) to reduce agglomeration. The CeO2
NPs were vortexed for 5 minutes and then sonicated on ice for another 5 minutes. Rats
were lightly anesthetized with isoflurane gas (5% induction) and intratracheally instilled with
a 300 µl bolus dose of CeO2 NPs stock solution to achieve the following final doses: 0, 10,
50, 100, 200, and 400 µg. Rats were monitored after instillation until they regained
consciousness. All animals recovered for 24 h prior to bronchoalveolar lavage (BAL) or
isolated microvessel experiments. Previous studies have shown that the saline and FBS
vehicle do not induce mechanical artifacts in terms of BAL and systemic microcirculation
in control rats (25;27).
Pulmonary Inflammation Assessment: A subset of 8 rats per dose (0, 10, 100,
and 400 µg of CeO2 NPs) were euthanized with sodium pentobarbital (≥ 100 mg/kg,
intraperitoneal injection). The trachea was cannulated and BAL was performed using icecold Ca2+/Mg2+ -free phosphate buffered saline (PBS). The first lavage (6 ml) was kept
separate from the rest of the lavage sample. Subsequent lavages used 10 ml PBS until 40
ml lavage fluid was collected. The samples were centrifuged at 650 x g, 5 min at 4°C. The
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supernatant from the first lavage was saved for lactate dehydrogenase (LDH) and albumin
assays. The pooled cells were resuspended in HEPES-buffered medium and cell counts
were determined with an electronic cell counter equipped with a cell-sizing attachment.
Cytospin Preparation: 1x106 BAL cells [both alveolar macrophages (AM) and
polymorphonuclear leukocytes (PMN)] in 200 µl HEPES-buffered medium were prepared
with a cytocentrifuge. The cytospin preparations were stained with modified Wright-Giemsa
stain and cell differentials were determined by light microscopy. The differential cell counts
were calculated by multiplying the total cell count by the cell differential percentage
obtained from the cytospin preparations. LDH Activity and albumin protein assays: LDH
and albumin measurements were taken the same day as the BAL was performed. The
techniques have previously been described (28). Briefly, the LDH activity was used as a
marker of cytotoxicity and was measured by monitoring the LDH driven oxidation of
pyruvate coupled with the reduction of nicotinamide adenine dinucleotide at 340 nm using
a commercial assay kit (Roche Diagnostic Systems, NJ). The concentration of albumin was
monitored as an indicator of the cellular integrity. This measurement was made with a
commercially available kit (Sigma Chemical Co., MO) and was based on albumin binding
to bromcresol green and measuring the color change at 628 nm. AM Chemiluminescence:
Resting AM chemiluminescence was identified by incubating 1 X106 AM /mL at 37°C for
20 min, followed by the addition of luminol (0.08 µg/mL) and then the chemiluminescence
was measured. To identify zymosan-stimulated chemiluminescence, unopsonized
zymosan (2 mg/mL) was added immediately prior to measurement. All measurements were
made with an automated luminometer at 390- 620 nm for 15 min
MAP Acquisition and Microvessel Preparation: Rats were anesthetized with isoflurane
gas (5% induction, 3-3.5% maintenance). The animals were placed on a heating pad to
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maintain a 37°C rectal temperature. The trachea was intubated to ensure an open airway
and the right carotid artery was cannulated to acquire MAP. The MAP will be recorded via
a pressure transducer and recorded by PowerLab830. The heart and/or the mesentery
were removed and placed in a dissecting dish with physiological salt solution (PSS)
maintained at 4°C. Coronary arterioles from the 3rd-5th branch off the left anterior
descending (LAD) artery, and 4th or 5th order mesenteric arterioles were isolated,
transferred to a vessel chamber, cannulated between two glass pipettes, and tied with silk
sutures in the vessel chamber (Living Systems Instrumentation, Burlington, VT). The
chamber was superfused with fresh oxygenated (5% CO2/ 21% O2) PSS and warmed to
37°C. Arterioles were pressurized to 45 mm Hg (coronary) or 80 mm Hg (mesenteric) using
a servo control system and extended to their in situ length (29;30). Internal and external
arteriolar diameters were measured using video callipers (Colorado Video, Boulder, CO).
Arteriolar Reactivity: Arterioles were allowed to develop spontaneous tone. After
equilibration, various parameters of arteriolar function were analyzed. Endotheliumdependent dilation: The arterioles were exposed to increasing concentrations of
acetylcholine (ACh, 10-9-10-4 M) or A23187, a Ca2+ ionophore (10 -9-10

-5

M) added to the

vessel chamber. Endothelium-independent dilation: Increasing concentrations of either
sodium nitroprusside (SNP, 10-9-10-4 M) or a spontaneous NO donor, spermine NONOate
(SPR, 10-9-10-4 M) were used to assess arteriolar smooth muscle responsiveness.
Myogenic Responsiveness: Myogenic responses were analyzed by increasing the
intraluminal pressure by 15 mm Hg increments from 0-90 mm Hg for coronary arterioles
and 0-105 mm Hg for mesenteric arterioles. Arteriolar Vasoconstriction: The arterioles were
exposed to increasing concentrations of phenylephrine (PE, 10-9-10-4 M) or serotonin (5HT, 10 -9-10 -4 M). The steady state diameter of the vessel was recorded for at least 2 min
69

after each dose. After each dose curve was completed, the vessel chamber was washed
to remove excess chemicals by carefully removing the superfusate and replacing it with
fresh warmed oxygenated PSS. After all experimental treatments were complete, the PSS
was replaced with Ca2+-free PSS until maximum passive diameter was established. All
arterioles with ≤ 20% spontaneous tone or ≥ 150 µm were not analyzed.
Equations and Statistics: Data are expressed as means ± standard error. Spontaneous
tone was calculated by the following equation: Spontaneous tone (%) = [(DM - DI)/ DM] x
100, where DM is the maximal diameter and DI is the initial steady state diameter recorded
prior to the experiment. Active responses to pressure were normalized to the maximal
diameter using the following formula: Normalized Diameter = DSS/DM, where DSS is the
steady state diameter recorded during each pressure change. The experimental responses
to ACh, A23187, SNP, and SPR are expressed using the following equation: Diameter
(percent maximal response) = [DSS-DCon)/ (DM- DCon)] x 100, where DCon is the control
diameter recorded prior to the dose curve, DSS is the steady state diameter at each dose
of the curve. The experimental response to PE and 5-HT are expressed using the following
equation: Diameter (percent maximal response) = - [DCon-DSS)/ DCon] x 100. Wall thickness
(WT) was calculated from the measurement of both inner (ID) and outer (OD) steady state
arteriolar diameters at the end of the Ca2+ free wash using the following equation: WT=
(OD- ID)/ 2. Wall-to-lumen ratio (WLR) was calculated using the following equation: WLR=
wall thickness (WT)/ ID. Point-to-point differences in the dose response curves were
evaluated using two-way repeated measures analysis of variance (ANOVA) with a
Bonferroni post-hoc analysis when significance was found. The slopes of the dose
response curves were determined through a nonlinear regression. The BAL data, animal
characteristics, vessel characteristics, and dose response curve slopes were analyzed
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using a one-way ANOVA with a Bonferroni post-hoc analysis when significance was found.
The concentration at which a 50% impairment in function (EC50) was determined using a
four parameter logistics analysis. All statistical analysis was completed with GraphPad
Prism 5 (San Diego, CA) and SigmaPlot 11.0 (San Jose, CA). Significance was set at p <
0.05.

71

Results:
CeO2 Nanoparticle Characteristics
Figure 1A displays the low magnification TEM image of the particles; the
micrograph shows that the dried synthesized suspension leads to a highly agglomerated
state. The higher magnification micrograph (Figure 1B) shows that the primary CeO2
nanoparticles were ~4 nm in average size with a spherical morphology and a calculated
surface area of 81.36 m2/g. The average agglomerate size in normosol and FBS stock
solution was measured to be 191±77 nm with a wide Gaussian distribution (Figure 1C).
Initially, XPS data was collected for the 3d orbital photo-electron line for Ce between
870-930 eV (not shown). The deconvolution of the Ce 3d orbital data is very complex due
to the multiple states that exist for the Ce 4f orbital level occupancy (31). Therefore, the
distinction of the Ce3+ and Ce4+ contribution is difficult to extract with the overlapping Ce
3d orbital features of each Ce ion (7). An indirect method to separate the presence of Ce3+
and Ce4+ is through the analysis of the O ion through the O 1s orbital XPS spectra. It is
known that the binding energy of O to Ce3+ is approximately 1-2 eV higher than the binding
energy to Ce4+ (7;32). Before completing the O 1s orbital analysis, an XPS scan was
completed between 281-294 eV to determine the state of the residual C, and more
importantly, the presence of C bonded to O. As displayed in the XPS graph (Figure 2A),
carbon has four different chemical states on CeO2 NPs surface; the spectra identified C
(284.7 eV), C-O (alcohols and carboxyl at 286.4 eV and 288.4 eV, respectively) and C-N
(287.8 eV) remaining on the dried surface (33), which may be the result of surface reactions
with the ammonia additives, washing process, and saline suspension in this work. This
data provides evidence that the O 1s orbital spectra will display a contribution of the C-O
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bonding, and this knowledge will need to be considered in the deconvolutions of the O 1s
orbital scan.
Figure 2B displays the XPS scan of the O 1s orbital scan between the binding
energies of 525-538 eV. The data graph displays that oxygen has five different chemical
states on the CeO2 NPs surface. As discussed for Figure 2A, the oxygen is bound within
alcohols and carboxyls, but the data also provides evidence that a portion of the oxygen is
also bound within various nitrates (~534.50 eV for O 1s orbital in nitrates). It is important
to note that nearly 50% of O-2 measured was bound within alcohols, carboxyls and nitrates
on the CeO2 NPs surface. The remaining part of the O-2 spectra was bound to Ce. By
including these contributions within the analysis, the measured XPS spectrum provides
evidence that the nanomaterial surface consists of ~19% Ce3+ (530.6 eV for O 1s orbital
Ce2O3) and ~81% Ce4+ (529.1 eV for O 1s orbital in CeO2).
Group Characteristics
There were no significant differences found in body weight, age, or heart weight
when comparing the control and exposed groups (Table I). A significant difference was
found between the 10 µg and 100 µg exposure groups for MAP (Table I). There may also
be a significant difference between the control group and the 100 µg group (p=0.055) which
warrants further investigation into the changes in MAP after CeO2 NP exposure.
Pulmonary Inflammation
BAL was performed to assess pulmonary inflammation post CeO2 NP exposure.
There was a significant increase in LDH 24 h post instillation in the 100 and 400 µg CeO2
NP exposure groups (Figure 3A). This indicated an increase in cytotoxicity; however, there
was no change in albumin indicating the epithelial-endothelium gas exchange barrier was
intact (Figure 3B). The activation of AM was also measured through zymogen stimulated
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chemiluminescence. There was a significant increase in the activated AM after exposure
to 100 and 400 µg CeO2 NPs (Figure 3C). Finally, there was a significant increase in PMNs
in the groups exposed to the two highest doses of CeO2 NPs (Figure 3D). Taken together,
these data provide evidence that dose-dependent pulmonary inflammation is present after
exposure to CeO2 NPs.
Vessel Characteristics
There were no significant differences in vessel size, spontaneous tone, wall to
lumen ratio or wall thickness between the control and exposed coronary arterioles; similar
results were obtained in the mesenteric arterioles (Table II). This provides evidence that
basal arteriolar tone and/or anatomy are not affected after CeO2 NP exposure. However,
this assessment was made in vitro, and while the effects on basal tone in vivo may be
different; this assessment is outside the scope of this manuscript.
Endothelium-Dependent Dilation
Endothelium-dependent dilation was stimulated with increasing concentrations of
either ACh or A23187. There was a reduced endothelium-dependent response to ACh in
coronary and mesenteric arterioles (Figure 3A and B). Additionally, from the CeO2 NP
dose response curve, 100 µg CeO2 NPs were determined to be maximum effect dose in
the mesenteric arterioles (Figure 4A) and 200 µg CeO2 NPs in coronary arterioles (Figure
4B). The lowest observable dose could not be determined based on the concentrations
used for these experiments (Figure 4A and B).
Because ACh activates additional pathways other than nitric oxide (NO) production,
A23187, a Ca2+ iontophore, was also used to more directly activate nitric oxide synthase
(NOS). Arterioles from both microvascular beds showed a significant impairment in
responsiveness to increasing concentrations of A23187 (Figure 5A and B). When
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analyzing the responses to A23187 for mesenteric microvessels, it was noted that at 1 x
10-5 M, the arterioles constricted. This may indicate that either exposure to CeO2 NPs alters
the arterioles sensitivity of A23187 or this concentration of A23187 is stimulating greater
changes in smooth muscle intracellular Ca2+, which would promote constriction (Figure
5A). Due to this constriction, 1 x 10-6 M was used to determine the maximum effect dose
(200 µg) of CeO2 NPs for mesenteric arterioles. The constriction, at 1 x 10-5 M was not
observed in the coronary arterioles; therefore this concentration of A23187 was used to
determine the maximum effect dose (200 µg) of CeO2 NPs. Taken together, these data
provided evidence of an impaired endothelium-dependent dilation after CeO2 NP exposure.
Endothelium-Independent Dilation
Vascular smooth muscle (VSM) NO sensitivity was assessed with the NO donor,
SNP. In both coronary and mesenteric arterioles, there was a decreased NO sensitivity 24
h after exposure to 100 µg CeO2 NPs (Figure 6A and B), which impairs the arterioles
ability to dilate. However, since SNP needs to contact a biological membrane in order to
release NO, we also used a spontaneous NO donor, SPR, to exclude the possibility that
the results obtained from SNP were due to the differential release of NO from SNP (34). A
similar attenuated dilation was observed in response to SPR (Figure 7A and B). This
response appeared to be dependent on the CeO2 NP dose and the maximal effect dose
for both microvascular beds was 200 µg CeO2 NPs (Figure 7A and B). Taken together,
the data for the NO donor provides evidence that impaired endothelium-independent
dilation may be attributed to a decrease in NO sensitivity after CeO2 NP exposure.
Vasoconstriction
Arteriolar vasoconstriction was assessed initially by exposing the vessel to the αadrenergic receptor agonist, PE. There were no significant differences in the response to
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increases in PE regardless of CeO2 NP concentration or microvascular bed (Figure 8A
and B). Since PE is a poor vasoconstrictor in the coronary vasculature, a more equitable
vasoconstrictor was also used. Serotonin caused a constriction in both microvascular beds
(Figure 9A and B). There were no significant differences in mesenteric arterioles, but there
was an augmented response in coronary arterioles after pulmonary exposure to 400 µg
CeO2 NPs (Figure 9A and B). These data provide evidence that adrenergic and 5-HT
sensitivity are intact after exposure to CeO2 NPs.
CeO2 Nanoparticle EC50
The calculated EC50 was determined for each agonist and ranged from 15 to 101
µg of CeO2 NPs (Table III). The EC50 was dependent on not only the chemical agonist, but
also the microvascular bed. The differential EC50 may be attributed to the different
metabolic demands of the tissue beds investigated and/or direct or indirect exposure
toCeO2 NPs.
Myogenic Responsiveness
Independent of microvascular bed or CeO2 NP exposure, the arterioles responded
similarly to changes in transmural pressure (Figure 10A and B). These data provide
evidence that the arteriolar myogenic responsiveness is intact after CeO2 NP instillation.
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Discussion
This study is the first to investigate the influence of pulmonary CeO2 NP exposure
on microvascular function. The major finding of this paper is: microvascular dysfunction
follows pulmonary CeO2 NP exposure, characterized by impaired endothelium-dependent
and -independent dilation.
One of the primary objectives of this investigation was to determine the
microvascular function following CeO2 NP exposure at occupationally relevant doses. To
accomplish this, rats were exposed by IT instillation to CeO2 NP doses which ranged up to
400 µg per rat. In order to evaluate the relevance of the doses used in this in vivo rat study
to humans, we need to determine if the CeO2 NP doses tested in rats are relevant to human
exposures. With a rat alveolar epithelium surface area of 0.4 m2 (35), the 400 µg CeO2 NP
lung burden would result in 1 mg CeO2/m2 alveolar epithelium. For a 5 µg/m3 aerosol of
CeO2 NPs with a mass median aerodynamic diameter (MMAD)=1.5 µm, minute ventilation
of 20 L/minute for a person performing light work (36), a deposition fraction of 30% (37)
and human alveolar epithelium surface area of 102 m2 (35), the 400 µg CeO2 NP lung
burden in rat approximates deposition for a person performing light work for 30 years
(assuming 240 work days per year). Currently, no exposure limits for CeO2 have been set
by OSHA, and thus the Permissible Exposure Limit (PEL) for CeO2 is that for
Particulates Not Otherwise Regulated (PNOR), which is 5 mg/m3 for the respirable fraction.
Thus, the highest rat CeO2 NP dose in this study approximates a human working for 30
years at an exposure level 1,000-fold below the current OSHA PEL for CeO2. The current
study focused on identifying the microvascular effects in young healthy male rats,
representative of a similar human population; however, we speculate that human
populations with increased susceptibility to cardiovascular disease (i.e. age, smoking,
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diagnosed cardiovascular risk factors), the observed microvascular dysfunction may
appear more severe or appear at lower lung burdens than those in this study.
BAL analysis revealed the presence of pulmonary inflammation following CeO2 NP
exposure in a dose dependent manner. The change in inflammatory status after pulmonary
CeO2 NP exposure was similar to previously reported studies that found an increase in
LDH, AM activation and PMN infiltration 24 h after exposure, however, an increase in
albumin in the BAL fluid after CeO2 NP exposure has been reported (16). In our study, the
lack of an increase in albumin in the BAL fluid indicates that the lung epithelial-endothelial
barrier is intact, and a similar lack of albumin was observed with low doses of TiO2 and
residual oil fly ash (ROFA) (25). These differences in the inflammatory profile may be due
to changes in the valence state of CeO2 NPs; however, alterations in the Ce3+/Ce4+
concentration is difficult to monitor in a biologic system, due to the ability of CeO2 NPs to
readily switch between these two valences (11). Because CeO2 NPs exist in two states,
and each state appears to influence different biological outcomes, the role of Ce3+/Ce4+
warrants further investigation, but is currently outside the scope of this study (11;12).
The results of this study have shown the presence of microvascular dysfunction
following CeO2 NP exposure even in the absence of overt pulmonary inflammation (Figure
3). Previous studies have also shown microvascular dysfunction despite relatively minor
inflammation following exposure to ROFA and fine TiO2 (38). This suggests that pulmonary
inflammation is not a pre-requisite for systemic dysfunction; however, because at high
doses of particles pulmonary and systemic effects are present, it is important to assess the
inflammatory state of the lungs. Additionally, it is reasonable to speculate that pulmonary
inflammation is not significantly influencing systemic microvascular function at low doses
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of CeO2 NPs (10 µg) but does, at least in part, influence microvascular function at higher
doses of CeO2 NPs (100 and 400 µg).
The sizes of the agglomerates are relevant to occupational and environmental
exposures. Studies with particulate matter and diesel exhaust particles have shown that
agglomerates between 100 and 1000 nm deposit in the lungs, however only particles 250
nm or less preferentially deposit in the respiratory zone of the lungs (15;39). Therefore, the
agglomerates in this study are capable of reaching the respiratory zone of the lungs.
Normal microvascular function was assessed by endothelium-dependent dilation
and -independent dilation, VSM constriction, and myogenic responsiveness. VSM
constriction and myogenic responsiveness appear to be intact in both microvascular beds
regardless of the dose of CeO2 NPs used and is consistent with previously reported
nanomaterials (27;40;41). This may be due to overlapping VSM signaling cascades in
response to these stimuli. In regards to normal arteriolar dilation, our results provide
evidence that there is a significantly impaired response to endothelium-dependent dilators,
ACh and A23187. This response was consistent with microvascular impairments that were
observed 24 h after pulmonary exposure to multi-walled carbon nanotubes, ultrafine TiO2,
and PM (27;40;41). However, exposure to CeO2 NPs also produced an unique
endothelium-independent impairment in coronary and mesenteric arterioles.
Endothelium-independent dysfunction following particle exposure was first
observed in pulmonary arteries following PM exposure by Courtois et al. (42), and this
finding is now extended to the systemic microcirculation after CeO2 NP exposure. The
results in this study provide evidence that arteriolar VSM NO sensitivity is altered after
CeO2 NP exposure. Because PM and ENM are fundamentally different the likelihood of
disparate mechanisms is high. This warrants further investigation to the mechanism(s) of
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CeO2 NP exposure, which may potentially be linked to alterations in NO bioavailability,
signaling and/or sensing.
The observed microvascular dysfunction could be due to either impaired NO
production, a shift in arachindonic acid metabolites, impaired VSM or a combination of the
three. The use of A23187 specifically examined endothelium NO production, however,
VSM impairments to NO may interfere with these results. Therefore, at this time we cannot
definitely determine the role of NO production and shifts in arachindonic acid metabolites
in the observed microvascular dysfunction. Future experiments, using inhibitors and
denuted arterioles, are necessary to definitely determine the influence of these factors. In
this study, we can infer that the endothelium is at least partially functional because after
stimulation with the Ca2+ iontophore A23187 there is an impaired dilation. Without this
limited endothelial function, the A23187 would act primarily on the VSM, resulting in a net
constriction. Typically, NO is released from the endothelial cells as a byproduct of Larginine conversion to L-citrulline. The NO then defuses to adjacent smooth muscle where
it interacts with soluble guanylyl cyclase and activates a signaling cascade that ultimately
sequesters Ca2+ and causes smooth muscle relaxation. A disruption at any point in this
pathway may result in a blunted dilation. One such disruption could be an increase of
hemoglobin α in the endothelial cell, in this study the level of hemoglobin α is inversely
proportional to NO bioavailability (43). In this case, if hemoglobin α concentration is
increased, endothelium derived NO could be bound to hemoglobin α; thus reducing NO
bioavailiblity, which could contribute to an impaired dilation. Alternatively, when
hemoglobin α binds NO the iron valence state changes, which is interestingly similar to the
valence state changes of CeO2 NPs (43). If CeO2 nanoparticles translocate, it is reasonable
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to speculate that CeO2 nanoparticles may also bind available NO thus decreasing NO
bioavailability It remains to be determined if this is the case for CeO2 NP exposures.
A previous study attributed the VSM dysfunction following PM exposure to changes
in the inflammatory state of the animals, independent of changes in oxidative stress;
whereas others have attributed impaired microvascular dysfunction to changes in oxidative
stress (40;42). The relationship between CeO2 NPs and changes in oxidative stress
warrants further investigation. Due to the changes in valence state, CeO2 NPs has the
ability to react with free radicals like superoxide, thus decreasing the level of oxidative
stress (12). Others have indicated that the level of free radicals increases after exposure
(44). Therefore, local oxidative stress must be assessed in the vascular wall to determine
its influence after exposure and if these changes affect reactivity.
In this study, it is important to note that there are distinct differences in microvascular
function and sensitivity between mesenteric and coronary arterioles. This illustrates the
importance of selecting the most appropriate microvascular bed for a given research
question because the findings from one microvascular bed may not be implicitly
extrapolated to another bed. These functional changes may arise from inherent differences
between the two microvascular bed such as time blood supply is received (systolic vs.
diastolic), metabolic demand (low vs. high), and response to changes in blood flow (varying
vs. constant). Each microvascular bed studied in this manuscript is of equal importance but
may be influenced by differing mechanisms. Additionally, modest changes in the coronary
microvasculature can result dire consequences for the heart due to local ischemia;
however, this same local ischemia maybe associated with less deleterious effects in the
mesentery where the microcirculation is accustom to changing blood flow and oxygen
levels.
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Alterations in microvascular function can have serious health consequences.
Notable common pathologies such as hypertension and diabetes initiate at the
microvascular level as a result of endothelial dysfunction (18). Of the many ENM we have
studied, CeO2 NPs are the first ENM we have observed to cause a significant increase in
MAP (Table I). This change in MAP may be a consequence of the observed alterations in
smooth muscle sensitivity to NO. MAP may also be influenced by changes in total
peripheral resistance and/or changes in cardiac output. The current ex vivo experimental
plan cannot accurately assess cardiac output, total peripheral resistance or their
interdependency. Thus, in vivo experiments that address these potential outcomes must
to be performed in the future. Alternatively, this change in MAP at the 100 µg dose may
also be a consequence of changes in autonomic control as a result of CeO2 NP exposure.
Evidence of this potential change may be represented by the lack of an increase in MAP
at higher doses. In order assess changes in MAP future studies should use chronic arterial
pressure monitoring to determine the influence of dose, time, and mechanistic interactions.
The microvascular dysfunction observed at the 10 µg exposure may also be due to
direct exposure and/or changes in autonomic control. It has been reported that dependent
on the time after pulmonary exposure, 20 to 50% of the ENM can be cleared from the lungs
(45;46). These cleared nanomaterials have several potential fates. The ENM may transition
into the systemic blood stream directly from the lung or they may be cleared via the
mucociliary escalator (45;46). In animals, ENM cleared from the lungs are ingested and
can be either absorbed into the blood, excreted in feces, or remain in the gut wall (45;46).
The clearance of CeO2 NPs from the lungs is significant because it may account for the
differences in the calculated EC50 for the vascular beds. The mesenteric arterioles may be
exposed both directly and indirectly to the effects of CeO2, NPs whereas the coronary
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arterioles are only indirectly exposed to CeO2 NPs. Additionally, the clearance of CeO2
NPs is significant because calculated lung exposure would be less than reported; however,
it should also be noted that the actual deposition in the lungs of CeO2 NPs post-24 h was
not calculated in this investigation.
In conclusion, this study provides evidence that pulmonary CeO2 NP exposure
causes alterations in MAP, in addition to endothelium-dependent and -independent
arteriolar impairment. The mechanism underlying this dysfunction warrants further
investigation due to the many potential uses of this ENM that may benefit human health.
Additionally, alternate exposure routes must be investigated to determine if this response
is unique to the lung exposures.
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Figure Legends:
Figure 1: TEM Images of CeO2 nanoparticles at A) low magnification B) high magnification.
Red dashes indicate individual particles that were estimated to be 4-6 nm. C) DLS
distribution curve of the suspended CeO2 NPs with an average agglomerate size for peak
1: 191 ± 77 nm; peak 1: 901 ± 391 nm; peak 3: 5081 ± 566 nm.

Figure 2: XPS Spectra of the hydrothermally synthesized and dried CeO2 nanoparticles
with deconvoluted peaks using a Gaussian fit A) C 1s B) O 1s.

Figure 3: Pulmonary inflammation was altered after exposure to CeO2 NPs. There was a
significant increase in LDH (A), AM activation (C), and PNM inflitration (D). However, there
was no change in albumin (B) levels after exposure. Values are means ± SE. † p≤ 0.05 vs.
control; ^ p≤ 0.05 vs. 100 µg CeO2 NPs.

Figure 4: ACh-induced vasodilation was impaired in mesenteric (A; n=8-13) and coronary
(B; n=7-9) arterioles from groups 24 hr post-exposure to CeO2 NPs. Values are means ±
SE. † p≤ 0.05 vs. control; * p≤ 0.05 vs. 10 µg CeO2 NPs. The right panel represents the
responses of the various doses of CeO2 NPs and was analyzed by nonlinear regression.
The left panel highlights the point-to-point differences between the control and CeO2 NP
exposed group.

Figure 5: The Ca2+ iontophore (A23187)-induced vasodilation was impaired in mesenteric
(A; n=6-11) and coronary (B; n=6-8) arterioles from groups 24 h post-exposure to CeO2
NPs. Values are means ± SE. † p≤ 0.05 vs. control. The right panel represents the
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responses of the various doses of CeO2 NPs and was analyzed by nonlinear regression.
The left panel highlights the point-to-point differences between the control and CeO2 NP
exposed group.

Figure 6: SNP-induced vasodilation was impaired in mesenteric (A; n=9-11) and coronary
(B; n=6-13) arterioles from groups 24 h post-exposure to CeO2 NPs. Values are means ±
SE. † p≤ 0.05 vs. control.

Figure 7: SPR-induced vasodilation was impaired in mesenteric (A; n=6-12) and coronary
(B; n=6-8) arterioles from groups 24 h post-exposure to CeO2 NPs. Values are means ±
SE. † p≤ 0.05 vs. control; * p≤ 0.05 vs. 10 µg CeO2 NPs; ‡ p≤ 0.05 vs. 50 µg CeO2 NPs; ^
p≤ 0.05 vs. 100 µg CeO2 NPs. The right panel represents the responses of the various
doses of CeO2 NPs and was analyzed by nonlinear regression. The left panel highlights
the point-to-point differences between the control and CeO2 NP exposed group.

Figure 8: PE-induced vasoconstriction was not significantly impaired in mesenteric (A;
n=5-13) and coronary (B; n=6-9) arterioles from groups 24 h post-exposure to CeO2 NPs.
Values are means ± SE. The right panel represents the responses of the various doses of
CeO2 NPs and was analyzed by nonlinear regression. The left panel highlights the pointto-point differences between the control and CeO2 NP exposed group.

Figure 9: 5-HT-induced vasoconstriction was not significantly impaired in mesenteric (A;
n=6-10) arterioles. An attenuated response was observed only in coronary (B; n=6-8)
arterioles from groups 24 h post-exposure to 400 µg CeO2 NPs. Values are means SE. ‡
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p≤ 0.05 vs. 50 µg CeO2 NPs; ^ p≤ 0.05 vs. 100 µgCeO2 NPs. The right panel represents
the responses of the various doses ofCeO2 NPs and was analyzed by nonlinear regression.
The left panel highlights the point-to-point differences between the control and CeO2 NP
exposed group.

Figure 10: Myogenic responsiveness was not impaired in mesenteric (A; n=10-15) and
coronary (B; n=6-9) arterioles from groups 24 h post-exposure to CeO2 NPs. Values are
means ± SE. The right panel represents the responses of the various doses of CeO2 NPs
and was analyzed by nonlinear regression. The left panel highlights the point-to-point
differences between the control and CeO2 NP exposed group.
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Abstract:
Cerium dioxide nanoparticles (CeO2 NP) hold great therapeutic potential, but the in
vivo effects of non-pulmonary exposure routes are unclear. The first aim was to determine
whether microvascular function is impaired after intravenous and gastric CeO2 NP
exposure. The second aim was to investigate the mechanism(s) of action underlying
microvascular dysfunction following CeO2 NP exposure. Rats were exposed to CeO2 NP
(primary diameter: 4 ± 1 nm, surface area: 81.36 m2/g) by intratracheal instillation,
intravenous injection, or gastric gavage. Mesenteric arterioles were harvested 24 h postexposure and vascular function was assessed using an isolated arteriole preparation.
Endothelium-dependent and -independent function and vascular smooth muscle (VSM)
signaling [soluble guanylyl cyclase (sGC), and cyclic guanosine monophosphate (cGMP)]
were assessed. Reactive oxygen species (ROS) generation and nitric oxide (NO)
production were analyzed. Compared to controls, endothelium-dependent and –
independent dilation were impaired following intravenous injection (by 61% and 45%) and
gastric gavage (by 63% and 49%). However, intravenous injection resulted in greater
microvascular impairment (16% and 35%) compared to gastric gavage at an identical dose
(100 µg). Furthermore, sGC activation and cGMP responsiveness were impaired following
pulmonary, intravenous, and gastric CeO2 NP treatment. Finally, nanoparticle exposure
resulted in route-dependent, increased ROS generation and decreased NO production.
These results indicate that CeO2 NP exposure route differentially impairs microvascular
function, which may be mechanistically linked to decreased NO production and subsequent
VSM signaling. Fully understanding the mechanisms behind CeO2 NP in vivo effects is a
critical step in the continued therapeutic development of this nanoparticle.
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Introduction:
Cerium dioxide nanoparticles (CeO2 NP) are an anthropogenic homogenous
mixture of particles with one dimension ≤ 100 nm (Borm et al. 2006). Unique physical
characteristics displayed at this size contribute to CeO2 NP diverse applications. Presently,
CeO2 NP are widely used as a fuel additive because they increase the combustion
efficiency of diesel engines (via enhanced catalytic activity) (Cassee et al. 2011). CeO2 NP
may also potentially protect against tissue damage associated with radiation treatments
and stroke in biomedical applications (Celardo et al. 2011). Tissue damage in these
conditions is largely derived from increased reactive oxygen species (ROS) generation.
CeO2 NP may prevent tissue damage from ROS due to their anti-oxidant capabilities (Kim
et al. 2012). This anti-oxidant potential comes from the ability of CeO2 NP to react with
ROS, which in turn alters its valence state (cycling between Ce4+ and Ce3+) (Heckert et al.
2008). The diverse and potentially widespread future applications mandate that the
concept of intentional and unintentional CeO2 NP exposure (via multiple routes) be given
full toxicological consideration.
Currently, the lungs are the most common CeO2 NP exposure route. This is largely
due to the occupational inhalation risk associated with the manufacturing process where
CeO2 NP are easily aerosolized (Department of Health and Human Services 2009).
Furthermore, the risk of environmental pulmonary exposures may increase due the
presence of CeO2 NP in diesel engine emissions. The lack of governmental regulations in
Europe and the United States further elevates this exposure risk (Cassee et al. 2011).
Pulmonary CeO2 NP exposure has been associated with inflammation and granuloma
formation (Ma et al. 2011). These exposures have also resulted in extra-pulmonary
biological effects including inflammation, organ toxicity, and vascular impairments
110

(Minarchick et al. 2013; Nalabotu et al. 2011; Wingard et al. 2011). While pulmonary CeO2
NP exposure is associated with several untoward biological outcomes, neither these
effects nor their intensities have been extensively studied or compared when the
nanoparticles are given by alternate exposure routes.
At this time, CeO2 NP exposure by non-pulmonary routes (intravenous and oral) is
not an obvious risk. However, if CeO2 NP are to be fully developed for systemic therapeutic
applications, the biological effects that follow CeO2 NP exposure by these clinicallyrelevant exposure routes must be better understood. In vivo, studies investigating the
outcomes of intravenous and oral CeO2 NP exposures have largely focused on long-term
biological responses (1 - 3 months post-exposure), including organ distribution, and overt
organ toxicity (Hirst et al. 2013; Yokel et al. 2012). Despite the fundamental role of the
microcirculation in blood flow control, pressure regulation, and permeability in all tissues
(Renkin 1984; Zweifach 1984), no investigation to date has analyzed the effects of
intravenous and oral CeO2 NP exposures on normal microvascular function.
In the microcirculation, the arterioles respond to a variety of chemical and
mechanical stimuli (Gewaltig and Kojda 2002). Under normal conditions, nitric oxide (NO)
diffuses freely from endothelial cells to vascular smooth muscle (VSM) cells. This initiates
a signaling cascade that activates soluble guanylyl cyclase (sGC), increases cyclic
guanosine monophosphate (cGMP), and stimulates cGMP-protein kinase (PKG)
(Schlossmann et al. 2003; Taylor et al. 2004). This signaling cascade decreases
intracellular calcium (Ca2+) and, ultimately, relaxes VSM (Taylor et al. 2004). Disruptions
in VSM signaling may compromise microvascular function and, if unresolved, may
contribute to the development of numerous pathological conditions (Li and Forstermann
2000).
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We have previously established that pulmonary CeO2 NP exposure results in
systemic microvascular dysfunction (Minarchick et al. 2013). However, the presence of
microvascular dysfunction following alternate exposure routes and the possible
mechanism of these impairments are currently unknown. Therefore, the aims of this study
were two-fold. The first aim was to determine if microvascular impairment followed
intravenous injection and gastric gavage of CeO2 NP. The second aim was to provide
mechanistic insight into the link between CeO2 NP exposure and microvascular function
following three distinct exposure routes (intratracheal instillation, intravenous injection, and
gastric gavage). Based on our pulmonary results, we hypothesized that intravenous and
gastric exposures will also result in microvascular impairment, but to differing degrees, and
the source of this dysfunction will be, at least partly, due to changes in NO bioavailability
and/or VSM signaling. Microvascular impairment and NO bioavailability were assessed in
freshly isolated arterioles 24 h following CeO2 NP exposure.
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Materials and Methods:
CeO2 NP Production and Characterization: CeO2 NP powders were synthesized by a
hydrothermal process as previously described (Minarchick et al. 2013). Briefly, cerium (IV)
ammonium nitrate [99+%, (Alfa Aesar, Ward Hill, MA)] was added to de-ionized water
(H2O) and this solution was added drop-wise into a basic solution of tetramethylammonium
hydroxide pentahydrate (TMAOH) and de-ionized H2O. The pH of the dispersion was
altered to ~10.5 with ammonium hydroxide and was maintained throughout the reaction.
The dispersion was placed in a 300 ml Autoclave Engineers EZE-Seal autoclave (Erie,
PA) at 240 ºC for 1 h. Once removed from the autoclave, the dispersion was placed into a
centrifuge and the liquid was removed and replaced with ethanol. After the washing step,
the dispersion was dried at 60 ºC overnight and sieved through a 200 mesh screen for
characterization. The nanoparticles were previously characterized (Minarchick et al. 2013).
The CeO2 NP had a surface area of 81.36 m2/g measured by Micromeritics ASAP 2020
(Norcross, GA). Transmission electron micrographs were used to analyze ~20
nanoparticles to determine the primary size (4 ± 1 nm) and shape (spherical) [JEOL JEM2100 High Resolution Transmission Electron Microscope (TEM) (Peabody, MA)]. The
average agglomerate size in saline [Normosol-R, (Nospira Inc., Lake Forest, IL)] and 5%
fetal bovine serum (FBS) was 191 nm as determined by dynamic light scattering [Malvern
Zetasizer version 7.01, (Westborough, MA)]. FBS was added to the solution because it has
the propensity to reduce nanoparticle agglomeration (Porter et al. 2008). Finally, the
valence state of the CeO2 NP was 81% Ce4+ and 19% Ce3+ determined by x-ray
photoelectron spectroscopy [PHI 5000 Versaprobe XPS, (Chanhassen, MN)].
Experimental Animals: Male Sprague-Dawley rats (8 - 11 wk old) were purchased from
Hilltop Laboratories (Scottsdale, PA). The rats were housed at the West Virginia University
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Health Sciences Center Vivarium, in laminar flow cages, under controlled humidity and
temperature, with a 12 h light/dark cycle, and food and water were provided ad libitum.
Prior to use, the animals were acclimated for at least 2 days. All procedures were approved
by the Institutional Animal Care and Use Committee at West Virginia University.
CeO2 NP Exposure Models: For the stock suspensions, the dry powder was weighed (0
- 10 mg) and added to 10 ml of Normosol-R with 5% FBS. The amount of dried powder
weighed initially was adjusted to obtain the following final CeO2 NP concentrations: 0
(saline and 5% FBS), 50, 65, 100, 300, 400, 600, and 900 µg per rat. The doses selected
for the intravenous injection (50, 100, and 900 µg) and gastric gavage (100, 300, and 600
µg) groups were selected to establish individual dose-response determinations for each
exposure route. They were selected in attempt to encompass the minimal and maximal
microvascular responses. We also anticipated these responses to be different for each
exposure route. These doses cover a range of 0.14 mg/kg to 2.57 mg/kg (based on
representative animal weight of 350 g) (Tables 1 and 2). This range is within those
previously reported for other in vivo studies with this nanoparticle (Hirst et al. 2013; Kim et
al. 2012; Yokel et al. 2012). The CeO2 NP were vortexed for 5 min and then sonicated on
ice for an additional 5 min. Rats were lightly anesthetized with isoflurane gas (5% induction,
2 - 3.5% maintenance) and exposed by one of the following exposure routes. Intravenous
Injection: Rats were injected in the tail vein with a bolus dose (900 µl) of CeO2 NP stock
suspension using a 23 G needle. The final doses were 0 (saline and 5% FBS), 50, 100,
and 900 µg per rat. Although the 100 µg dose was part of the initial dose-response
determination, this was also the dose that caused a 50% impairment in arteriolar reactivity
(EC50) and was then used for the subsequent experiments utilizing the EC50. Gastric
Gavage: Rats were gavaged with a bolus dose (300 µl) of CeO2 NP stock suspension via
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a ball tipped needle. The final doses were 0 (saline and 5% FBS), 100, 300, 400, and 600
µg per rat. The 400 µg dose was the result of the EC50 calculation, and was only used after
the initial dose-response was determined. Intratracheal Instillation: The dose-dependent
microvascular effects of CeO2 NP after pulmonary instillation have been investigated
previously (Hirst et al. 2013; Minarchick et al. 2013); however, the mechanism(s) of toxicity
involved is still unknown. Therefore, intratracheal instillation, intravenous injection, and
gastric gavage were used to study the mechanism(s) of action for CeO2 NP. In the current
study, rats were instilled with a bolus dose (300 µl) of CeO2 NP stock suspension via a ball
tipped needle. The final dose was 65 µg per rat. This dose was selected because previous
experiments established that 65 µg of CeO2 NP was the EC50 for this exposure route
(Minarchick et al. 2013). Furthermore, this dose was also determined to be relevant to
occupational exposures (Minarchick et al. 2013). Rats were monitored after treatment until
they regained consciousness. All animals were allowed to recover for 24 h prior to
experimental assessments.
Arterial Pressure Acquisition and Isolated Arteriole Preparation: Arterial pressure and
microvascular assessments were completed 24 h post-CeO2 NP exposure.
Rats were anesthetized with isoflurane gas (5% induction, 2 - 3.5% maintenance) and
placed on a heating pad to maintain a 37 ºC rectal temperature. The trachea was intubated
to ensure an open airway and the right carotid artery was cannulated to measure arterial
pressure. Data was measured with a pressure transducer and recorded with PowerLab830
(ADInstruments, Colorado Springs, CO). Animals were euthanized by removal of the heart.
The mesentery was then removed and placed in a dissecting dish with physiological salt
solution (PSS) maintained at 4 ºC. Multiple (1 - 3) 4th and 5th order mesenteric arterioles
were isolated, excised, and transferred to individual vessel chambers, cannulated between
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two glass pipettes, and secured with silk sutures (Living Systems Instrumentation,
Burlington, VT). Each chamber was superfused with fresh, oxygenated (5% CO2/21% O2)
PSS and warmed to 37 ºC. Arterioles were pressurized to 80 mm Hg using a servo control
system and extended to their in situ length (Sun et al. 1992). Internal and external arteriolar
diameters were measured with video calipers (Colorado Video, Boulder, CO).
Arteriolar Reactivity: During equilibration, arterioles were allowed to develop
spontaneous tone (≥ 20%) after which various parameters of arteriolar function were
analyzed. Spontaneous tone is a unitless number that ranges from 0 to 100%, where 0%
indicates an arteriole with no tone (or is at its maximal diameter) and 100% indicates an
arteriole that is fully constricted. This number was calculated using the following equation:
[(DM – DI)/DM] x 100, where DM is the maximal diameter (obtained at the conclusion of the
experiment) of the arteriole and DI is the initial steady state diameter at the beginning of
the experiment. Steady state diameter is defined as an arteriolar diameter that is constant
for at least 1 min. Endothelium-Dependent Dilation: Arterioles were exposed to increasing
concentrations of acetylcholine (ACh, 10-9 - 10-4 M) added to the vessel bath. Arterioles
were also incubated with NG-monomethyl-L-arginine (L-NMMA, 10-4 M), a NO synthase
inhibitor (NOS), and/or indomethacin (INDO, 10-5 M), a cyclooxygenase (COX) inhibitor,
prior to the ACh dose-response determination when indicated. These inhibitors were used
to assess the influence of NO and COX products, respectively. Endothelium-Independent
Dilation: Increasing concentrations of the spontaneous NO donor, spermine NONOate
(SPR, 10-9 - 10-4 M) were used to assess VSM responsiveness. Mechanotransduction: The
VSM response to transmural pressure changes was analyzed by increasing the
intraluminal pressure in 15 mm Hg increments from 0 to 120 mm Hg. The endothelial
response to shear stress was assessed by increasing intraluminal flow in 5 µl/min
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increments from 0 to 30 µl/min. Arteriolar Vasoconstriction: The arterioles were exposed to
increasing concentrations of the α-adrenoceptor agonist, phenylephrine (PE, 10-9 - 10-4 M).
Vascular Smooth Muscle Signaling: The arterioles were exposed to increasing
concentrations of the sGC activator, 3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole [YC-1,
(10-9 - 10-4 M)] and the cGMP mimetic, 8-bromo-cGMP (10-7 - 10-4 M), to assess VSM
signaling. YC-1 was used to determine NO independent activation of sGC; however, YC-1
is capable of increasing sGC sensitivity to NO. Therefore, the YC-1 dose determination
was completed in the presence of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 104

M), an irreversible NOS inhibitor.
In all experiments, the steady state diameter of the arteriole was recorded for at

least 1 min at each dose. Once a dose-response determination was completed, the vessel
chamber was washed by carefully removing the superfusate and replacing it with fresh,
warmed, oxygenated PSS. The dose-response determinations (typically 3 - 5) were
performed in random order, expect for YC-1, which was performed last because of the
irreversible nature of ODQ. After all experimental treatments were completed, the PSS was
replaced with Ca2+-free PSS until the maximum passive diameter was established. All
arterioles with ≤ 20% spontaneous tone or ≥ 150 µm internal diameter were not analyzed.
NO Measurements: NO measurements were obtained using a free radical analyzer
[Apollo 4000, (World Precision Instruments, Inc., Sarasota, FL)]. A four-port water jacketed
(34ºC), biosensing chamber was used for the NO measurements. Three ports contained
electrochemical probes that were covered with a semi-permeable membrane that was NO
selective (ISO-NOP, World Precision Instruments, Inc., Sarasota, FL). The probes were
connected to the Apollo 4000 unit to make direct electrochemical NO measurements in
real time (Nurkiewicz et al. 2009; Zhang 2004). The 4th port contained a temperature probe
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that was removed to add reagents with a digital micropipettor. Electrodes were calibrated
prior to use via S-nitroso-N-acetyl-D,L-penicillamine (SNAP, 4 x 10-5 – 1.6 x 10-4 M)
decomposition to NO in a copper catalyst solution (cuprous chloride, 0.1 M). Data were
collected at a rate of 10 samples per sec and measurements were made only during steady
state responses that were at least 30 sec in duration. Acellular Measurements: CeO2 NP
(0 - 2 µg/ml) were placed in the water-jacketed chamber that contained 2 ml cuprous
chloride (0.1 M). NO was measured in response to SNAP (1.6 x 10-4 M) decomposition in
this solution. Vascular Measurements: Mesenteric arteries and arterioles were dissected
(24 h post-CeO2 NP exposure via all three exposure routes) in 4 ºC PSS, excised, and
pooled to form a loose pellet. The pellet was placed into the water jacketed chamber that
contained 2 ml Dulbecco’s phosphate buffered saline with Ca2+ (3.6 mM), L-arginine (0.2
mM) and tetrahydrobiopterin (BH4, 4 µM). NO production was stimulated with a bolus dose
of the Ca2+ ionophore, A23187 (10-5 M). Data were normalized to tissue mass (nM/mg).
Free Radical Assessments: Electron spin resonance (ESR) was used for the detection
of short-lived free radicals (superoxide and hydroxyl). Since these free radicals are highly
reactive, an indirect method (spin-trapping) was used to measure these changes. This
method required binding with a paramagnetic compound to form a longer-lived free radical
product (spin adduct) and was ideal for detection and identification because of its specificity
and sensitivity. All ESR measurements were collected using a Bruker EMX spectrometer
(Billerica, MA). Hyperfine couplings were measured (to 0.1 G) directly from magnetic field
separation

using

potassium

tetraperoxochromate

(K3CrO3)

and

1,1-diphenyl-2-

picrylhydrazyl (DPPH) as reference standards (Buettner 1987; Janzen et al. 1987). The
instrument settings were consistent for all experiments [center field (3475 G), sweep width
(100 G), resolution (1024 points), gain (2.52 x 104), mod frequency (100 kHz), mod
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amplitude (1 G)]. All spectra measured were the accumulation of multiple (1 - 3) scans.
The relative free radical concentration was estimated by measuring the peak-to-peak
height (mm) of the observed spectra. Acellular Measurements: Xanthine (14 mM), xanthine
oxidase (2 U) and the spin trap 5,5-dimethyl-1-pyrroline-N-oxide [DMPO, (100 mM)] were
added to an ESR flat cell and measured immediately to detect the generation of superoxide
free radicals. Iron sulfate (0.001 mM), hydrogen peroxide (0.1 mM) and DMPO (100 mM)
were added to an ESR flat cell and measured immediately to detect the generation of
hydroxyl free radicals. These reactions were completed in both the presence and absence
of CeO2 NP (0.5 and 2 mg/ml). Cellular Measurements: Alveolar macrophages (AM) from
control and CeO2 NP exposed rats (via all three exposure routes) were harvested 24 h
post-CeO2 NP exposure via bronchoalveolar lavage (BAL) (Minarchick et al. 2013). AM
were suspended in phosphate buffered saline (3 x 106 cells/ml) and incubated with DMPO
(200 mM) in the presence and absence of a positive control, hexavalent chromium (Cr6+, 2
mM) and CeO2 NP (1 mg/ml) for 2 min at 37 ºC prior to being transferred to an ESR flat
cell for measurements.
Equations: Spontaneous tone was calculated using the following equation: Spontaneous
tone (%) = [(DM - DI)/DM] x 100, where DM is the maximal diameter and DI is the initial steady
state diameter recorded prior to any experimental assessments. Active responses to
pressure were normalized to the maximal diameter using the following formula: Normalized
diameter = DSS/DM, where DSS is the steady state diameter recorded during each pressure
change. The experimental responses to ACh, SPR, and flow are expressed using the
following equation: Diameter (percent maximal response) = [DSS - DCon)/(DM - DCon)] x 100,
where DCon is the control diameter recorded immediately prior to the dose-response
determination, DSS is the steady state diameter at each dose of the determination. Shear
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stress (τ) was calculated from volumetric flow (Q) using the following formula: τ = 4ηQ/πr3,
where η is viscosity (0.8 cp), Q is volumetric flow rate [measured with a calibrated flow
indicator (Living System Instruments, Burlington, VT)], and r is arteriole radius. The
experimental response to PE is expressed using the following equation: Diameter (percent
maximal response) = - [DCon - DSS)/DCon] x 100. Wall thickness (WT) was calculated from
the measurement of both inner (ID) and outer (OD) steady state arteriolar diameters at the
end of the Ca2+-free wash using the following equation: WT = (OD - ID)/2. Wall-to-lumen
ratio (WLR) was calculated using the following equation: WLR = WT/ID.
Statistics: Data are expressed as means ± standard error (SE). Point-to-point differences
in the dose-response determinations were evaluated using two-way repeated measures
analysis of variance (ANOVA) with a Student-Newman-Keuls post-hoc analysis when
significance was found. Statistical differences among the slopes of the dose-response
determinations were determined by either a linear or nonlinear regression analysis.
Regression analysis was used to determine differences among collective data sets. Linear
regression analysis was performed for predictable data sets where a step-wise stimuli or a
typical biological response were observed. However, in biological systems a typical linear
response is not always observed. In this case, a nonlinear regression analysis was applied
to the data set. The animal characteristics, arteriolar characteristics, free radical peak
height, and NO levels were analyzed using a one-way ANOVA with a Student-NewmanKeuls post-hoc analysis when significance was found. The EC50 was determined using a
four parameter logistic analysis. All statistical analyses were completed with GraphPad
Prism 5 (San Diego, CA) and SigmaPlot 11.0 (San Jose, CA). Significance was set at p ≤
0.05 and n is the number of arterioles.
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Results:
Animal and Arteriolar Characteristics: There were no differences in animal age (Table
1). Similarly, CeO2 NP exposure route did not influence animal weight, mean arterial
pressure or heart weight (Table 1). Basal arteriolar diameter, spontaneous tone, WT, or
WLR were also not affected by exposure route or dose (Table 2). These data suggest that
basal arteriolar tone and/or anatomy are not affected by exposure route or CeO2 NP.
However, it remains to be determined if such exposures influence arteriolar tone in vivo.
Endothelium-Dependent Dilation: Endothelium-dependent arteriolar dilation was
impaired significantly in a dose-dependent fashion following intravenous CeO2 NP
injections of 50, 100, and 900 µg (Figure 1A). Gastric CeO2 NP exposure impaired dilation
to a lesser extent at the 100 and 300 µg doses, but the effect was similar at the higher
doses (600 µg and 900 µg, Figures 1A vs.1B). Taken together, these results indicate that
CeO2 NP exposure impairs endothelium-dependent microvascular function via nonpulmonary exposure routes.
Endothelium-Independent Dilation: Vasodilation in response to NO donation was
impaired significantly following intravenous CeO2 NP injection, but this effect was not dosedependent (Figure 2A). Exposure via gastric gavage also altered arteriolar VSM
responsiveness. Interestingly, there was an augmented response to NO following 100 µg
of CeO2 NP; however, 600 µg of CeO2 NP significantly attenuated the response to NO
(Figure 2B). These results provide evidence that CeO2 NP exposure also impairs
endothelium-independent arteriolar VSM signaling.
Mechanotransduction: Myogenic responsiveness was assessed from step-wise
increases in transmural pressure. There were no significant differences in the myogenic
responsiveness to pressure independent of CeO2 NP exposure route or dose (Figure 3A
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and B). It is worthwhile to note that there was an augmentation of the myogenic response
at the highest pressure (120 mm Hg) following gastric gavage of 100 µg of CeO2 NP
(Figure 3B). Because there were no overall differences in the slopes of these
determinations and this augmentation occurred at a single pressure, the biological
relevance of this observation is unclear. Vasodilation in response to changes in shear
stress was assessed via increases in intraluminal flow. Independent of exposure route,
there were no significant differences in the response to changes in intraluminal flow or
endothelial shear stress (Figures 4A - D). These data demonstrate that the ability of
arterioles to transduce physical forces is unaffected by CeO2 NP given by alternate
exposure routes.
Arteriolar Vasoconstriction: There was an augmented response to PE (10-6 and 10-5 M)
following 100 µg of intravenously injected CeO2 NP; however, there were no differences in
the overall slopes of the determinations for any dose (Figure 5A). CeO2 NP (100 µg) given
by gastric gavage resulted in an augmented response to PE (10-5 M), but there were no
differences in the overall slopes of the determinations for any CeO2 NP dose (Figure 5B).
These data provide evidence that VSM adrenergic sensitivity may be augmented following
intravenous CeO2 NP injections, but additional studies with other vasoactive agonists are
necessary.
CeO2 NP EC50: The calculated EC50 for ACh and SPR was determined for each exposure
route (Figures 6A and B). The CeO2 NP EC50 ranged from 62 to 450 µg and was exposure
route-dependent. Because we wanted to compare the influence of different exposure
routes on microvascular function, the remainder of the experiments in this study used an
average CeO2 NP dose derived from the EC50 calculation (Tables 1 and 2). The scatter
plot represents the maximal response to ACh (10-4 M) for all exposure routes (Figure 6C).
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The maximal impairment occurred at the highest doses. However, these doses were
different between the exposure routes (Figure 6C). This suggests that further increasing
the dose from a given exposure route’s current highest dose would have further impaired
microvascular function only minimally. The similar maximal responses for each exposure
route at the highest dose and the variable EC50 highlights that the severity of the
microvascular dysfunction following CeO2 NP administration is exposure route-dependent.
Contribution of NO and COX Products to ACh-Induced Vasodilation: There were no
significant differences in the responses of control arterioles among all the exposure routes
(data not shown). This indicates that no experimental artifact resulted from the different
exposure routes and, therefore, results from control animals were pooled for the analyses
reported in Figures 7 - 10. Incubation of control arterioles with either L-NMMA or INDO
significantly reduced vasodilation in response to ACh, and incubation with both inhibitors
abolished arteriolar dilation (Figure 7A). Intratracheal instillation of CeO2 NP significantly
impaired endothelium-dependent arteriolar dilation; however, L-NMMA incubation restored
vasodilation in response to ACh (10-5 and 10-4 M) (Figure 7B). Intravenous CeO2 NP
injection significantly impaired the ACh response and this was further impaired during
INDO incubation (Figure 7C). Finally, the significantly impaired dilation response to ACh
that followed gastric gavage of CeO2 NP was attenuated further during L-NMMA incubation
(Figure 7D). Overall, these data provide initial evidence that the differential contribution of
NO and COX products to vasodilation after CeO2 NP exposure is a function of the different
routes through which these materials enter the body.
NO Measurements: The ability of CeO2 NP to react with NO was assessed first in an
acellular environment. NO was spontaneously released using a bolus dose of SNAP (1.6
x 10-4 M) in the presence of increasing doses of CeO2 NP. As the CeO2 NP concentration
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increased, the amount of detectable NO decreased, indicating that CeO2 NP are capable
of reacting with NO (Figure 8A). In a second set of experiments, microvascular tissue was
used to assess its ability to produce NO. In these experiments, vascular NO production
was stimulated by a bolus dose of the Ca2+ ionophore, A23187 (10-5 M). This stimulation
increased significantly the amount of NO detected. In the CeO2 NP intravenous injection
group, this response was significantly impaired (relative to control and intratracheal
instillation exposure groups) (Figure 8B). These results suggest that intravenous injection
of CeO2 NP may have a greater impact on NO bioavailability than either intratracheal
instillation or gastric gavage.
Free Radical Assessments: ESR was used to determine if CeO2 NP were capable of
generating and/or scavenging free radicals. There was a significant reduction in the level
of free radicals detected in the presence of CeO2 NP (Figure 9A). This finding supports
that CeO2 NP are capable of reacting with free radicals in an acellular environment, and
this is consistent with anti-oxidant behavior. AM alone did not generate a significant amount
of free radicals; however, when directly exposed to CeO2 NP (1 mg/ml), there was a
significant increase in free radical generation (Figure 9B). Furthermore, in a positive
control experiment, AM generated a significant increase in free radical generation during
incubation with Cr6+ (2 mM) (Figure 9B). Interestingly, when CeO2 NP and Cr6+ were
simultaneously incubated with the AM there was a significant decrease in the amount of
free radicals detected compared to Cr6+ alone (Figure 9B). It appears that CeO2 NP are
capable of generating and scavenging free radicals in a cellular environment. Further
experimentation with additional CeO2 NP doses would not have revealed more insight into
their anti-oxidant potential because the current experiments determined that, although the
doses used did affect the level of free radicals in vitro, the effect was not dose-dependent.
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AM were harvested from rats that had been exposed via intratracheal instillation,
intravenous injection, or gastric gavage. The AM alone from these animals did not generate
any detectable free radicals (Figure 9C). In contrast, there was a significant increase in
free radical generation compared to the controls in all exposure groups when CeO2 NP
were incubated with the AM (Figure 9C). However, the AM generated significantly fewer
free radicals [following an additional CeO2 NP (1 mg/ml) dose] from intratracheal instillation
and intravenous injection exposure groups compared to the control and gastric gavage
exposure groups (Figure 9C). While it is not surprising that the CeO2 NP are capable of
stimulating AM free radical generation, it is interesting that in the correct environment, they
may alternatively function as a reducing agent.
Smooth Muscle Signaling: There was a significant decrease in vasodilation at low YC-1
concentrations (10-7 - 10-5 M) in all exposure groups (Figure 10A). The responsiveness to
increasing concentrations of cGMP was also assessed. Similarly, there was a significant
impairment in the response to increasing levels of 8-bromo-cGMP (10-4 M) in all three
exposure groups (Figure 10B). These results provide evidence that CeO2 NP exposure
impairs VSM relaxation via a signaling mechanism downstream of initial sGC activation.
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Discussion:
There are three major findings in this investigation. To our knowledge, this study is
the first to establish the presence of both endothelium-dependent and -independent
microvascular dysfunction following intravenous and gastric CeO2 NP exposure. This
observed microvascular dysfunction was similar to those impairments following
intratracheal instillation (Minarchick et al. 2013). However, the severity of this dysfunction
was route-dependent (intratracheal instillation > intravenous injection > gastric gavage).
The second major finding was that there were exposure route-dependent decreases in NO
production and increases in ROS generation. Finally, independent of exposure route, CeO2
NP significantly impaired sGC activation and cGMP responsiveness.
CeO2 NP hold great potential for future therapeutics, and investigations of the
biological effects associated with CeO2 NP need to encompass therapeutically-relevant
dose ranges (Celardo et al. 2011). Our initial toxicological assessments utilized a range
that ensured overlap between exposure routes, while also being therapeutically-relevant.
In terms of therapeutic applications, intravenous and oral exposures are common in human
pharmaceutical uses and often expose patients to several milligrams of drug per dose
(Brannon-Peppas and Blanchette 2004; Sastry et al. 2000). To our knowledge, CeO2 NP
have yet to be used therapeutically via ingestion. The intravenous doses used in this
experiment are similar to CeO2 NP concentrations that are being tested for protection
against ischemic stroke in animals (Kim et al. 2012). Therefore, the doses used to establish
the EC50 for intravenous and gastric exposures here are relevant as they are within
therapeutic or pharmaceutical ranges.
It is reasonable to speculate that different blood nanoparticle concentrations could
be achieved by administering CeO2 NP via different exposure routes and the levels of direct
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nanoparticle-endothelial interaction within 24 h would vary (Stapleton and Nurkiewicz
2014). Intravenous exposure, undoubtedly, resulted in the highest level of direct
nanoparticle-endothelial contact. We can assume that at time naught (initial injection) all
the CeO2 NP are in the plasma (Stapleton and Nurkiewicz 2014). Over time, these
nanoparticles could be distributed to other organs and/or cleared from the body (Yokel et
al. 2012). From a pulmonary standpoint, ferric oxide nanoparticles translocate from the
lung to other systemic organs at a rate of 3.06 µg/day (Zhu et al. 2009). It is possible that
a similar amount of CeO2 NP translocates from the lungs, but the exact rate is currently
unknown. This migration of nanoparticles may result in direct endothelial interaction for
some of the nanoparticles. It has been shown that within 24 to 48 h after inhalation or
intravenous injection of CeO2 NP, the nanoparticles translocate to various organs,
specifically the liver and spleen (Geraets et al. 2012; Yokel et al. 2012). Following
inhalation, 0.10% of the inhaled dose was observed in the liver and 0.006% in the spleen
(Geraets et al. 2012). Intravenous injection increased this translocation to as high as 10%
of the dose in the same organs (Yokel et al. 2012). Furthermore, accumulation in various
organs may also impact microvascular function following different exposure routes due to
indirect effects from these organs.
Gastric exposure resulted in the delivery of a bolus dose of CeO2 NP directly into
the stomach. Peristalsis then contributes to the distribution of the nanoparticles throughout
the small and large intestines. Titanium dioxide nanoparticles have been shown to
translocate from the gut and it is possible that CeO2 NP may respond in a similar fashion
(Brun et al. 2014). Additionally, studies have shown that following gastric CeO2 NP
exposure ~5% of the total dose is absorbed, which indicates the actual exposure dose for
gastric gavage may be lower than the initial bolus dose (Hirst et al. 2013). This difference
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in the absorbed and initial concentrations may account for why there is minimal dysfunction
at the lower CeO2 NP gastric gavage doses. It may also account for larger microvascular
impairment following 600 µg of CeO2 NP because the nanoparticles may be absorbed in
more areas (and to a greater extent) throughout the gastrointestinal tract. Furthermore, pH,
vascularization, and water content varies throughout the digestive tract (e.g. stomach,
small and large intestines) and may affect the reactivity, concentration, and translocation
of the nanoparticles (Hayes et al. 2002; Xu and Qu 2014). Our study did not assess CeO2
NP blood concentration or clearances following the three exposure routes. Therefore, the
blood concentrations prior to microvascular assessments are unknown.
Finally, it should be noted that the likelihood of direct endothelial interaction does
not implicitly predict the severity of microvascular dysfunction. Pulmonary exposure
resulted in the greatest microvascular dysfunction despite likely having lower CeO2 NP
endothelial contact. This indicates that other factors (e.g. inflammation, neurogenic stimuli,
and free cerium ions) may play a role in the resultant microvascular dysfunction. The
influences and identification of these factors warrant further investigation.
Endothelium-dependent dilation is the net product of many factors, and CeO2 NP
exposure may alter the origin and/or targets of these factors. For example, after pulmonary
CeO2 NP exposure, NOS inhibition restores microvascular function at the highest ACh
concentrations (Figure 7B). This could be partially due to the activation of endotheliumderived hyperpolarizing factor (EDHF), which NO has been shown to inhibit (Nishikawa et
al. 2000). It is possible that when NO production is inhibited, EDHF may promote VSM
relaxation through a pathway independent of sGC/cGMP signaling (Parkington et al. 2008).
Additional experiments are needed to deduce the activation and roles of compensatory
vasodilatation mechanisms following CeO2 NP exposure.
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CeO2 NP are capable of being internalized by cardiac progenitor cells, potentially
through clathrin- and/or caveolae-mediated endocytic pathways (Pagliari et al. 2012; Singh
et al. 2010) . If CeO2 NP are internalized by endothelial cells, the function of enzymes (e.g.
NOS), substrates (e.g. L-arginine), and organelles (e.g. mitochondria) are potentially
compromised. Diesel exhaust exposure and decreased L-arginine availability lead to
increased superoxide via NOS uncoupling (Boger and Bode-Boger 2000; Cherng et al.
2011). Therefore, changes in NOS activity may also be mechanistically linked to
microvascular impairment and decreased NO bioavailability following CeO2 NP exposure.
The observed changes in NO bioavailability may be linked to the valence state of
the cerium. CeO2 NP exist in two valence states (Ce4+ and Ce3+) and readily switch
between them based on local environmental factors (e.g. ROS, and pH) (Hayes et al. 2002;
Xu and Qu 2014). The ratio of the valence states may be predicative of reactivity in a
biological environment. The CeO2 NP used in this study were 81% Ce4+/19% Ce3+. This
ratio would be consistent with decreased NO bioavailability following intravenous exposure
as Ce4+ is more prone than Ce3+ to reacting with NO (Xu and Qu 2014). Furthermore, CeO2
NP valence state alterations may also account for the lack of decreased NO bioavailability
following pulmonary exposure. Previous studies with other nanoparticles have resulted in
a decreased NO bioavailability due to increased ROS production following pulmonary
exposure (Nurkiewicz et al. 2009). It is possible that the valence state of the CeO2 NP
(either as a reductant or oxidant) protects/preserves NO bioavailability following pulmonary
exposure due to its ability to react with ROS. Gastric exposure to CeO2 NP also results in
contact with stomach acid (pH ~2). This exposure to a highly acidic environment may
increase the Ce3+ concentration, thereby decreasing its reactivity with NO (Hayes et al.
2002). However, it is unclear if the altered Ce3+ concentration is maintained once the CeO2
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NP exit the acidic environment of the stomach and enter the basic environment of the
intestine. This potential valence state shift may be a contributing factor to the absence of
significant changes in NO bioavailability and a higher CeO2 NP EC50 following gastric
exposures.
NO bioavailability is also influenced by changes in local ROS levels, which can
impair microvascular function (LeBlanc et al. 2010). Many factors, including mitochondrial
dysfunction, NOS uncoupling, and possibly CeO2 NP themselves, influence ROS
generation (Cherng et al. 2011; Dabkowski et al. 2009). CeO2 NP exposure has been
associated with decreased or unaffected ROS, thus characterizing the CeO2 NP as an antioxidant, whereas other studies have documented increased ROS generation following
either co-incubation, pulmonary, or intravenous exposure (Gojova et al. 2009; Pagliari et
al. 2012; Srinivas et al. 2011; Yokel et al. 2012). Our study contributes conflicting results
when comparing the influence of CeO2 NP and ROS. Initial exposure to CeO2 NP did not
affect ROS generation; however, a subsequent CeO2 NP treatment did cause an increase
in ROS generation, indicating that the first exposure activated and/or primed AM following
intratracheal instillation and intravenous injection. We speculate that the activated AM, are
already producing ROS (although undetectable with ESR) so that in the presence of an
additional CeO2 NP exposure, the nanoparticles may begin to act as an anti-oxidant and
react with surrounding ROS. The increased ROS production following this dose in the
control and gastric gavage groups may be because the AM are seeing the nanoparticles
for the first time (Figure 9). In this environment, CeO2 NP act as a pro-oxidant to increase
basal ROS production in order to shift valence states. It appears the initial environment
and the basal ROS concentration may influence CeO2 NP pro- and anti-oxidant activity.
We speculate that in a low ROS environment (e.g. unstimulated AM), CeO2 NP react with
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surrounding cells, which lead to increased ROS generation. This elevated level of ROS
may be needed for CeO2 NP to shift between Ce4+ and Ce3+ valence states. However, in
a high ROS environment, these nanoparticles may not generate additional ROS because
the level is sufficient to shift valence states. The influence of CeO2 NP treatment on AM
activation requires additional investigation, but is currently outside the scope of this
manuscript. Finally, this study focused on harvested AM and ROS generation and/or
scavenging, so the influence of ROS at the microvascular level following CeO2 NP
exposure is still unknown.
The observed endothelium-independent impairment is, at least partially, due to VSM
dysfunction, as sGC and downstream elements (e.g. cGMP) were observed to display
attenuated responses to YC-1 and 8-bromo-cGMP. Changes in cGMP signaling may
disrupt myoendothelial junction regulation, which can lead to an increase in intracellular
Ca2+ in the VSM and impair relaxation (Dora et al. 1997). Cyclic GMP is critical for PKG
activation by binding to specific sites on the enzyme (Taylor et al. 2004). If activation is
insufficient and intracellular Ca2+ does not decrease, the VSM cannot relax properly.
Furthermore, it is possible that PKG formation and/or functional levels decrease after CeO2
NP exposure. If PKG function is decreased, there may be a change in the enzyme’s kinetics
and intracellular Ca2+ may not be adequately sequestered, thus impairing dilation (Perri et
al. 2006). Lastly, increased phosphodiesterase activity can impair VSM relaxation by
prematurely or rapidly decreasing cGMP (Rybalkin et al. 2003). Investigations into the
specific roles of cGMP, PKG, and phosphodiesterase are necessary to determine their
impact on endothelium-independent microvascular impairment following CeO2 NP
exposure.
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In conclusion, we provide evidence that intravenous and gastric CeO2 NP exposures
cause endothelium-dependent and -independent arteriolar dysfunction. Furthermore,
these impairments may be mechanistically linked to decreased NO bioavailability and
altered VSM signaling, specifically involving cGMP. These results increase our insight of
the effects of exposure to CeO2 NP; however, the effects reported here must be, ultimately,
directly tested in vivo. This understanding is critical for the continued and expanded
development of therapeutic applications for CeO2 NP.
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Figure Legends:
Figure 1: ACh-induced vasodilation was impaired in arterioles following intravenous
injection (A: n = 8 - 15) and gastric gavage (B: n = 9 - 13) of CeO2 NP. * p ≤ 0.05 vs. control,
† p ≤ 0.05 vs. low dose CeO2 NP (50 µg for intravenous injection and 100 µg for gastric
gavage), ‡ p ≤ 0.05 vs. middle dose CeO2 NP (100 µg for intravenous injection and 300 µg
for gastric gavage). The brackets indicate differences in the overall slope of the
determination.

Figure 2: NO-induced vasodilation (via SPR) was impaired in mesenteric arterioles
following intravenous injection (A: n = 8 - 12) and gastric gavage (B: n = 8 - 10) of CeO2
NP. * p ≤ 0.05 vs. control, † p ≤ 0.05 vs. low dose CeO2 NP (50 µg for intravenous injection
and 100 µg for gastric gavage), ‡ p ≤ 0.05 vs. middle dose CeO2 NP (100 µg for intravenous
injection and 300 µg for gastric gavage), ^ p ≤ 0.05 vs. high dose CeO2 NP (900 µg for
intravenous injection and 600 µg for gastric gavage). The brackets indicate differences in
the overall slope of the determination.

Figure 3: Vasodilation in response increasing intraluminal pressure following intravenous
injection (A: n = 8 - 13) and gastric gavage (B: n = 9 - 10) of CeO2 NP was not significantly
different. * p ≤ 0.05 vs. control.

Figure 4: The left panels are vasodilation in response to increases in intraluminal flow
following intravenous injection (A: n = 5 - 10) and gastric gavage (B: n = 6 - 8) of CeO2 NP.
The right panels are vasodilation in response to increasing shear stress following
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intravenous injection (C: n = 6 - 10) and gastric gavage (D: n = 6 - 8) of CeO2 NP. * p ≤
0.05 vs. control.

Figure 5: Vasoconstriction stimulated by PE following intravenous injection (A: n = 7 - 12)
and gastric gavage (B: n = 9 - 11) of CeO2 NP was not significantly different. * p ≤ 0.05 vs.
control.

Figure 6: Calculated of EC50 for ACh (A) and SPR (B) for intratracheal instillation,
intravenous injection, and gastric gavage. The scatter plot (C) shows dilation response to
ACh (10-4 M) for all exposure routes. The following linear equations (y = mx + b) and r2
values were obtained for each exposure route: intratracheal instillation: y = -0.07x + 41.26,
r2 = 0.2513, intravenous injection: y = -0.03x + 49.39, r2 = 0.1994, and gastric gavage: y =
-0.05x + 54.71, r2 = 0.2465.

Figure 7: Vasodilation in response to ACh following incubation with either L-NMMA (10-4
M), INDO (10-5 M) or both inhibitors. There was a significant impairment in dilation of control
arterioles following incubation with L-NMMA and INDO (A: n = 14 - 34). There was a partial
restoration in function following incubation with L-NMMA after intratracheal instillation of 65
µg CeO2 NP (B: n = 5 - 14). Intravenous injection of 100 µg CeO2 NP caused an attenuated
response to ACh after incubation with INDO that was significantly different from the CeO2
NP exposure alone (C: n = 5 - 9). Gastric gavage of 400 µg CeO2 NP) caused a significant
impairment in arteriolar dilation following L-NMMA incubation compared to the CeO2 NP
exposure alone (D: n = 8 - 15). * p ≤ 0.05 vs. L-NMMA (10-4 M), † p ≤ 0.05 vs. INDO (10-5
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M), ‡ p ≤ 0.05 vs. both inhibitors, ^ p ≤ 0.05 vs. CeO2 NP exposure. The brackets indicate
differences in the overall slope of the determination.

Figure 8: CeO2 NP reacted with NO in an acellular environment (A). There was a
significant decrease in the amount of NO detected following intravenous injection (B: n =
14 - 21). NO was released with SNAP (1.6 x 10-4 M) for the acellular assessments and with
A23187 (10-5 M) for the cellular assessments. * p ≤ 0.05 vs. control, † p ≤ 0.05 vs.
intratracheal instillation.

Figure 9: CeO2 NP ability to scavenge and/or generate free radicals was assessed in an
acellular environment (A: n = 3), with control AM (B: n = 4 - 7), and with AM from CeO2
exposed animals via different exposure routes (C: n = 7 - 9). Images of representative
superoxide and hydroxyl free radical spectra are inset in panel A. * p ≤ 0.05 vs. control, †
p ≤ 0.05 vs. Cr6+ alone, ‡ p ≤ 0.05 vs. control AM + CeO2 NP, ^ p ≤ 0.05 vs. gastric gavage
AM + CeO2 NP. NoP = No detectable ESR peaks.

Figure 10: VSM function was impaired following CeO2 NP exposure and was not exposure
route-dependent. Soluble GC activation was assessed with YC-1 (A: n = 8 - 11). Cyclic
GMP responsiveness was assessed with 8-bromo-cGMP (B: n = 10). * p ≤ 0.05 vs. control,
† p ≤ 0.05 vs. intratracheal instillation. The brackets indicate differences in the overall slope
of the determination.
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Tables:

Table 1: Animal Characteristics
Groups

N

Age
(weeks)

Weight
(g)

MAP
(mm Hg)

Heart Weight
(g)

Control-Saline
41
10.61 ± 0.4
392 ± 10 105 ± 4
1.28 ± 0.03
Intravenous Injection Dose-Response Determination
50 µg CeO2 NP
7
8.43 ± 0.3
338 ± 8
102 ± 2
1.22 ± 0.02
100 µg CeO2 NP
8
9.76 ± 0.09
382 ± 3
112 ± 3
1.34 ± 0.01
900 µg CeO2 NP
8
9.50 ± 0.28
364 ± 6
107 ± 2
1.31 ± 0.02
Gastric Gavage Dose-Response Determination
100 µg CeO2 NP
9
10.11 ± 0.4
383 ± 11 98 ± 4
1.30 ± 0.03
300 µg CeO2 NP
8
9.38 ± 0.6
371 ± 17 100 ± 3
1.33 ± 0.04
600 µg CeO2 NP
8
8.88 ± 0.4
376 ± 18 96 ± 4
1.29 ± 0.06
Calculated EC50 Doses (µg)
65 µg CeO2 NP
14
9.45 ± 0.1
381 ± 4
99 ± 2
1.29 ± 0.02
(0.19 mg/kg via
intratracheal
instillation)
100 µg CeO2 NP
11
9.27 ± 0.1
384 ± 5
109 ± 1
1.32 ± 0.03
(0.29 mg/kg via
intravenous
injection)
400 µg CeO2 NP 21
9.59 ± 0.2
365 ± 8
98 ± 5
1.36 ± 0.07
(1.14 mg/kg via
gastric gavage)
Values are means ± SE. N = number of animals. MAP = Mean Arterial Pressure. The mg/kg
concentrations were calculated based on a representative animal weight of 350 g.
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Table 2: Basal Arteriolar Characteristics
Diameter (µm)
Groups

n

Steady
Max
Tone
WT
WLR
State
(%)
(µm)
Control-Saline
57 81 ± 2
117 ± 14
27 ± 2
16 ± 1.6
0.18 ± 0.01
Intravenous Injection Dose-Response Determination
50 µg CeO2 NP
9
73 ± 3
104 ± 4
29 ± 2
13 ± 0.4
0.18 ± 0.01
100 µg CeO2 NP 10 74 ± 3
104 ± 3
29 ± 3
12 ± 0.6
0.17 ± 0.01
900 µg CeO2 NP 12 77 ± 3
111 ± 3
30 ± 2
13 ± 0.9
0.16 ± 0.01
Gastric Gavage Dose-Response Determination
100 µg CeO2 NP 13 76 ± 4
104 ± 5
28 ± 2
12 ± 0.8
0.16 ± 0.01
300 µg CeO2 NP 11 80 ± 3
113 ± 4
28 ± 2
14 ± 0.5
0.17 ± 0.01
600 µg CeO2 NP 12 78 ± 4
107 ± 5
27 ± 2
12 ± 0.5
0.16 ± 0.01
Calculated EC50 Doses (µg)
65 µg CeO2 NP
13 80 ± 3
110 ± 4
27 ± 2
11 ± 0.5
0.14 ± 0.01
(0.19 mg/kg via
intratracheal
instillation)
100 µg CeO2 NP 11 75 ± 4
108 ± 3
30 ± 3
12 ± 1.1
0.16 ± 0.01
(0.29 mg/kg via
intravenous
injection)
400 µg CeO2 NP 20 75 ± 2
101 ± 3
26 ± 1
12 ± 0.5
0.15 ± 0.01
(1.14 mg/kg via
gastric gavage)
Values are means ± SE. n = number of vessels. WT= Wall Thickness WLR= Wall to Lumen
Ratio. The mg/kg concentrations were calculated based on a representative animal weight
of 350 g.
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Abstract:
Cerium dioxide nanoparticles (CeO2 NP) hold great theranostic potential, but their
in vivo anti-oxidant activity is unclear. Due to this anti-oxidant action and previous
microvascular assessments, we hypothesize that CeO2 NP injection would result in
decreased microvascular dysfunction and oxidative stress associated with hypertension.
In order to simulate a therapeutic application, spontaneously hypertensive (SH) and WistarKyoto (WKY) rats were intravenously injected with either saline or CeO2 NP. Twenty-four
hours post-exposure mesenteric arteriolar reactivity was assessed via intravital
microscopy. Endothelium-dependent and –independent function was assessed via
acetylcholine and sodium nitroprusside. Microvascular oxidative stress was analyzed using
fluorescent staining in isolated mesenteric arterioles. Finally, systemic inflammation was
examined using a multiplex analysis and venular leukocyte flux. Endothelium-dependent
dilation was significantly decreased in the SH rats and this microvascular dysfunction was
significantly improved following CeO2 NP exposure. There was also an increase in
oxidative stress in the SH rats, which was abolished following CeO2 NP treatment. These
results provided evidence that CeO2 NP act as an anti-oxidant in vivo. There were also
changes in the inflammatory profile in the WKY and SH rats. In WKY rats, IL-10 and TNFα were increased following CeO2 NP treatment. Finally, leukocyte flux was increased in the
SH rats, but this activation was decreased following exposure. These results indicated that
CeO2 NP may alter the inflammatory response in both SH and WKY rats. Taken together,
these results provide evidence that CeO2 NP act an anti-oxidant in vivo and may improve
the health outcomes associated with hypertension.
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Introduction:
The term “theranostic” is an emerging concept that combines the terms therapeutic
and diagnostic (Kelkar and Reineke 2011). Theranostic research aims to identify agents
that possess both therapeutic and diagnostic properties, which ideally would result in more
precise

and

individualize

treatments

(Kelkar

and

Reineke

2011).

Engineered

nanomaterials (ENM) are prime candidates for theranostic applications for several reasons
(Kelkar and Reineke 2011). First, the size of ENM (≤ 100 nm in at least on dimension)
creates a large surface area for the attachment of various pharmaceuticals and/or imaging
agent (Borm et al. 2006). Secondly, by altering the surface chemistry and/or using specific
ENM, they may be precisely aimed at target areas in the body, which (in conjunction with
a high surface) reduces the dosage needed to treat certain pathologies (Roco et al. 2010;
Yu et al. 2010a). Finally, many ENM possess inherent unique characteristics (e.g. autofluorescence, and anti-oxidant activity) that can be exploited to increase their
pharmaceutical relevance (Borm et al. 2006).
Cerium dioxide nanoparticles (CeO2 NP), an ENM, are being researched for their
possible theranostic significance (Colon et al. 2009; Kim et al. 2012; Madero-Visbal et al.
2012). CeO2 NP have catalytic activity, which arises from the presence of two valances
states (Ce3+ and Ce4+) in the nanoparticles (Celardo et al. 2011). Due to the oxygen
vacancies present in these nanoparticles, they are able to react with surrounding reactive
oxygen species (ROS), thus introducing CeO2 NP as a potential in vivo mimetic for
endogenous anti-oxidants like superoxide dismutase (Dunnick et al. 2015; Heckert et al.
2008; Xu and Qu 2014).
However, like many pharmaceuticals, CeO2 NP research has produced conflicting
results about the efficiency of its potential anti-oxidant activity. In vitro analysis has resulted
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in an increase in ROS and inflammation following CeO2 NP co-incubation; however, other
studies with cardiac progenitor and endothelial cells have shown a decrease in both these
parameters (Gojova et al. 2009; Horie et al. 2011; Pagliari et al. 2012; Park et al. 2008;
Wingard et al. 2011). The in vivo analysis of these particles is even more complex.
Experimentally, injected CeO2 NP have shown decreased tissue damage and area of
infarct associated with radiation treatment and stroke (Colon et al. 2009; Kim et al. 2012).
Despite these promising results, CeO2 NP injected into young healthy rats may have
detrimental effects that result in microvascular dysfunction (Minarchick et al. 2015).
Currently, it is unclear if the potential positive effects of CeO2 NP are pathology specific.
Furthermore, it is also unknown how these alterations in ROS production affect
microvascular function.
Hypertension affects one out of three Americans and is a leading factor in the
development of cardiovascular disease (Nwankwo T et al. 2013). This increase in blood
pressure is associated with microvascular dysfunction, increased sympathetic stimulation
and increased wall-to-lumen ratios (Feletou and Vanhoutte 2006; Okamoto et al. 1967).
Microvascular dysfunction is, at least partially, attributed to increased ROS generation due
to chronic inflammation, mitochondrial dysfunction, and/or nitric oxide synthase (NOS)
uncoupling (Brito et al. 2015). In addition to decreasing vasoactive factors directly, the
elevated levels of ROS are capable of increasing steroid hormone production, which can
impair NOS activity and prostaglandin formation (Suzuki et al. 1995). These changes may
result in endothelium dysfunction, which increases the risk of organ damage, and the
development of hypertension. These influences of ROS on microvascular function in
hypertension has led to the investigation of anti-oxidants as a therapeutic treatment (Brito
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et al. 2015). If the anti-oxidant potential of CeO2 NP were better understood, this ENM
could be developed to decrease the high levels of ROS associated with hypertension.
Therefore, the purpose of this study was to assess the in vivo anti-oxidant potential
of CeO2 NP in a high ROS environment, specifically hypertension. Previous in vitro studies
have shown that in the presence of elevated ROS CeO2 NP act as an anti-oxidant and can
decrease ROS levels (Minarchick et al. 2015). Based on these results, we hypothesize that
following injection the CeO2 NP will act as an anti-oxidant and reduce the oxidative stress
and microvascular dysfunction that is associated with hypertension. Microvascular
dysfunction and oxidative stress were assessed in the mesentery of spontaneously
hypertensive rats 24 h post-exposure to CeO2 NP via intravital microscopy and the isolated
arteriole technique.
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Methods and Materials:
Cerium Dioxide Nanoparticle (CeO2 NP) Production and Characterization: CeO2 NP
powders were synthesized by a hydrothermal process as previously described (Minarchick
et al. 2013). Cerium (IV) ammonium nitrate (99+% Alfa Aesar, Ward Hill, MA) was added
to de-ionized water (H2O) and this solution was added drop-wise into a basic solution of
tetramethylammonium hydroxide pentahydrate and de-ionized H2O. The pH of the
dispersion was altered to ~10.5 with ammonium hydroxide and was maintained throughout
the reaction. The dispersion was placed in a 300 ml Autoclave Engineers EZE-Seal
autoclave (Erie, PA) at 240˚C for one h. Once removed from the autoclave, the dispersion
was placed into a centrifuge and the liquid was removed and replaced with ethanol. After
the washing step, the dispersion was dried at 60 ˚C overnight and sieved through a 200
mesh screen for characterization. The nanoparticles were previous characterized
(Minarchick et al. 2013). Briefly, the CeO2 NP had a surface area of 81.36 m2/g measured
by Micromeritics ASAP 2020 (Norocross, GA). JEOL JEM-2100 High Resolution
Transmission Electron Microscope (TEM) (Peabody, MA) determined the primary particle
size (~2-4 nm) and shape (spherical). The average agglomerate size in saline (Normosol,
Nospira Inc., Lake Forest, IL) and 5% fetal bovine serum (FBS) was 191 nm as determined
by dynamic light scattering via a Malvern Zetasizer version 7.01 (Westborough, MA).
Finally, the valence state of the CeO2 NP was ~81% Ce4+ and ~19% Ce3+ determined by
x-ray photoelectron spectroscopy (PHI 5000 Versaprobe XPS, Chanhassen, MN).

Experimental Animals: Male spontaneously hypertensive (SH) rats and WistarKyoto (WKY) rats (~10 weeks old) were purchased from Harlan laboratories (Indianapolis,
IN). SH rats were studied because they are a well-established model of microvascular
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dysfunction and local ROS (Bakker et al. 2014; Brito et al. 2015). WKY rats are the
appropriate normotensive control for the SH and were used as the control model for these
experiments (Okamoto et al. 1967). The rats were housed at the West Virginia University
Health Sciences Center Vivarium, in laminar flow cages, under controlled humidity and
temperature, with a 12 h light/dark cycle, and food and water were provided ad libitum. The
animals were acclimated for a minimum of two days prior to use. The Institutional Animal
Care and Use Committee at West Virginia University approved all procedures.
CeO2 NP Solution Preparation and Exposure: For the stock suspension, 1.1 mg of
dry powder added to 10 ml of Normosol with 5% FBS to reduce agglomeration. The CeO2
NP were vortexed for five min and then sonicated on ice for an additional five min. Rats
were lightly anesthetized with isoflurane gas (5% induction, 2-3.5% maintenance). Rats
were divided into four groups and were intravenously injected in the tail vein with a 900 µl
bolus dose of saline (WKY-Sham, SH-Sham) or CeO2 NP stock suspension (WKY-CeO2
NP, SH-CeO2 NP) using a 23G needle. The final dose was 100 µg per rat. This dose was
predetermined to be the dose that caused a 50% impairment in microvascular function in
Sprague-Dawley rats (Minarchick et al. 2015). Rats were monitored after treatment until
they regained consciousness. All animals were allowed to recover for 24 h prior to
experimental assessments.
Intravital Microscopy Preparation: Animals were anesthetized with Inactin [100
mg/kg, intraperitoneal (i.p.) injection] and placed on a heating pad to maintain a 37 °C rectal
temperature. The trachea was intubated to maintain a patent airway, and the right carotid
artery was cannulated to monitor MAP and heart rate. A loop of the small intestine (ileum)
was surgically exteriorized. Once exteriorized, two small incisions 6-10 cm apart were
made along the intestinal wall using thermal cautery and the chyme was flushed from the
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lumen through the incisions. The ileum was then carefully placed over a clear pedestal,
and gently secured so that the mesenteric circulation was at its in situ length. Throughout
the preparation and experiment, the exposed mesentery was continuously superfused with
an electrolyte solution (119 mM NaCl, 25 mM NaHCO3, 6 mM KCl, and 3.6 mM CaCl2) that
was warmed to 37 ºC and equilibrated with 95% N and 2-5% CO2 (pH 7.35-7.40). Intestinal
motility was suppressed using isoproterenol hydrochloride (10 mg/l, Sigma-Aldrich, St.
Louis MO) and phenytoin (20 mg/l, Sigma-Aldrich, St. Louis MO). At these concentrations,
isoproterenol and phenytoin have no significant effect on arteriolar tone (Bohlen et al.
1978). The superfusate rate was maintained at 4-6 ml/min to minimize equilibration with
atmospheric oxygen (Boegehold and Bohlen 1988). The animal preparation was then
transferred to the stage of an intravital microscope coupled to a charge-coupled device
(CCD) video camera. Observations were made with a 20x water immersion objective.
Video images were displayed on a high-resolution color video monitor and recorded for offline analysis. During analysis, arteriolar inner diameters were measured with a video
caliper and one to three arterioles were studied per rat.
Microvascular Analysis: Arteriolar endothelium-dependent dilation was evaluated using
acetylcholine (ACh, 0.25 M). ACh was iontophoretically applied to individual 5th order
arterioles (20, 100, and 150 nAmp). Glass micropipettes were beveled at 23-25º angle with
2-4 µm inner diameter tip and filled with ACh (Nurkiewicz et al. 2004). The pipette tip was
placed in light contact with the arteriolar wall and a current programmer (model 260; World
Precision Instruments, New Haven, CT) was used to deliver continuous ejection currents
(two min). A recovery period (at least two min) followed each application. The ACh
response determination was repeated in the presence of several chemical interventions
which were applied via syringe pump (0.4 ml/min) into the superfusate delivery line for 30
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min. The mesentery was incubated with NG-monomethyl-L-arginine (L-NMMA, 10-4 M), a
NOS inhibitor, to assess the influence of NO. Incubation with indomethacin (INDO, 10-5 M),
a cyclooxygenase (COX) inhibitor, was used to assess the influence of COX products. The
mesentery was also incubated with 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL, 10-4
M), a superoxide dismutase mimetic, and catalase (50 units/ml), a hydrogen peroxide
scavenger, to assess the influence of ROS. All four chemical interventions (L-NMMA,
INDO, TEMPOL and catalase) were applied to the mesentery to determine influence of
NO, COX products, and ROS simultaneously. Vascular smooth muscle responsiveness to
NO was assessed using sodium nitroprusside (SNP, 0.05 M). SNP was iontophoretically
applied to arterioles as previously described (10, 50, and 150 nAmp) (Nurkiewicz et al.
2004). Microvascular reactivity assessments and ejection currents were randomized and
two to three assessments were completed per rat. At the end of each experiment,
adenosine (ADO, 10-4 M) was added to the superfusate via syringe pump to determine the
passive diameter of each arteriole studied.
Finally, leukocyte flux was assessed in mesenteric venules to determine potential
microvascular inflammation. Leukocytes that were either stationary or moving but
maintained consistent contact with the arteriolar wall for at least 200 µm were counted for
one min in each venule studied.
Oxidative Stress Analysis: A separate subset of animals (~10 weeks old) was used
to determine changes in microvascular oxidative stress via fluorescent analysis. SH and
WKY rats were exposed to either saline or CeO2 NP as previous described. Twenty-four h
post-exposure, the animals were anesthetized with Inactin (100 mg/ kg, ip injection) and
were placed on a heating pad to maintain a 37 °C rectal temperature. The right carotid
artery was cannulated to acquire blood for subsequent cytokine analysis (see Pro162

Inflammatory Cytokine Analysis). The mesentery was removed and placed in a dissecting
dish with physiological salt solution (PSS) maintained at 4 °C (Minarchick et al. 2015).
Mesenteric arterioles (4th and 5th order) were isolated, transferred to a vessel chamber,
cannulated between two glass pipettes, and tied with silk sutures (Living Systems
Instrumentation, Burlington, VT). In the absence of light, dihydroethidium (DHE, 10-4 M)
was intraluminally infused for 20 min followed by a 20 min wash with PSS to remove excess
DHE. Prior to imaging, the arterioles were pressurized to 80 mm Hg using a servo control
system (Sun et al. 1992). The vessel chamber was placed on an Olympus BX51WI upright
microscope for imaging. The arteriole was first imaged briefly under traditional bright field
settings. The arteriole was illuminated with a mercury lamp for one second with the
appropriate excitation and emission filters for detection of ethidium bromide fluorescence
(480-550 nm bandpass, 590 nm barrier) and hydroethidine fluorescence (330-385 nm
bandpass, 590 nm barrier). DHE was used because it easily permeates cell membranes
and can be oxidized by superoxide to form ethidium bromide which intercalates into nuclear
DNA (Benov et al. 1998; Morgan et al. 1979).
ROS-associated fluorescence was quantified in the arteriolar wall. A user-defined
region of interest (ROI) box (10 X 100 µm) was placed vertically on the endothelial cell
layer of the bright field image. It was previously determined that the mesenteric arteriolar
wall thickness was approximately 13 µm; therefore, the ROI box encompassed the entire
endothelial cell layer and most of the smooth muscle layer. The images were analysed
using open access imaging software (ImageJ). The hydroethidine image represented
background and non-specific fluorescence, therefore in order to analyse only fluorescence
which had been intercalated into the DNA this fluorescence was removed from the ethidium
bromide image. The ROI was superimposed on the resulting image in order to acquire the
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mean fluorescence of the arteriole. Total fluorescence intensity was calculated as average
fluorescence intensity per pixel x surface area.
Pro-Inflammatory Cytokine Analysis: The blood collected from the SH and WKY rats
was centrifuged (1100 x g) to separate the blood components. The plasma was collected,
flash frozen in liquid nitrogen, and stored in a -80 °C freezer until analysis. A proinflammatory cytokine multi-spot assay was completed per manufacturer's directions
(MesoScale Diagnostics, Rockville, MD). The pro-inflammatory cytokines assessed were:
interferon gamma (IFN-γ), interleukins-1beta, 4, 5, 6, 10 and 13 (IL-1β, IL-4, IL-5, IL-6, IL10,

and

IL-13),

tumor

necrosis

factor

alpha

(TNF-α)

and

keratinocyte

chemoattractant/human growth-regulated oncogene (KC/GRO).
Equations: Basal tone was calculated by the following equation,

Basal Tone (%) = [(DM - DBD)/ DM] x 100,

where DBD is the baseline diameter measured prior to any current application, and DM is
the passive diameter recorded in the presence of ADO. The experimental responses to
ACh and SNP are expressed using the following equation:

Diameter (Percent Maximal Response) = [DSS - DBD)/ (DM - DBD)] x 100,

where DSS is the maximal diameter recorded at each current.
Statistics: Data are expressed as means ± standard error (SE). Point-to-point
differences in the dose-response determinations were evaluated using two-way repeated
measures analysis of variance (ANOVA) with a Student-Newman-Keuls post-hoc analysis
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when significance was found. Statistical differences in the slopes of the dose-response
determinations were determined by linear regression analysis. The animal characteristics,
arteriole characteristics, oxidative stress, and pro-inflammatory cytokine results were
analyzed using a one-way ANOVA with a Student-Newman-Keuls post-hoc analysis when
significance was found. All statistical analysis was completed with SigmaPlot 11.0 (San
Jose, CA) and GraphPad Prism 5 (San Diego, CA). Significance was set at p ≤ 0.05, n is
the number of arterioles, and N is the number of animals.
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Results:
Animal and Arteriolar Characteristics: There were no significant changes in age or
heart rate between the four groups (Table 1). MAP and heart weight were significantly
increased in the SH-Sham and SH-CeO2 NP groups compared to the normotensive WKY
groups (Table 1). These findings are consistent with SH rat characteristics. There was also
a significant increase in body weight in the SH-CeO2 NP group compared to the WKY
groups (Table 1). Finally, there were no observed arteriolar differences in starting diameter,
maximal diameter, and basal tone between the four groups (Table 2). These results
indicate that CeO2 NP injection exposure does not influence blood pressure or arteriolar
tone, when comparing WKY and SH groups.
Endothelium-Dependent Dilation: Endothelium-dependent dilation was significantly
impaired in the SH-Sham group compared to the WKY groups (Figure 1). Following 100
µg injection of CeO2 NP, there was a significant augmentation in endothelium-dependent
dilation in the SH-CeO2 NP group compared to the SH-Sham group (Figure 1). However,
this dilation was still significantly impaired compared to the WKY-Sham group (Figure 1).
These data provide evidence that injected CeO2 NP can partially improve the
microvascular dysfunction associated with hypertension.
Endothelium-Independent Dilation: Endothelium-independent dilation was not
impaired in the SH or WKY groups (Figure 2). This indicates that CeO2 NP injection
exposure and hypertension, either alone or together, do not impair arteriolar vascular NO
smooth muscle signaling.
Contribution of NO, COX Products, and ROS to ACh-Induced Vasodilation: The role of NO
in ACh-induced vasodilation was assessed during incubation with L-NMMA. Incubation of
the mesentery with L-NMMA significantly reduced vasodilation in response to ACh, both in
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terms of the overall slopes and at the highest ejection current, in the WKY-Sham and WKYCeO2 NP groups (Figures 3A and 4A). There was a significant increase in dilation in the
SH-Sham during incubation with L-NMMA, but there was no improvement in arteriolar
dilation during incubation in the SH-CeO2 NP group (Figure 4A).
The role of COX products were assessed during incubation with INDO. There was
also a significant impairment in arteriolar reactivity, in regards to the overall slopes and at
the highest ejection current, during incubation with INDO in the WKY-Sham and WKYCeO2 NP groups (Figures 3B and 4B). There was no change in vasodilation during
incubation in the SH-Sham group (Figure 4B). Finally, there was a significant increase in
vasodilation in the SH-CeO2 NP during INDO incubation (Figure 4B).
Local ROS was scavenged during simultaneous incubation with TEMPOL and
catalase. There was no change in arteriolar vasodilation during TEMPOL and catalase
incubation in the WKY-Sham, WKY-CeO2 NP, and SH-CeO2 NP groups (Figure 3C and
4C). There was a significant increase in the response to ACh in the SH-Sham group during
incubation with exogenous anti-oxidants (Figure 4C).
Finally, arteriolar dilation was assessed during co-incubation with all four chemical
interventions. In regards to the overall slopes and the highest ejection current, there was
significant decrease in arteriolar reactivity in the WKY-Sham and WKY-CeO2 NP (Figures
3D and 4D). In the SH groups, there was no significant changes in arteriolar vasodilation
in the SH-Sham group, but there was a significant increase in dilation in the SH-CeO2 NP
group (Figure 4D). Overall, these data provide initial evidence that there is differential
contributions of NO, COX products, and ROS to vasodilation after CeO2 NP injection
exposure in the SH rats. Additionally, these data provide evidence that CeO2 NP act as an
anti-oxidant in vivo.
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Microvascular Oxidative Stress: There was a significant increase in microvascular
oxidative stress in the SH-Sham group compared to the WKY groups (Figures 5A and B).
The level of oxidative stress in the SH rats was significantly decreased following CeO2 NP
exposure and the level of oxidative stress in the SH-CeO2 NP was similar to the WKYSham group (Figures 5A and B). There were also no significant differences between the
WKY-Sham and WKY-CeO2 NP groups (Figures 5A and B). Taken together, these results
provide evidence that CeO2 NP have anti-oxidant activity in vivo.
Systemic Inflammation and Biomarkers: Venular leukocyte flux was assessed in all
four groups. There was a significant increase in leukocyte activation in the SH-Sham group
compared to the WKY-Sham, WKY-CeO2 NP, and SH-CeO2 NP groups (Figure 6A). This
activation was significantly decreased in the SH animals following exposure to CeO2 NP
(Figure 6A). There was also no change in leukocyte activation between the WKY-Sham
and WKY-CeO2 NP (Figure 6A). Pro-inflammatory cytokines were analyzed in harvested
plasma. There were no significant differences in IFN-γ, IL-4, IL-5, IL-6, IL-13, and KC/GRO
between the groups (data not shown). There was a significant increase in IL-10 and TNFα in the WKY-CeO2 NP group compared to the other three groups (Figures 6B and C).
Finally, there was a decrease in IL-1β in the SH-Sham and SH-CeO2 NP groups compared
to both WKY groups (Figure 6D). Taken together these results provide evidence that
injected CeO2 NP may alter inflammatory signaling pathways in both normotensive and
hypertensive animals.
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Discussion:
To our knowledge, this study was the first to investigate the in vivo anti-oxidant
potential of CeO2 NP in a hypertensive animal model. The first major finding of this study
is that CeO2 NP act as an anti-oxidant in vivo resulting in decreased microvascular
dysfunction and oxidative stress that is associated with hypertension. The second finding
of this study was that there were changes in the pro-inflammatory cytokine profile following
CeO2 NP exposure.
Intravenously injected CeO2 NP significantly reduced the level of oxidative stress
in the SH rats, which contributed to decreased microvascular dysfunction. This finding
supports the notion that CeO2 NP act as an anti-oxidant, and this finding is corroborated
by numerous studies (Colon et al. 2010; Estevez et al. 2011; Kim et al. 2012). Despite this
positive result, previous studies have shown a decrease in vascular function following
CeO2 NP exposure (Minarchick et al. 2015; Wingard et al. 2011). These disparate effects
may be due to several reasons including the basal level of ROS and the animal model.
SH rats have an increase basal level of ROS, that was not present in the SpragueDawley rats that were used in previous studies (LeBlanc et al. 2010). An increase in ROS
generation is also observed during radiation treatments and stroke, where these ENM were
shown to be beneficial. This conceptual need for an increased basal level of ROS is also
supported in vitro. Cardiac progenitor cells and cardiomyocytes were protected from high
ROS levels when CeO2 NP were present (Niu et al. 2011; Pagliari et al. 2012).
Furthermore, there were not high initial levels of ROS production in studies that reported
an increase in ROS following CeO2 exposure (Horie et al. 2011; Park et al. 2008). When
taken together these studies support the hypothesis that CeO2 NP work optimally as an
anti-oxidant when there are elevated levels of ROS prior to or in conjunction with exposure.
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In addition to the potential changes in ROS, the selected animal model may also
influence the lack of microvascular influences following CeO2 NP in the WKY rats. Both the
WKY and SH animals are inbred strains compared to the outbred Sprague-Dawley rat used
in other studies with CeO2 NP. Genetic modifications have been shown to alter the effects
of ENM exposure. CeO2 NP exposed mice have an increase in pulmonary inflammation
and vascular dysfunction; however, when the mice were genetically modified to knockout
mast cell production these effects were absent (Wingard et al. 2011). Therefore, it is
reasonable to speculate that genetic differences between the WKY, SH, and SpragueDawley rat lineages may contribute to the differences observed in microvascular reactivity.
Further studies are required to investigate potential genetic differences and their influence
on the cardiovascular outcomes following ENM exposure.
Despite the partial decrease in microvascular dysfunction, CeO2 NP could not
completely restore normal microvascular function in the SH animal model (Figure 1). This
lack of an overall improvement could be due to arachidonic acid (AA) metabolism via COX.
This study provides evidence that CeO2 NP exposure results in an apparent shift between
NOS and COX activity, resulting in a potential increase prostaglandins production, via
increased COX activity. Furthermore, the changes in AA signaling appear to be unique to
CeO2 NP exposure in the SH animal model. An increase in prostaglandin production can
affect microvascular reactivity by influencing both vasodilation and vasoconstriction. Based
on this data, it can be speculated that CeO2 NP exposure increases thromboxane A2
activity,

which

would

result

in

vasoconstriction.

This

increased

influence

on

vasoconstriction would prevent the arterioles from fully dilating in response to ACh.
However, additional studies will need to be completed to determine the influence of CeO2
NP on AA signaling and COX activation.
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This study provides promising evidence of the in vivo anti-oxidant potential of CeO2
NP; however, it is currently unclear if CeO2 NP are operating at their maximal efficiency in
vivo. One of the primary factors that could affect the cardiovascular outcomes of CeO2 NP
(and ENM in general) is the dose. The dose used in this study was approximately 0.42
mg/kg based on an average animal weight of 240 g. This dose was on the lower end of the
published effective doses (0.4-0.7 mg/kg) used to protect mice from stroke damage (Kim
et al. 2012). Therefore, it is reasonable to speculate that increasing the dose may improve
CeO2 NP anti-oxidant effectiveness in hypertensive animals. Therefore, dose refinement
could potentially result in a further improvement in microvascular function and decreased
oxidative stress. Understanding the cardiovascular effects particularly in regards to the
effective dose is vital if CeO2 NP are to be developed as a pharmaceutical agent.
Additionally, the dose needs to be better understood because research has shown that
higher concentrations of CeO2 NP may result in decreased anti-oxidant activity and an
increase in pro-oxidant activity (Horie et al. 2011). This shift in activity highlights the need
to investigate various doses within a model, and additional doses will need to be tested to
explore the full potential of CeO2 NP treatment to improve the microvascular dysfunction
associated with hypertension.
Another factor that may influence the efficiency of CeO2 NP anti-oxidant activity is
the primary size of the nanoparticles. The ENM used in this study and in another stroke
study had a primary size of 3-4 nm; however, studies that used larger ENM (> 20 nm) have
been associated with an increase in ROS as opposed to a decrease (Kim et al. 2012; Park
et al. 2008). This difference in the cellular effects has also been observed with other ENM.
Silver nanoparticles with a diameter < 40 nm had increased cell permeability and toxicity
versus their larger counterparts (> 40 nm) (Sheikpranbabu et al. 2010; Trickler et al. 2010).
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This not only illustrates the importance of characterizing the size of the ENM used but also
how a small change in ENM size can alter the biological effects.
The proposed anti-oxidant activity is most likely connected to the valance states
(Ce3+ and Ce4+) that are present in CeO2 NP. Both valance states can react with any free
radical, but research has shown that depending on the valence state this ENM will
preferentially react with various oxidants. Under in vitro conditions, Ce3+ preferentially
reacts with superoxide and Ce4+ reacts with NO (Xu and Qu 2014). The CeO2 NP used in
this study were ~19% Ce3+ and 81% Ce4+ indicating they may react more readily with NO
and may not be functioning at their maximal level (Minarchick et al. 2013). This potential
decreased effectiveness may explain why the level of microvascular ROS was not below
control levels. Additionally, it has been shown that pH can affect the valance state stability
of CeO2 NP suggesting that the ENM may change valance states in an in vivo setting;
however, it is currently unknown to what extent CeO2 NP are modified following in vivo
exposure (Hayes et al. 2002).
CeO2 NP exposure has also been associated with changes in inflammation. Similar
to this study, others have shown an increase in pro-inflammatory cytokines, changes in the
leukocyte, and inflammatory NOS expression following in vivo CeO2 NP exposure but
these results are often inconsistent (Cho et al. 2010; Hirst et al. 2009; Hussain et al. 2012).
In this study, an increase in cytokines expression (e.g. TNF-α and IL-10) was present in
the normotensive CeO2 NP exposed animals and it has been well established that
inflammation is associated with microvascular dysfunction (LeBlanc et al. 2009; Nurkiewicz
et al. 2006). Furthermore, an increase in TNF-α and IL-10 is associated with the activation
of macrophages via toll-like receptors, which further supports CeO2 NP potential to modify
inflammation (Mosser 2003).
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Furthermore, these changes in inflammatory cytokines and leukocyte flux could
indicated that CeO2 NP modify thrombosis development. The increase in leukocyte flux in
the SH rats provide indirect evidence for endothelial cells activation, which results in the
production various adhesion proteins and factors essential for impairing fibrinolysis (i.e.
plasminogen activator inhibitor-1). Plasminogen activator inhibitor-1 (PAI-1) is secreted by
macrophages, endothelial cells and vascular smooth muscle cells. Furthermore, this factor
is controlled by oxidative stress. Studies with nano-copper oxide have shown an increase
in PAI-1 secretion following exposure and it is possible that this factor is also elevated in
the SH-Sham rats, thus increasing risk of thrombosis (Yu et al. 2010b). However, following
CeO2 NP exposure there is a decrease in leukocyte flux in the SH rats, which could indicate
a decreased thrombosis risk.
It should also be noted that in this study there was no microvascular impairment in
the normotensive rats despite an increase in pro-inflammatory cytokines. This lack of
impairment may be contributed to the time post-exposure (24 h) when reactivity was
assessed and the lack of an increased leukocyte flux in the WKY group further supports
this notion. If the animals were exposed for a longer period of time (over 24 h), an increase
in the activation of adhesion molecules and, ultimately, leukocyte extravasation may lead
to an increase in microvascular dysfunction and thrombosis development.
Finally, the time of inflammatory assessments may also have contributed the
changes in circulating cytokines. TNF-α is classically considered a pro-inflammatory
cytokine that is involved in macrophage activation, whereas IL-10 is often considered an
anti-inflammatory cytokine because is it capable of inhibiting TNF-α and IFN-γ (Feghali and
Wright 1997). In this study, it is possible that at 24 h IL-10 is beginning to increase, whereas
TNF-α may be beginning to decrease, and this change in expression could result in the
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brief elevation of both cytokines. Additionally, based on these results, it is reasonable to
speculate that CeO2 NP may have anti-inflammatory potential due to the increase in IL-10.
Furthermore, SH rats typically have chronic inflammation, which contributes to their
microvascular dysfunction (Sanz-Rosa et al. 2005). This study showed limited changes in
inflammation in the SH animals and this lack of pro-inflammatory cytokine production may
due to the age of the animals and/or the assessment time used in this study. Further studies
will need to investigate the relationship between CeO2 NP, the inflammatory response, and
exposure time in normotensive and hypertensive rats.
In conclusion, this study provides evidence that exposure to CeO2 NP decrease
microvascular dysfunction due to a decrease in microvascular oxidative stress. These
results further our understanding of CeO2 NP behavior in vivo and highlight their
therapeutic potential as an anti-oxidant, particularly in pathologies associated with elevated
ROS. Furthermore, this study showed changes in the inflammatory profile following CeO2
NP exposure. These changes were primarily observed in the WKY group, which highlight
the need for further research on this ENM in order to understand fully its influences on
systemic inflammation. Fully understanding how CeO2 NP act in vivo in both low and high
ROS environments is critical for the continued and expanded development of this potential
theranostic agent.
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Figure Legends:
Figure 1 Endothelium-Dependent Dilation: ACh-induced vasodilation was impaired in
arterioles from SH-Sham animals but was significantly improved in the SH-CeO2 NP group
comparted to the SH-Sham (n = 12-29). * p ≤ 0.05 vs. WKY-Sham, † p ≤ 0.05 vs. WKYCeO2 NP, ‡ p ≤ 0.05 vs. SH-Sham
Figure 2 Endothelium-Independent Dilation: Vascular smooth muscle responsiveness
to NO was not impaired in the Sham groups or following CeO2 NP exposure (WKY-CeO2
NP and SH-CeO2 NP groups; n = 9-19).
Figure 3 Overall Influences of NO, COX products, and ROS: The line graphs are the
arterioles overall response to the various chemical interventions. A: The role of NO was
assessed during incubation with L-NMMA (n = 14-18). This incubation resulted in a
significant difference in the overall slopes of the dose-response determination within the
WKY groups only. B: The role of COX products was assessed during incubation with INDO
(n = 9-14). This incubation resulted in a significant difference in the overall slopes of the
dose-response determination within the WKY groups only. C: Local ROS was scavenged
during incubation with TEMPOL and catalase (n = 6-18). This incubation resulted in no
changes in the overall slopes of the dose-response determination in any of the four
treatment groups. D: ACh-induced vasodilation was assessed during co-incubation with
the four chemical interventions (n = 10-15). This incubation resulted in a significant
difference in the overall slopes of the dose-response determination within the WKY groups
only. * p ≤ 0.05 vs. WKY-Sham, † p ≤ 0.05 vs. WKY-CeO2 NP
Figure 4 Influences of NO, COX products, and ROS at 150 nAmp: The bar graph is the
dilation that was observed at 150 nAmp for each animal group in the presence of the
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selected chemical intervention. A: The role of NO was assessed during incubation with LNMMA (n = 14-18). This incubation resulted in a significant decrease in arteriolar
vasodilation in the WKY groups. There was a significant increase in vasodilation during
incubation in the SH-Sham group but there was no change in ACh-induced dilation in the
SH-CeO2 NP group. B: The role of COX products was assessed during incubation with
INDO (n = 9-14). This incubation resulted in a significant decrease in arteriolar vasodilation
in the WKY groups. There was no change in vasodilation in the SH-Sham group, but there
was a significant increase in vasodilation following CeO2 NP (SH-CeO2 NP). C: Local ROS
was scavenged during incubation with TEMPOL and catalase (n = 6-18). This incubation
resulted in no change in arteriolar vasodilation in the WKY groups and the SH-CeO2 NP
group. There was increase in vasodilation in the SH-Sham group during incubation. D:
ACh-induced vasodilation was assessed during co-incubation with the four chemical
interventions (n = 10-15). This incubation resulted in a significant decrease in arteriolar
vasodilation in the WKY groups. There was no change in vasodilation in the SH-Sham
group but there was a significant increase in vasodilation following CeO2 NP (SH-CeO2
NP). The open bars represent responses to ACh in the presence of a chemical mediator.
* p ≤ 0.05 vs. WKY-Sham, † p ≤ 0.05 vs. WKY-CeO2 NP, ‡ p ≤ 0.05 vs. SH-Sham, ^ p ≤
0.05 vs. SH-CeO2 NP
Figure 5 Vascular Oxidative Stress: A: Representative ethidium bromide images
indicating an increase in oxidative stress in the SH-Sham group. B: Quantitative analysis
of the ethidium bromide images revealed a significant increase in vascular oxidative stress
in the SH-Sham group that was reduced in the SH-CeO2 group (n = 6-10). These levels
were similar to the WKY-Sham and WKY-CeO2 NP groups. * p ≤ 0.05 vs. WKY-Sham, † p
≤ 0.05 vs. WKY-CeO2 NP, ‡ p ≤ 0.05 vs. SH-Sham
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Figure 6 Systemic Inflammation: A: Leukocyte flux was assessed in venules during
intravital microscopy. There was a significant increase in leukocyte flux in the SH-Sham
group, which was decreased following CeO2 NP exposure (n = 12-15). B: Plasma IL-10
levels were significantly increased in the WKY-CeO2 NP, but not in the other three groups
(N = 7). C: Plasma TNF-α levels were significantly increased in the WKY-CeO2 NP, but
not in the other three groups (N = 6-7). D: Plasma IL-1β levels were significantly
decreased in the SH-Sham and SH-CeO2 NP groups, but were unaltered in the WKYCeO2 NP group (N = 6-7). * p ≤ 0.05 vs. WKY-Sham, † p ≤ 0.05 vs. WKY-CeO2 NP, ‡ p ≤
0.05 vs. SH-Sham, ^ p ≤ 0.05 vs. SH-CeO2 NP
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Tables:
Table 1: Animal Characteristics
Treatment N
Age
(wks)
WKY- Sham
WKYCeO2 NP
SHSham
SHCeO2 NP

Weight
(g)

Heart
Weight
(g)

MAP
(mm Hg)

Heart Rate
(beats/min)

22

10.48 ± 0.30

230.5 ± 5.99

0.97 ± 0.03

66.25 ± 2.33

446.20 ± 25.03

19

10.42 ± 0.18

226.7 ± 3.73

0.93 ± 0.02

69.29 ± 2.23

471.24 ± 7.21

10.08 ± 0.32

245.7 ± 6.20

1.12 ± 0.03*†

113.33 ± 5.37*†

427.83 ± 18.49

10.17 ± 0.33

253.0 ± 5.41*†

1.14 ± 0.04*†

106.66 ± 5.27*†

494.37 ± 12.69

24
24

Values are means ± SE, N = number of animals, MAP = mean arterial pressure
* p ≤ 0.05 versus WKY-Sham; † p ≤ 0.05 versus WKY-CeO2 NP

184

Table 2: Arteriole Characteristics
Treatment n
Starting
Maximal
Diameter
Diameter
(µm)
(µm)
WKY42
59.35 ± 2.67
88.00 ± 3.40
Sham
WKY40
59.04 ± 2.65
92.60 ± 3.65
CeO2 NP
SH58
57.44 ± 2.30
85.81 ± 3.18
Sham
SH50
60.21 ± 2.65
96.80 ± 4.08
CeO2 NP
Values are means ± SE, n = number of arterioles
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Basal Tone
(%)
32.75 ± 1.25
35.42 ± 1.53
32.82 ± 1.16
37.02 ± 1.49

Figures:
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V. General Discussion
The microcirculation is essential to maintain vascular homeostasis and unresolved
dysfunction can contribute to the development of many pathologies (e.g. hypertension and
diabetes) (Prewitt et al. 2002; Zweifach et al. 1981). Despite this knowledge, the
microvascular impacts of ENM exposures remain relatively unknown. ENM, such as CeO2
NP, hold great potential for both consumer and therapeutic applications. These uses
increase the risk of exposure by non-pulmonary exposure routes; however, many studies
do not account for them. Furthermore, if CeO2 NP are to be developed for therapeutic
applications the exposures would occur in individuals with pre-existing diseases, yet very
few studies have investigated the impact of CeO2 NP exposure on various pathologies.
Therefore, the first overarching aim of these studies was to investigate the microvascular
consequences of CeO2 NP exposure with respect to microvascular bed, exposure route,
pathology, and dose.
Aim 1: Microvascular Consequences
In general, the results of the three studies presented herein indicate that
microvascular alterations are a consequence of CeO2 NP exposure, and the outcomes are
unique based on vascular bed, exposure route, and pathology. The outcomes of Chapter
2: Pulmonary Cerium Dioxide Nanoparticles Exposure Differentially Impairs Coronary and
Mesenteric Arteriolar Reactivity establish the influences of pulmonary exposure on
microvascular function and highlight the microvascular differences between vascular beds.
Pulmonary CeO2 NP exposure is linked to endothelium-dependent dysfunction, and this
dysfunction is consistent with observations made with other ENM (LeBlanc et al. 2010;
Stapleton et al. 2012). Furthermore, these effects were not isolated to a singular vascular
bed, which indicates that ENM exposure may influence overall systemic microvascular
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function, an observation that again is corroborated by other ENM studies (LeBlanc et al.
2010; Nurkiewicz et al. 2009). Furthermore, this influence on multiple microvascular beds
indicates that there may be off-target effects of an ENM, which would result in increases
toxicity in multiple organs.
The second significant finding from Chapter 2 was that CeO2 NP exposure resulted
in endothelium-independent dysfunction. Although endothelium-independent dysfunction
was a novel finding for ENM exposure, it has been documented following PM exposure in
pulmonary arteries (Courtois et al. 2008). Furthermore, this observation was not isolated
to pulmonary exposure as indicated by the microvascular assessments performed
following the injection and ingestion of CeO2 NP in Chapter 3: Intravenous and Gastric
Cerium Dioxide Nanoparticle Exposure Disrupts Microvascular Smooth Muscle Signaling.
These exposure routes were selected since CeO2 NP have theranostic potential and there
are limited studies that focus on non-pulmonary exposure routes. The microvascular
dysfunction from these exposure routes were similar to those observed following
pulmonary exposure, indicating potential overlapping mechanisms such as changes in NO
bioavailability and/or impaired vascular smooth muscle (VSM) signaling (see Aim 2:
Potential Mechanisms).
Chapters 2 and 3 also established a dose-response determination for each
exposure route and, to our knowledge; these studies (Chapters 2 and 3) were the first to
compare microvascular differences between exposure routes. The establishment of a
dose-response curve is essential for not only establishing safety and exposure limit
guidelines, but also for determining the effective dose when ENM are being developed for
theranostic applications. The different toxicities between exposure routes were compared
by calculating the EC50 for each exposure route’s dose-response determination. Pulmonary
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exposure had the lowest calculated EC50, which indicated that this route was associated
with the highest microvascular toxicity. Injection exposure had the second lowest EC50
followed by ingestion CeO2 NP exposure. These differences in toxicity are also apparent
in the literature. In vivo assessments of pulmonary CeO2 NP exposure have resulted in
organ and vascular toxicity, which is likely unique to this exposure route (Ma et al. 2011;
Nalabotu et al. 2011; Wingard et al. 2011). There have been few evaluations of the
biological effects following injection and ingestion exposures compared to pulmonary
assessments; however, these limited studies result in less organ damage indicating these
exposure routes may be less toxic (Hirst et al. 2013; Kim et al. 2012; Madero-Visbal et al.
2012). Furthermore, these different EC50 values highlight need to examine the health
effects of ENM using multiple exposure routes and doses.
Finally, based on the dose-response detemination and potential anti-oxidant activity
established in Chapter 3, we sought to utilize CeO2 NP in a more therapeutic application.
In Chapter 4: Cerium Dioxide Nanoparticles Improve Microvascular Dysfunction and
Reduce Oxidative Stress in Spontaneously Hypertensive Rats, in vivo microvascular
assessments were analyzed in the presence of a pre-existing pathology, hypertension. The
injection of CeO2 NP in SH rats resulted in a decrease in microvascular dysfunction.
Additionally, there was no microvascular dysfunction observed following CeO2 NP in the
normotensive WKY rats. Other studies have also associated CeO2 NP with having positive
in vivo effects. The injection of CeO2 NP have been shown to decrease the damage and
area of infarct after stroke (Kim et al. 2012). They have also been shown to protect neurons
within the hippocampal region of the brain and gastrointestinal (GI) epithelial cells from
radiation damage (Colon et al. 2010; Estevez et al. 2011). Taken together, these studies
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indicate that the positive effects of CeO2 NP are not unique to hypertension and provide
preliminary evidence to the possibility of utilizing CeO2 NP as a pharmaceutical agent.
It should be noted that the disparate microvascular effects between animals used
Chapters 2 and 3 and those used in Chapter 4 may be due to the animal model or
assessment techniques. The WKY and SH animals strains are inbred strains that have
genetic differences compared to the Sprague-Dawley (SD) rats used in Chapters 2 and 3.
It has been established that genetic alterations can influence the biological effects of CeO2
NP (Wingard et al. 2011). Therefore, it is reasonable to speculate that the lack of
microvascular dysfunction in the WKY rats may be to due genetic differences, which protect
the rat from CeO2 NP, but additional comparative studies between the WKY and SD rats
are needed to confirm this hypothesis. Additionally, due to the inbred nature and genetic
alterations in the WKY strain it has been speculated that this may not be the best control
for SH rats (St et al. 1992). SD rats have been proposed as a more appropriate control for
the SH rats (St et al. 1992). The different microvascualar responses of the SD, WKY, and
SH rats highlight the potential influences of genetic alterations and pre-existing pathologies
on the effects of CeO2 NP exposure.
The experimental techniques utilized in Chapters 2-4 may also have contribute to
the differential microvascular effects. Initial microvascular assessments were made using
the isolated microvessel technique, which allows for determining the specific influences of
certain agonists without the influences of blood flow and autonomic innervations. The
studies in Chapter 4 were conducted using intravital microscopy to determine if the
observations from previous experiments persisted in the whole animal. Therefore, the lack
of overt endothelium-dependent and -independent microvascular dysfunction could be due
to the activation of compensatory mechanisms, sympathetic stimulation, and/or blood flow,
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which may hide underlying dysfunction when microvascular assessments were made using
intravital microscopy.
Overall, these studies (Chapters 2-4) provide evidence that CeO2 NP disrupt
microvascular function and the extent of this dysfunction is dependent on the microvascular
bed, exposure route, dose, and pre-existing pathologies. Finally, the range of
microvascular consequences, both positive and negative, associated with CeO2 NP
highlight the complexity of this ENM and the need for extensive toxicological evaluations
to understand the full potential of CeO2 NP.
The literature has established that CeO2 NP exposure is associated with
physiological alterations and the studies (Chapter 2-4) within this dissertation support this
notion from a microvascular perspective (Hirst et al. 2013; Kim et al. 2012; Ma et al. 2011;
Nalabotu et al. 2011; Wingard et al. 2011; Yokel et al. 2012). Despite this knowledge, the
mechanisms of action for the observed effects are largely unknown. Therefore, a
secondary aim of was to investigate the potential changes in inflammation, intracellular
signaling and ROS generation, all of which could have contributed to the observed
microvascular alterations.
Aim 2: Potential Mechanisms
The observed alterations in microvascular reactivity could result from a myriad of
mechanisms including inflammation, direct nanoparticle interaction, NO bioavailability,
internal cellular signaling disruptions and/or ROS alterations. Furthermore, it would be
naïve to think that only one of these mechanisms is responsible for the observed
microvascular outcomes. In reality, ENM often disrupt one or more of these mechanisms
and affect multiple physiological systems; therefore, it is reasonable to speculate that the
manifestation of the observed effects is likely the result of multiple mechanisms
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(Legramante et al. 2009; Pacurari et al. 2012; Porter et al. 2010; Stapleton et al. 2012).
Therefore, these studies briefly investigated several of these potential mechanisms in an
attempt to understand the mechanisms of action for CeO2 NP exposure.
Within the literature, there are three common hypotheses used to explain the
mechanisms of action for ENM (as described in the literature review), and the inflammation
hypothesis is the most investigated of the three. Hence, changes in pulmonary and
systemic inflammation were assessed throughout these experiments. Lung inflammation
was present following pulmonary CeO2 NP exposure and was characterized by increased
LDH activity, AM activation, and increased PMN leukocytes (Chapter 2), which was not
present following the injection of CeO2 NP (Appendix A). The presence of pulmonary
inflammation was not assessed following ingestion exposure but it is reasonable to
speculate that this exposure route would also not result in pulmonary inflammation. The
lack of pulmonary inflammation but the presence of microvascular dysfunction following
injection and ingestion exposures indicates that pulmonary inflammation is not required for
systemic microvascular disruptions. However, the presence of pulmonary inflammation
may be a compounding factor that contributes to increased toxicity associated pulmonary
exposure.
Other microvascular studies have also observed pulmonary inflammation and
microvascular disruptions but the mechanism between these two outcomes is still unknown
(Nurkiewicz et al. 2004). In theory, pulmonary inflammation and/or direct particle interaction
could result in systemic inflammation due to cytokine spillover and/or signaling. This
increase in systemic inflammation could lead to changes in vascular ROS and increased
leukocyte extravasation, both of which can disrupt microvascular function. Following CeO2
NP exposure in SD rats there was no significant increase in circulating pro-inflammatory
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cytokines; however, there was a decrease in circulating IFN-γ and IL-13 regardless of
exposure route (Appendix B). This decrease in circulating cytokines introduces the notion
that CeO2 NP may have anti-inflammatory properties.This ani-inflammatory acticity may be
benifical in pathologies associated with chronic inflammation, however; it may also be
deterimental if innate immune responses are compromised, which could increases
infection risks. Additional studies will need to be completed to understand the full in vivo
impact of CeO2 NP proposed anti-inflammatory properties and determine this property is
assicated with positive or negative outcomes.
These potential anti-inflammatory properties have been documented in the literature
but were also observed the SH rats after the injection of CeO2 NP due to a decreased
leukocyte flux (Hirst et al. 2009). Interestingly, injection exposure also caused an increase
in IL-10 and TNF-α in the normotensive WKY rats, which could indicate either anti- or proinflammatory properties. TNF-α is a pro-inflammatory cytokine involved in the activation of
macrophages, whereas IL-10 is an anti-inflammatory cytokine that can inhibit the
production of many pro-inflammatory cytokines (e.g. TNF-α, and IFN-γ) (Feghali and
Wright 1997). Hypothetically, an increase in both these markers could indicate that at the
time of assessment (24 h), IL-10 is beginning to increase and inhibiting TNF-α production;
whereas, TNF-α would be starting to decrease due to this inhibition, which would highlight
potential anti-inflammatory action. A second hypothesis that may explain the simultaneous
increase in these cytokines is the activation of macrophages via toll-like receptors leading
to the secretion of IL-10 and TNF-α, thus indicating pro-inflammatory action (Mosser 2003).
Overall, additional studies at different time points, exposure routes (e.g. inhalation and
ingestion), and pathologies are needed to confirm the anti- or pro-inflammatory activity of
CeO2 NP.
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In addition to these inflammatory changes, there is also evidence that the alterations
in microvascular function following CeO2 NP exposure is partially, due to direct
nanoparticle interaction. It should be mentioned that the three exposure routes assessed
would result in different levels of direct CeO2 NP interaction at the microvascular level and
these differing amounts could have a huge impact on the observed microvascular
outcomes. Theoretically, the injection of ENM would result in the highest level of direct
endothelial exposure due to the bulk of the particles directly entering the circulation
(Stapleton and Nurkiewicz 2014). At this time, it is unknown what the clearance rate from
and within the GI tract is for EMN. Studies have shown that following CeO2 NP exposure
upwards of 95% of the dose is cleared from the gut in the feces within 24 h (Hirst et al.
2013). This high clearance rate would have a significant impact on the dose that is capable
of interacting with other systemic organs. In addition to overall clearance, the clearance
time of ENM between various organs of the GI tract is also important to consider. The time
that an ENM spends in the stomach or small intestine could have a significant impact on
its chemical properties due to the different pH in these organs (Hayes et al. 2002). These
chemical changes may have a significant impact on CeO2 NP effects following ingestion.
Furthermore, GI tract clearance can also occur due to translocation, which would result in
direct exposure to the liver. TiO2 NP are capable of translocating from the GI tract into the
circulation and therefore it is reasonable to speculate the CeO2 NP behave similarly but
the level of direct exposure at 24 h is unknown (Brun et al. 2014). Finally, it has been
documented the ENM are capable of translocating from the lungs at a relatively slow rate,
which implies that at the time of assessment a small percentage of the CeO2 NP dose
would have directly interacted with the systemic microcirculation following pulmonary
exposure (Geraets et al. 2012; Zhu et al. 2009).
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All three exposure routes resulted in endothelium-dependent and -independent
microvascular dysfunction, which may be linked to changes in NO bioavailability and impair
VSM signaling. NO bioavailability can be altered in multiple ways including decreased NO
production, and increased NO scavenging. The injection of CeO2 NP resulted in a decrease
in NO production. This decrease in production could be from NOS uncoupling, decreased
intracellular L-arginine, and/or direct contact with CeO2 NP (Cherng et al. 2011).
Furthermore, ENM exposure can result in decrease NO bioavailability due to an increase
in MPO activity (Nurkiewicz et al. 2011). This increased activity alters NO bioavailality by
increasing the concentration of hypoclorous acid, which scavenges NO and can react with
intracellular L-arginine. Additionally, there was also evidence that pulmonary CeO2 NP
exposure may be associated with NOS uncoupling (Chapter 3). Ultimately, these changes
in NO bioavailability may impair vascular smooth muscle relaxation, due less NO reaching
the VSM cells.
The observed impairments in endothelium-independent dilation may also be due to
changes in VSM signaling. Preliminary evidence from Chapter 3 indicates that independent
of exposure route the arterioles are unable to respond to NO due potentially to attenuated
responses to VSM mediators (e.g. sGC and cGMP) needed for vasodilation. In addition to
these mediators, there may also be changes in calcium handling, PKG activity, and/or
increased phosphodiesterase activity all of which may also impair the signaling of NO
within the VSM (Dora et al. 1997; Perri et al. 2006; Rybalkin et al. 2003). Further studies
are needed in order to identify the exact mechanism for the attenuated endotheliumindependent dilation associated with CeO2 NP exposure in a young health male animal
model.
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In addition to VSM signaling, changes in intracellular signaling may also effect
endothelial cells. AA metabolism via COX activation can be initiated within the endothelial
cells. This activation can promote vasodilation and/or vasoconstriction through a NOindependent pathway. The injection of CeO2 NP appeared to cause a shift in AA
metabolism in SH rats (Chapter 4). This shift is signaling may have resulted in an increase
in TXA2 production, a known vasoconstrictor. This change from prostaglandin production
to TXA2 production may be a contributing factor to the inability of CeO2 NP to restore
complete ACh-induced dilation in the hypertensive rats (Chapter 4).
Another contributing factor to the observed microvascular consequences may be
ROS alterations. ROS production can be increased by the CeO2 NP themselves,
inflammation, NOS uncoupling, increased NADPH oxidase activity, MPO activity and/or
mitochondria dysfunction (Cherng et al. 2011; Dabkowski et al. 2009; Park et al. 2008;
Nurkiewicz et al. 2011). An increase in ROS may impair the ability of NO to diffuse to the
VSM, which would impair the arterioles ability to dilation. However, in vivo studies (Chapter
4) have also shown that CeO2 NP are capable of decreasing the level of vascular ROS,
which highlights its anti-oxidant activity. The pro- or anti-oxidant potential of CeO2 NP may
be influenced by the initial basal level of ROS. Theoretically, CeO2 NP may function
optimally in the presence of high ROS, which is associated with hypertension. However, if
there are low levels of basal ROS CeO2 NP may exhibit pro-oxidant activity, but further
investigations are needed to confirm this theory.
In addition to ROS, NO is also capable of being scavenged by the CeO2 NP directly
(Xu and Qu 2014), which may account for some of the observed microvascular alterations.
This preference to react with NO and other ROS is derived from the valance state of the
CeO2 NP. These nanoparticles exist in two valence state, Ce3+ and Ce4+ and the ratio of
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these valence states can affect the function of CeO2 NP. Research has shown that Ce4+
reacts more readily with NO, whereas Ce3+ reacts with superoxide (Xu and Qu 2014). This
preference could not only influence the anti-oxidant activity of CeO2 NP but also their
impact on microvascular reactivity. It is also important to note, that at this time it is unclear
how valence state is altered during in vivo exposures, especially since pH can influence
the overall ratio (Hayes et al. 2002). Future studies need to not only establish the
importance of valence state on the anti-oxidant potential of CeO2 NP but also how in vivo
exposure alters the valence state ratio of these nanoparticles.
Additionally, CeO2 NP exposure may modify thrombosis development, particualy in
the SH rats. The increased leukocyte flux in the SH rats provided indirect evidence for
endothelial cell activation, which results in the production various adhesion proteins and
factors essential for impairing fibrinolysis (i.e. PAI-1). PAI-1 is secreted by macrophages,
endothelial cells and vascular smooth muscle cells. Furthermore, this factor is controlled
by oxidative stress. Studies with nano-copper oxide have shown an increase in PAI-1
secretion following exposure and it is possible that this factor is also elevated in the SHSham rats, thus increasing risk of thrombosis (Yu et al. 2010). However, following CeO2
NP exposure there is a decrease in leukocyte flux in the SH rats, which could indicate a
decreased thrombosis risk. Furthremore, addtional studies will be needed to determine if
these factors (i.e. leukocyte flux, adhesion proteins, and PAI-1) are also altered in the SD
rats and if they are altered overtime in the WKY following CeO2 NP exposure via multiple
exposure routes.
Overall, it is clear that one mechanism cannot account for the observed
microvascular dysfunction. Furthermore, the mechanisms of action are likely to change
based on exposure route and/or pathology. Regardless these studies have indicated that
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NO bioavailability and ROS alterations are likely to play a key role in CeO2 NP in vivo
activity and future studies should focus a defining the specific influences of these two
mechanisms.
Finally, despite the presence of overt microvascular dysfunction, changes in ROS
and NO bioavailability, there were no systemic changes observed in the animals following
exposure (e.g. MAP). The control of MAP is dynamic and the body is able to make
adjustments for minute-to-minute fluctuations in pressure (via baroreceptors); therefore,
there would not initially be observable systemic effects at the timepoint assessed in these
studies. Additionally, there is inherit redundancy within the microcirculation, which allows
for continued function if one source of reactivity (e.g. NO signaling) is impaired. However,
overtime (several weeks to months) the cardiovascular system would not be able to
compensate for the impaired microvascular dysfunction and changes in MAP may begin to
emerge. Furthermore, the measurements in these experiments were conducted at 24 h
post-exposure. At this time point there would not have been ample time for cardiovascular
remodeling (e.g. microvascular rarefraction and cardiac hypertrophy), which can take
several weeks (or years in humans) to develop. These structural changes would also
contribute to an increase in MAP that would not be able to be compensated for by normal
controls (e.g. HR, and vasodilation) and would not have be observed in these experiments.
Furthermore, reactive changes in blood pressure and HRV in response to the CeO2 NP
treatements over a short period of time could be monitored via implantation of telemeters,
which would record real-time data on HR, and MAP.
Conclusions and Future Directions
Clearly, the microvascular effects of CeO2 NP exposure are vast and the potential
mechanisms are extensive. Despite this complexity, the studies in Chapters 2-4 have
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advanced our knowledge of this ENM. There is clear evidence that CeO2 NP disrupt
microvascular reactivity in a young healthy male model; however, in the presence of a
disease state CeO2 NP may improve microvascular function. These differing effects
highlight the need to investigate CeO2 NP activity in several animal models (e.g.
hypertension, obesity, and diabetes). It also highlights the potential anti-oxidant and antiinflammatory activity of these nanoparticles, which support the development of this ENM
as a therapeutic.
Defining the pro- or anti- oxidant activity of CeO2 NP is critical if this ENM is to be
developed for clinical applications. This includes establishing an effective dose as well as
investigating the physiological impacts at various time points. Chapter 4 only investigated
the influence one dose and one time point. Future studies need to focus on establishing
the effective doses in a hypertensive animal model. These studies should also investigate
several time points as the anti-oxidant, anti-inflammatory, and microvascular impacts may
change if the animals are exposed for shorter or longer time points.
Mechanistically these studies have also begun to investigate the influences of
inflammation and direct nanoparticle exposure, however; alterations in autonomic signaling
were not studied. Determining the potential changes in autonomic regulations, both within
the heart and at the microvascular level are essential if CeO2 NP are to be development
for therapeutic applications, since cardiovascular side effects are one reason that
pharmaceuticals are not FDA approved.
CeO2 NP research and therapeutic development is still in its infancy and many
questions about its in vivo activity remain unexplored. The studies presented in this
dissertation help to shed light on the microvascular influences of this potential anti-oxidant.
They highlight the influences of exposure route and the importance of selecting an
204

appropriate animal model, which is essential in understanding the overall impact of these
nanoparticles are they continue to be developed for commercial and pharmaceutical
applications.
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VI. Appendices
Appendix A
Methods: Pulmonary Inflammation Assessment: A subset of 12 Wistar and Spontaneously
Hypertensive rats were intraveously injection with CeO2 NP (0 or 100 µg) were anethetized
with isofluane (5% induction and 2-3.5% maintence). The rats were euthanized via
exsanguination. The trachea was cannulated and BAL was performed using ice-cold
Ca2+/Mg2+ -free phosphate buffered saline (PBS). The first lavage (6 ml) was kept separate
from the rest of the lavage sample. Subsequent lavages used 10 ml PBS until 40 ml lavage
fluid was collected. The samples were centrifuged at 650 x g, 5 min at 4°C. The pooled
cells were resuspended in HEPES-buffered medium and cell counts were determined with
an electronic cell counter equipped with a cell-sizing attachment. Cytospin Preparation:
1x106 BAL cells [both alveolar macrophages (AM) and polymorphonuclear leukocytes
(PMN)] in 200 µl HEPES-buffered medium were prepared with a cytocentrifuge. The
cytospin preparations were stained with modified Wright-Giemsa stain and cell differentials
were determined by light microscopy. The differential cell counts were calculated by
multiplying the total cell count by the cell differential percentage obtained from the cytospin
preparations.
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Figure:

Figure Legend:
Figure 1 Pulmonary inflammation: Pulmonary inflamamtion was not altered after
exposure to CeO2 NP in SH or WK rats. There was no significant increase in A: AM or B:
PMN infiltration
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Appendix B
Methods: Pro-Inflammatory Cytokine Analysis: Sprague-Dawley rats were exposed to
either saline or CeO2 NP via intravenously injection (0 or 100 µg), gastric gavage (0 or 400
µg) or intratracheally instilled (0 or 65 µg). 24 h post-exposure the blood was collected via
caroid artrey and centrifuged (1100 x g) to separate the blood components. The plasma
was collected, flash frozen in liquid nitrogen, and stored in a -80°C freezer until analysis. A
pro-inflammatory cytokine multi-spot assay was completed per manufacturer's directions
(MesoScale Diagnostics, Rockville, MD). The pro-inflammatory cytokines assessed were:
interferon gamma (IFN-γ), interleukins-1beta, 4, 5, 6, 10 and 13 (IL-1β, IL-4, IL-5, IL-6, IL10,

and

IL-13),

tumor

necrosis

factor

alpha

(TNF-α)

chemoattractant/human growth-regulated oncogene (KC/GRO).
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and

keratinocyte

Figure:

Figure Legend:
Figure 1 Systemic Inflammation:. A: Plasma IFN-γ levels were significantly decreased
in all three exposure groups compared to saline controls (N = 3). B: Plasma IL-13 levels
were significantly decreased in all three exposure groups compared to saline controls (N
= 3). There were no significant differences in plasma IL-1β, IL-4, IL-5, IL-6, IL-10, TNF-α,
or KC/GRO levels (data not shown). * p ≤ 0.05 vs. Control
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(2013) Impact of Cerium Dioxide Nanoparticle Exposure on Microvascular
Function. The Cardiovascular Forum Outstanding for Promoting Centers of
Excellence and Young Investigators
24. Minarchick VC, Stapleton PA, Fix NR, Leonard SS, Sabolsky EM, Nurkiewicz
TR. (2014) Nano-Cerium Dioxide Exposure and Arteriolar Dysfunction: What Is
the Mechanism?. The Toxicologist. Volume 138 (1): 127 #488.
25. Stapleton PG, Minarchick VC, Yi J, Frisbee J, Nurkiewicz TR. (2014)
Engineered Nanomaterial Exposure and the Metabolic Syndrome. The
Toxicologist. Volume 138 (1): 225 #872.
26. Madejczyk MS, Baer CE, Dennis WE, Minarchick VC, Leonard SS, Jackson DA.
(2014) Temporal Changes in Rat Liver Gene Expression after Cadmium and
Chromium Exposure. The Toxicologist. Volume 138 (1): 344 #1297.
27. Stapleton PG, Nichols CE, Yi J, Minarchick VC, Hollander JM, Nurkiewicz TR.
(2014) Gestational Nanomaterial Exposures What Does the Future Hold?. The
Toxicologist. Volume 138 (1): 440 #1689.
28. Minarchick VC, Stapleton PA, Fix NR, Leonard SS, Sabolsky EM, and
Nurkiewicz TR. (2014) Cerium Dioxide Nanoparticles: Determining the Source of
Microvascular Dysfunction. Van Liere Research Day West Virginia University
29. Minarchick VC, Stapleton PA, Fix NR, Leonard SS, Sabolsky EM, Nurkiewicz
TR. (2014) Nanomaterial Exposure Route Differentially Affects Microvascular
Function. NanoSAFE Bioelectronics and Biosensing Symposium.
30. Minarchick VC, Stapleton PA, Fix NR, Leonard SS, Sabolsky EM, Nurkiewicz
TR. (2014) Determining a Mechanistic Link Between Cerium Dioxide
Nanoparticles and Arteriolar Dysfunction. Allegheny-Erie Regional Chapter of the
Society of Toxicology 28th Annual Meeting
31. Minarchick VC, Stapleton PA, Fix NR, Leonard SS, Sabolsky EM, Nurkiewicz
TR. (2014) Smooth Muscle Signaling: A Mechanism for Cerium Dioxide
Nanoparticle Toxicity. West Virginia University School of Pharmacy Regional
Research Forum
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32. Minarchick VC, Stapleton PA, Sabolsky EM, Nurkiewicz TR. (2014) Cerium
Dioxide Nanoparticles: Pro- or Anti-Oxidant Potential In Vivo?. Society of
Toxicology Annual Meeting. March 2015
33. Minarchick VC, Stapleton PA, Sabolsky EM, and Nurkiewicz TR. (2015) Cerium
Dioxide Nanoparticles Display Microvascular Anti-oxidant Activity In Vivo. Van
Liere Research Day West Virginia University
Invited Oral Presentations:
1. Size Matters: Understanding Nanomaterials. (March 2012) Science on Tap. West
Virginia University Biology Department. Morgantown, WV.
2. Pulmonary Nanoceria Exposure Impairs Coronary and Mesenteric Arteriolar
Reactivity. (March 2012) Society of Toxicology National Meeting. San Francisco,
CA.
3. Inflammatory and Free Radical Generation Characteristics of Nano-Cerium
Dioxide. (March 2013) Society of Toxicology National Meeting. San Antonio, TX.
4. Cerium Dioxide Nanoparticles: Determining the Source of Microvascular
Dysfunction. (February 2014). Van Liere Convocation. Morgantown, WV.
5. Nanomaterial Exposure Route Differentially Affects Microvascular Function. (April
2014). NANOSafe 2014 Bioelectronics and Biosensing Symposium.
Morgantown, WV.
6. Determining a Mechanistic Link Between Cerium Dioxide Nanoparticles and
Arteriolar Dysfunction. (May 2014). Allegheny-Erie Regional Chapter of the
Society of Toxicology 28th Annual Meeting. Morgantown, WV.
7. Smooth Muscle Signaling: A Mechanism for Cerium Dioxide Nanoparticle
Toxicity. (June 2014). West Virginia University School of Pharmacy Regional
Research Forum. Morgantown, WV.
8. Cerium Dioxide Nanoparticles Display Microvascular Anti-oxidant Activity In Vivo.
(February 2015). Van Liere Convocation. Morgantown, WV.
9. Determining the Anti-oxidant Potential of Cerium Dioxide Nanoparticles (May
2015). International Symposium on Organic Electronics and Bioelectronics.
Clemson, SC.
Department Seminars:
1. Effects of Pulmonary Ceria Nanoparticles on Arteriolar Reactivity. (March 2011).
Department of Physiology and Pharmacology. Morgantown, WV.
2. Pulmonary Nano-Cerium Dioxide Exposure Impairs Coronary and Mesenteric
Arteriolar Reactivity (December 2011) Department of Physiology and
Pharmacology. Morgantown, WV.
3. Influence of Nanomaterial Exposure Route on Microvascular Function
(December 2012). Department of Physiology and Pharmacology. Morgantown.
WV.
4. Cerium Dioxide Nanoparticles and Microvascular Dysfunction: The Role of Nitric
Oxide (December 2013). Department of Physiology and Pharmacology.
Morgantown. WV
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5. Cerium Dioxide Nanoparticle Exposure: Microvascular Dysfunction and Potential
Mechanisms (December 2014). Department of Physiology and Pharmacology.
Morgantown. WV
Professional Memberships:
•

•
•

Society of Toxicology (2011- Present)
o Allegheny-Erie Society of Toxicology Regional Chapter (2011- Present)
o Society of Toxicology Cardiovascular Specialty Section (2011- Present)
o Society of Toxicology Nanotoxicology Specialty Section (2011- Present)
o Women in Toxicology Special Interest Group (2011- Present)
American Association of Pharmaceutical Scientists (2013- 2014)
Association for Women in Science (2013- Present)

Meetings Attended:
•
•
•
•
•
•
•
•

5th Conference on Metal Toxicity and Carcinogenesis 2008
Engineered Nanomaterials Grand Opportunity Consortium Meeting 2011
Society of Toxicology National Meeting 2011-2014
Allegheny-Erie Regional Chapter of the Society of Toxicology Annual Meeting
2011-2014
Van Liere Research Day West Virginia University 2011-2014
NanoSAFE Bioelectronics and Biosensing Symposium 2013-2014
West Virginia University School of Pharmacy Regional Research Forum 20132014
The Cardiovascular Forum for Promoting Centers of Excellence and Young
Investigators 2013

Honors and Awards:
•

Dr. William J. von Liebig Award for Student Research, May 1 2007
~award for top presentation for undergraduate research at the
Juniata College research symposium

•
•

Graduated with Distinction in the Biology POE. May 2007
Second Place Poster at Van Liere Research Day. West Virginia University.
March 2011
Graduate Student Travel Award- Sponsored by Danish Myo Technology, from
the Cardiovascular Toxicology Specialty Section of the Society of Toxicology.
March 2012
Second Place Poster at Van Liere Research Day. West Virginia University.
March 2012
Second Place Poster at Van Liere Research Day. West Virginia University.
February 2013

•
•
•
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•
•
•
•
•
•
•
•

First Place Poster Presentation at West Virginia University School of Pharmacy
Regional Research Forum. West Virginia University. May 2013
Outstanding Poster Presentation at The Cardiovascular Forum for Promoting
Centers of Excellence and Young Investigators sponsored by the International
Academy of Cardiovascular Sciences. University of Louisville. August 2013
Nominated and Selected for Morgantown Magazine 30 Under 30 Contest.
December 2013
Graduate Student Achievement Award. Women in Toxicology Special Interest
Group. Society of Toxicology Annual Meeting. Phoenix, AZ. March 2014.
Outstanding Graduate Student 1st Place Award. Nanotoxicology Specialty
Section. Society of Toxicology Annual Meeting. Phoenix, AZ. March 2014.
1st Place Video. YouTox Video Challenge. Society of Toxicology Annual Meeting.
Phoenix, AZ. March 2014
2nd Place Podia Presentation. West Virginia University School of Pharmacy
Regional Research Forum. Morgantown, WV. June 2014
2nd Place Oral Presentation. Van Liere Research Day. West Virginia University.
February 2015

Professional Service:
Positions:
•
•

Society of Toxicology Graduate Student Leadership Council Member (May 20132015)
Society of Toxicology Student Representative for the Cardiovascular Toxicology
Specialty Section (May 2013-2015)

Ad hoc Reviewer:
Inhalation Toxicology
Cardiovascular Toxicology
Medicine and Science in Sport and Environmental Health Perspectives
Exercise
Nanotoxicology
Life Sciences
Particle and Fibre Toxicology
Microcirculation
Reproductive Toxicology
Toxicological Sciences
Biochemical Sciences
Frontiers in Physiology
American Journal of Physiology

PLoS ONE
Toxicology and Applied Pharmacology
WIREs
Nanomedicine
and
Nanobiotechnology
Chemosphere

Training/Teaching:
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•
•
•
•
•
•
•
•
•
•
•

Evan Vogel (2010): Summer Laboratory Internship; Catholic University of
America, Washington, D.C.
Kenzie Dent (2010): WV-INBRE; West Virginia Wesleyan College, WV.
Nick Mazzone (2011): Summer Laboratory Internship, WVU Exercise Physiology
Program, WV.
Cody Nichols (2011): Rotation Student, WVU Biomedical Sciences Ph.D.
Program, WV.
Jonathan Boyd (2011): Rotation Student, WWU Biomedical Sciences Ph.D.
Program, WV.
Katie Spears (2012): WVNano National Science Foundation - Research
Experience for Undergraduates; Maryville College, TN.
Shannon Aippersbach (2013): WVU NanoSAFE National Science Foundation–
Research Experience for Undergraduates; Penn State, PA
Gaurav Gautam (2013): Undergraduate Research Experience, West Virginia
University, WV
Ashley Kerr (2014): Rotation Student, WVU Biomedical Sciences Ph.D. Program,
WV
Quincy Hathaway (2014): WVU NanoSAFE National Science Foundation –
Research Experience for Undergraduates; Wanyesburg University, PA
Alaeddin Abukabda (2014): Rotation Student, WVU Biomedical Sciences Ph.D.
Program, WV

Career Development:
Nominated for involvement with the Linking Innovation Industry and
Commercialization (LIINC) Program through West Virginia University's Office of
Research and Economic Development (2013)
Community Service:
• March 2012 - WVU Nanodays. WVNano. Mountaineer Mall. Volunteer.
Morgantown, WV.
• November 2012 - Science Day. NanoSAFE. Mountaineer Mall. Volunteer.
Morgantown, WV.
• March 2013 - WVU Nanodays. NanoSAFE. Mountaineer Mall. Volunteer.
Morgantown, WV.
• September 2013 – Invited Presenter. “Being a Scientist” Philipsburg-Osceola
Elementary School. Philipsburg, PA.
• March 2014 –WVU Nanodays. NanoSAFE. Mountaineer Mall. Volunteer.
Morgantown, WV.
• March 2014 – Math and Science Night. Mountainview Elementary School.
Volunteer. Morgantown, WV.
• August 2014 –State Fair of West Virginia. Volunteer. Lewisburg, WV.
• November 2014 - Science Day. Mountaineer Mall. Volunteer. Morgantown, WV.
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